{"idB": "1006281_18_item1_p0_s0", "idA": "1006281_17_item1_p0_s0", "sentA": "We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx protein expression system, or ProCellEx.", "sentB": "We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx protein expression system.", "type": 2, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "and", "commercialization", "of", "recombinant", "therapeutic", "proteins", "based", "on", "our", "proprietary", "ProCellEx", "protein", "expression", "system,", "or", "ProCellEx.", "<tag2>", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "and", "commercialization", "of", "recombinant", "therapeutic", "proteins", "based", "on", "our", "proprietary", "ProCellEx", "protein", "expression", "system.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "and", "commercialization", "of", "recombinant", "therapeutic", "proteins", "based", "on", "our", "proprietary", "ProCellEx", "protein", "expression", "system,", "or", "ProCellEx."], "wordsB": ["We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "and", "commercialization", "of", "recombinant", "therapeutic", "proteins", "based", "on", "our", "proprietary", "ProCellEx", "protein", "expression", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.18039560317993164, 0.058344293385744095, 0.027321793138980865, 0.21395446360111237, 0.17659398913383484, 0.05490155145525932, 0.021277032792568207, 0.017402444034814835, 0.05487300828099251, 0.023597590625286102, 0.06189190596342087, 0.02855672873556614, 0.2256246656179428, 0.26516392827033997, 0.3384536802768707, 0.04599244147539139, 0.03656577691435814, 0.028305331245064735, 0.14424487948417664, 0.629561722278595, 0.2048359513282776, 0.1578730344772339, 0.16874830424785614, -1]}
{"idB": "1006281_18_item1_p0_s2", "idA": "1006281_17_item1_p0_s2", "sentA": "With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.", "sentB": "With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications, including applying the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.", "type": 2, "words": ["<tag1>", "With", "our", "experience", "to", "date,", "we", "believe", "ProCellEx", "will", "enable", "us", "to", "develop", "additional", "proprietary", "recombinant", "proteins", "that", "are", "therapeutically", "superior", "to", "existing", "recombinant", "proteins", "currently", "marketed", "for", "the", "same", "indications.", "<tag2>", "With", "our", "experience", "to", "date,", "we", "believe", "ProCellEx", "will", "enable", "us", "to", "develop", "additional", "proprietary", "recombinant", "proteins", "that", "are", "therapeutically", "superior", "to", "existing", "recombinant", "proteins", "currently", "marketed", "for", "the", "same", "indications,", "including", "applying", "the", "unique", "properties", "of", "our", "ProCellEx", "system", "for", "the", "oral", "delivery", "of", "therapeutic", "proteins.", "<tag3>"], "wordsA": ["With", "our", "experience", "to", "date,", "we", "believe", "ProCellEx", "will", "enable", "us", "to", "develop", "additional", "proprietary", "recombinant", "proteins", "that", "are", "therapeutically", "superior", "to", "existing", "recombinant", "proteins", "currently", "marketed", "for", "the", "same", "indications."], "wordsB": ["With", "our", "experience", "to", "date,", "we", "believe", "ProCellEx", "will", "enable", "us", "to", "develop", "additional", "proprietary", "recombinant", "proteins", "that", "are", "therapeutically", "superior", "to", "existing", "recombinant", "proteins", "currently", "marketed", "for", "the", "same", "indications,", "including", "applying", "the", "unique", "properties", "of", "our", "ProCellEx", "system", "for", "the", "oral", "delivery", "of", "therapeutic", "proteins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.012011571787297726, 0.009988349862396717, 0.020765746012330055, 0.012516304850578308, 0.012752882204949856, 0.011109260842204094, 0.014421803876757622, 0.028359079733490944, 0.010353093035519123, 0.013328094966709614, 0.012747216038405895, 0.008170410059392452, 0.011420605704188347, 0.008962410502135754, 0.011025549843907356, 0.02430022321641445, 0.02978726476430893, 0.008988112211227417, 0.008679882623255253, 0.016942862421274185, 0.0841217115521431, 0.01241915300488472, 0.01540413685142994, 0.018633205443620682, 0.016969315707683563, 0.007899649441242218, 0.007515146862715483, 0.007744837086647749, 0.009135610423982143, 0.010710923001170158, 0.016949327662587166, 0.0074903336353600025, 0.10101483762264252, 0.019605588167905807, 0.090079165995121, 0.06041213870048523, 0.028125466778874397, 0.015517977997660637, 0.09552766382694244, 0.15315446257591248, 0.022081181406974792, 0.026204245164990425, 0.40311571955680847, 0.3175643980503082, 0.05094801262021065, 0.09868530929088593, 0.14593832194805145, -1]}
{"idB": "1006281_18_item1_p109_s0", "idA": "1006281_17_item1_p100_s0", "sentA": "As of December 31, 2016, our patent portfolio consisted of several patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and system and product candidates, as follows:", "sentB": "As of December 31, 2017, our patent portfolio consisted of several patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and system and product candidates, as follows:", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2016,", "our", "patent", "portfolio", "consisted", "of", "several", "patent", "families", "(consisting", "of", "patents", "and/or", "patent", "applications)", "covering", "our", "technology,", "protein", "expression", "methodologies", "and", "system", "and", "product", "candidates,", "as", "follows:", "<tag2>", "As", "of", "December", "31,", "2017,", "our", "patent", "portfolio", "consisted", "of", "several", "patent", "families", "(consisting", "of", "patents", "and/or", "patent", "applications)", "covering", "our", "technology,", "protein", "expression", "methodologies", "and", "system", "and", "product", "candidates,", "as", "follows:", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2016,", "our", "patent", "portfolio", "consisted", "of", "several", "patent", "families", "(consisting", "of", "patents", "and/or", "patent", "applications)", "covering", "our", "technology,", "protein", "expression", "methodologies", "and", "system", "and", "product", "candidates,", "as", "follows:"], "wordsB": ["As", "of", "December", "31,", "2017,", "our", "patent", "portfolio", "consisted", "of", "several", "patent", "families", "(consisting", "of", "patents", "and/or", "patent", "applications)", "covering", "our", "technology,", "protein", "expression", "methodologies", "and", "system", "and", "product", "candidates,", "as", "follows:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.013630090281367302, 0.03128950670361519, 0.018864469602704048, 0.02387569472193718, 0.9485999941825867, 0.008128794841468334, 0.04906425625085831, 0.031654782593250275, 0.009832298383116722, 0.011711705476045609, 0.00981471873819828, 0.055293064564466476, 0.029376588761806488, 0.009624834172427654, 0.010489927604794502, 0.01366937905550003, 0.0161503404378891, 0.014378138817846775, 0.011246930807828903, 0.009704983793199062, 0.0077538928017020226, 0.013215357437729836, 0.011866209097206593, 0.014366958290338516, 0.013260727748274803, 0.008184580132365227, 0.009922055527567863, 0.007926699705421925, 0.009140819311141968, 0.009254174306988716, 0.009255696088075638, 0.017465824261307716, -1]}
{"idB": "1006281_18_item1_p110_s2", "idA": "1006281_17_item1_p101_s1", "sentA": "Among other things, the patents cover the methods that we use for culturing and harvesting plant cells and/or tissues in consecutive cycles.", "sentB": "One patent relating to a separate family, covering methods for culturing and harvesting plant cells and/or tissues in consecutive cycles is expected to expire in 2025.", "type": 2, "words": ["<tag1>", "Among", "other", "things,", "the", "patents", "cover", "the", "methods", "that", "we", "use", "for", "culturing", "and", "harvesting", "plant", "cells", "and/or", "tissues", "in", "consecutive", "cycles.", "<tag2>", "One", "patent", "relating", "to", "a", "separate", "family,", "covering", "methods", "for", "culturing", "and", "harvesting", "plant", "cells", "and/or", "tissues", "in", "consecutive", "cycles", "is", "expected", "to", "expire", "in", "2025.", "<tag3>"], "wordsA": ["Among", "other", "things,", "the", "patents", "cover", "the", "methods", "that", "we", "use", "for", "culturing", "and", "harvesting", "plant", "cells", "and/or", "tissues", "in", "consecutive", "cycles."], "wordsB": ["One", "patent", "relating", "to", "a", "separate", "family,", "covering", "methods", "for", "culturing", "and", "harvesting", "plant", "cells", "and/or", "tissues", "in", "consecutive", "cycles", "is", "expected", "to", "expire", "in", "2025."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.12198762595653534, 0.2787160575389862, 0.06501241773366928, 0.07074087113142014, 0.08381596952676773, 0.7309824228286743, 0.729371190071106, 0.003973679151386023, 0.006644472945481539, 0.001771128154359758, 0.0031226747669279575, 0.0016651074402034283, 0.0024604753125458956, 0.002351605799049139, 0.002381107537075877, 0.002811289159581065, 0.0023579192347824574, 0.0015255153411999345, 0.002410820685327053, 0.002727742772549391, 0.004667680710554123, 0.011596925556659698, 0.012649188749492168, 0.020175008103251457, 0.035230111330747604, 0.06328561902046204, -1]}
{"idB": "1006281_18_item1_p111_s0", "idA": "1006281_17_item1_p103_s0", "sentA": "We held a patent family containing 25 issued patents in India, South Africa, Russian Federation, Australia, China, the United States, Ukraine, Singapore, Japan, Europe, Hong Kong, Mexico, Korea, Canada, Brazil and Israel and three patent applications relating to the production of recombinant glycosylated lysosomal proteins in our plant culture platform, including taliglucerase alfa, and uses of these proteins and cells containing these proteins for the treatment of lysosomal disorders.", "sentB": "We held a patent family containing 24 issued patents and one patent application in India, South Africa, Russian Federation, Australia, China, the United States, Ukraine, Singapore, Japan, Europe, Hong Kong, Mexico, Korea, Canada, Brazil and Israel relating to the production of recombinant glycosylated lysosomal proteins in our plant culture platform, including taliglucerase alfa, and uses of these proteins and cells containing these proteins for the treatment of lysosomal disorders.", "type": 2, "words": ["<tag1>", "We", "held", "a", "patent", "family", "containing", "25", "issued", "patents", "in", "India,", "South", "Africa,", "Russian", "Federation,", "Australia,", "China,", "the", "United", "States,", "Ukraine,", "Singapore,", "Japan,", "Europe,", "Hong", "Kong,", "Mexico,", "Korea,", "Canada,", "Brazil", "and", "Israel", "and", "three", "patent", "applications", "relating", "to", "the", "production", "of", "recombinant", "glycosylated", "lysosomal", "proteins", "in", "our", "plant", "culture", "platform,", "including", "taliglucerase", "alfa,", "and", "uses", "of", "these", "proteins", "and", "cells", "containing", "these", "proteins", "for", "the", "treatment", "of", "lysosomal", "disorders.", "<tag2>", "We", "held", "a", "patent", "family", "containing", "24", "issued", "patents", "and", "one", "patent", "application", "in", "India,", "South", "Africa,", "Russian", "Federation,", "Australia,", "China,", "the", "United", "States,", "Ukraine,", "Singapore,", "Japan,", "Europe,", "Hong", "Kong,", "Mexico,", "Korea,", "Canada,", "Brazil", "and", "Israel", "relating", "to", "the", "production", "of", "recombinant", "glycosylated", "lysosomal", "proteins", "in", "our", "plant", "culture", "platform,", "including", "taliglucerase", "alfa,", "and", "uses", "of", "these", "proteins", "and", "cells", "containing", "these", "proteins", "for", "the", "treatment", "of", "lysosomal", "disorders.", "<tag3>"], "wordsA": ["We", "held", "a", "patent", "family", "containing", "25", "issued", "patents", "in", "India,", "South", "Africa,", "Russian", "Federation,", "Australia,", "China,", "the", "United", "States,", "Ukraine,", "Singapore,", "Japan,", "Europe,", "Hong", "Kong,", "Mexico,", "Korea,", "Canada,", "Brazil", "and", "Israel", "and", "three", "patent", "applications", "relating", "to", "the", "production", "of", "recombinant", "glycosylated", "lysosomal", "proteins", "in", "our", "plant", "culture", "platform,", "including", "taliglucerase", "alfa,", "and", "uses", "of", "these", "proteins", "and", "cells", "containing", "these", "proteins", "for", "the", "treatment", "of", "lysosomal", "disorders."], "wordsB": ["We", "held", "a", "patent", "family", "containing", "24", "issued", "patents", "and", "one", "patent", "application", "in", "India,", "South", "Africa,", "Russian", "Federation,", "Australia,", "China,", "the", "United", "States,", "Ukraine,", "Singapore,", "Japan,", "Europe,", "Hong", "Kong,", "Mexico,", "Korea,", "Canada,", "Brazil", "and", "Israel", "relating", "to", "the", "production", "of", "recombinant", "glycosylated", "lysosomal", "proteins", "in", "our", "plant", "culture", "platform,", "including", "taliglucerase", "alfa,", "and", "uses", "of", "these", "proteins", "and", "cells", "containing", "these", "proteins", "for", "the", "treatment", "of", "lysosomal", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.03270764648914337, 0.02820011042058468, 0.011084185913205147, 0.05065358802676201, 0.03139863535761833, 0.021152138710021973, 0.11030957102775574, 0.0895361378788948, 0.123928502202034, 0.019114432856440544, 0.17156687378883362, 0.149028480052948, 0.06411805748939514, 0.020179202780127525, 0.03739464655518532, 0.026315992698073387, 0.03536779060959816, 0.03247451409697533, 0.04772988706827164, 0.047836221754550934, 0.041047997772693634, 0.022805122658610344, 0.04276181757450104, 0.05012768134474754, 0.05514691397547722, 0.04313720762729645, 0.04997379332780838, 0.040154676884412766, 0.036669205874204636, 0.04534867778420448, 0.04472929611802101, 0.04957885667681694, 0.03268388286232948, 0.03378675505518913, 0.02706749550998211, 0.03786236420273781, 0.03340185061097145, 0.025586485862731934, 0.02327282913029194, 0.03562163561582565, 0.03119075857102871, 0.09267950057983398, 0.06386680901050568, 0.07139261811971664, 0.0513080358505249, 0.021282123401761055, 0.021809540688991547, 0.030264075845479965, 0.0368010476231575, 0.03420218825340271, 0.021780049428343773, 0.04089653119444847, 0.039614178240299225, 0.020345455035567284, 0.027965374290943146, 0.027327418327331543, 0.026992328464984894, 0.04479207843542099, 0.022039365023374557, 0.0391119159758091, 0.03505513444542885, 0.023954370990395546, 0.03762785717844963, 0.023333633318543434, 0.023235956206917763, 0.024822602048516273, 0.021685641258955002, 0.048085298389196396, 0.033013563603162766, -1]}
{"idB": "1006281_18_item1_p113_s0", "idA": "1006281_17_item1_p105_s0", "sentA": "We held a patent family containing three issued patents in South Africa, Australia and Israel, and one pending patent application relating to a new method for delivering active recombinant proteins systemically through oral administration of transgenic plant cells.", "sentB": "We held a patent family containing four issued patents in Europe, South Africa, Australia and Israel, and one pending patent application relating to a new method for delivering active recombinant proteins systemically through oral administration of transgenic plant cells.", "type": 2, "words": ["<tag1>", "We", "held", "a", "patent", "family", "containing", "three", "issued", "patents", "in", "South", "Africa,", "Australia", "and", "Israel,", "and", "one", "pending", "patent", "application", "relating", "to", "a", "new", "method", "for", "delivering", "active", "recombinant", "proteins", "systemically", "through", "oral", "administration", "of", "transgenic", "plant", "cells.", "<tag2>", "We", "held", "a", "patent", "family", "containing", "four", "issued", "patents", "in", "Europe,", "South", "Africa,", "Australia", "and", "Israel,", "and", "one", "pending", "patent", "application", "relating", "to", "a", "new", "method", "for", "delivering", "active", "recombinant", "proteins", "systemically", "through", "oral", "administration", "of", "transgenic", "plant", "cells.", "<tag3>"], "wordsA": ["We", "held", "a", "patent", "family", "containing", "three", "issued", "patents", "in", "South", "Africa,", "Australia", "and", "Israel,", "and", "one", "pending", "patent", "application", "relating", "to", "a", "new", "method", "for", "delivering", "active", "recombinant", "proteins", "systemically", "through", "oral", "administration", "of", "transgenic", "plant", "cells."], "wordsB": ["We", "held", "a", "patent", "family", "containing", "four", "issued", "patents", "in", "Europe,", "South", "Africa,", "Australia", "and", "Israel,", "and", "one", "pending", "patent", "application", "relating", "to", "a", "new", "method", "for", "delivering", "active", "recombinant", "proteins", "systemically", "through", "oral", "administration", "of", "transgenic", "plant", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.003357846522703767, 0.004734212066978216, 0.0025523980148136616, 0.011497490108013153, 0.00785178691148758, 0.009647892788052559, 0.7648884654045105, 0.17539004981517792, 0.2813742458820343, 0.002479397691786289, 0.01217743568122387, 0.0036995853297412395, 0.004350149072706699, 0.004293971695005894, 0.003941826056689024, 0.003984122071415186, 0.0046124826185405254, 0.0035371347330510616, 0.003231070004403591, 0.004325482994318008, 0.0033557808492332697, 0.0033851503394544125, 0.004162502940744162, 0.002933408599346876, 0.0025188447907567024, 0.002504338277503848, 0.0027054634410887957, 0.0030297343619167805, 0.003035150468349457, 0.006134797353297472, 0.02321733348071575, 0.0029627217445522547, 0.003020195523276925, 0.003491494571790099, 0.0032238569110631943, 0.003120696870610118, 0.003387065138667822, 0.0030797210056334734, 0.0030414850916713476, -1]}
{"idB": "1006281_18_item1_p114_s0", "idA": "1006281_17_item1_p106_s0", "sentA": "We held a patent family containing three granted patents in the United States, South Africa and Australia, and two pending patent applications relating to saccharide containing protein conjugates.", "sentB": "We held a patent family containing five granted patents in the United States, Europe, South Africa, Israel and Australia, relating to saccharide containing protein conjugates.", "type": 2, "words": ["<tag1>", "We", "held", "a", "patent", "family", "containing", "three", "granted", "patents", "in", "the", "United", "States,", "South", "Africa", "and", "Australia,", "and", "two", "pending", "patent", "applications", "relating", "to", "saccharide", "containing", "protein", "conjugates.", "<tag2>", "We", "held", "a", "patent", "family", "containing", "five", "granted", "patents", "in", "the", "United", "States,", "Europe,", "South", "Africa,", "Israel", "and", "Australia,", "relating", "to", "saccharide", "containing", "protein", "conjugates.", "<tag3>"], "wordsA": ["We", "held", "a", "patent", "family", "containing", "three", "granted", "patents", "in", "the", "United", "States,", "South", "Africa", "and", "Australia,", "and", "two", "pending", "patent", "applications", "relating", "to", "saccharide", "containing", "protein", "conjugates."], "wordsB": ["We", "held", "a", "patent", "family", "containing", "five", "granted", "patents", "in", "the", "United", "States,", "Europe,", "South", "Africa,", "Israel", "and", "Australia,", "relating", "to", "saccharide", "containing", "protein", "conjugates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0027225357480347157, 0.007860521785914898, 0.0017554698279127479, 0.01593932695686817, 0.01346674282103777, 0.04183783009648323, 0.9244112968444824, 0.09553215652704239, 0.1249430850148201, 0.0017260874155908823, 0.0016872460255399346, 0.003999204840511084, 0.006150461733341217, 0.006452750880271196, 0.004890925716608763, 0.006977833807468414, 0.012661526910960674, 0.005129748955368996, 0.008558055385947227, 0.0019449560204520822, 0.0016730033094063401, 0.0023542807903140783, 0.0017831568839028478, 0.001894626533612609, 0.0020987677853554487, -1]}
{"idB": "1006281_18_item1_p115_s0", "idA": "1006281_17_item1_p107_s0", "sentA": "We held a patent family containing one granted patent in Japan and eight pending patent applications relating to Nucleic Acid construct for expression of alpha-galactosidase enzyme in plants and plant cells.", "sentB": "We held a patent family containing four granted patents in Japan, United States, Europe and China, and six pending patent applications relating to Nucleic Acid construct for expression of alpha-galactosidase enzyme in plants and plant cells.", "type": 2, "words": ["<tag1>", "We", "held", "a", "patent", "family", "containing", "one", "granted", "patent", "in", "Japan", "and", "eight", "pending", "patent", "applications", "relating", "to", "Nucleic", "Acid", "construct", "for", "expression", "of", "alpha-galactosidase", "enzyme", "in", "plants", "and", "plant", "cells.", "<tag2>", "We", "held", "a", "patent", "family", "containing", "four", "granted", "patents", "in", "Japan,", "United", "States,", "Europe", "and", "China,", "and", "six", "pending", "patent", "applications", "relating", "to", "Nucleic", "Acid", "construct", "for", "expression", "of", "alpha-galactosidase", "enzyme", "in", "plants", "and", "plant", "cells.", "<tag3>"], "wordsA": ["We", "held", "a", "patent", "family", "containing", "one", "granted", "patent", "in", "Japan", "and", "eight", "pending", "patent", "applications", "relating", "to", "Nucleic", "Acid", "construct", "for", "expression", "of", "alpha-galactosidase", "enzyme", "in", "plants", "and", "plant", "cells."], "wordsB": ["We", "held", "a", "patent", "family", "containing", "four", "granted", "patents", "in", "Japan,", "United", "States,", "Europe", "and", "China,", "and", "six", "pending", "patent", "applications", "relating", "to", "Nucleic", "Acid", "construct", "for", "expression", "of", "alpha-galactosidase", "enzyme", "in", "plants", "and", "plant", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004483757074922323, 0.0073127783834934235, 0.0033617124427109957, 0.02546044997870922, 0.013882657513022423, 0.026890795677900314, 0.808986246585846, 0.06374481320381165, 0.09149165451526642, 0.002474771812558174, 0.009060104377567768, 0.00815123226493597, 0.008200054056942463, 0.004637666512280703, 0.003962883725762367, 0.0062433769926428795, 0.004912855569273233, 0.6242391467094421, 0.014455092139542103, 0.035426173359155655, 0.008997820317745209, 0.002562430454418063, 0.00257394858635962, 0.003397170687094331, 0.0032677333801984787, 0.0035350413527339697, 0.0021699240896850824, 0.003365265903994441, 0.0027156465221196413, 0.006662311032414436, 0.003307945095002651, 0.0019681761041283607, 0.002427760511636734, 0.0023016033228486776, 0.0027580501046031713, 0.002860714914277196, -1]}
{"idB": "1006281_18_item1_p14_s0", "idA": "1006281_17_item1_p10_s0", "sentA": "PRX-102 for the Treatment of Fabry disease .", "sentB": "Pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease .", "type": 2, "words": ["<tag1>", "PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", ".", "<tag2>", "Pegunigalsidase", "alfa", "(PRX-102)", "for", "the", "Treatment", "of", "Fabry", "Disease", ".", "<tag3>"], "wordsA": ["PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", "."], "wordsB": ["Pegunigalsidase", "alfa", "(PRX-102)", "for", "the", "Treatment", "of", "Fabry", "Disease", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.9717065095901489, 0.6928180456161499, 0.03621704503893852, 0.002620716579258442, 0.002101434161886573, 0.009405220858752728, 0.0025480312760919333, 0.005240290425717831, 0.004821441601961851, 3.422884037718177e-05, -1]}
{"idB": "1006281_18_item1_p4_s0", "idA": "1006281_17_item1_p10_s0", "sentA": "PRX-102 for the Treatment of Fabry disease .", "sentB": "In December 2017, the European Commission granted Orphan Drug Designation for pegunigalsidase alfa for the treatment of Fabry disease.", "type": 2, "words": ["<tag1>", "PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", ".", "<tag2>", "In", "December", "2017,", "the", "European", "Commission", "granted", "Orphan", "Drug", "Designation", "for", "pegunigalsidase", "alfa", "for", "the", "treatment", "of", "Fabry", "disease.", "<tag3>"], "wordsA": ["PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", "."], "wordsB": ["In", "December", "2017,", "the", "European", "Commission", "granted", "Orphan", "Drug", "Designation", "for", "pegunigalsidase", "alfa", "for", "the", "treatment", "of", "Fabry", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0216008760035038, 0.056052111089229584, 0.07981033623218536, 0.014795323833823204, 0.052237752825021744, 0.10337873548269272, 0.07414048910140991, 0.16001376509666443, 0.19920983910560608, 0.15697167813777924, 0.04375015199184418, 0.3877137005329132, 0.1657782644033432, 0.004203966353088617, 0.003831719048321247, 0.006618928164243698, 0.0035004783421754837, 0.007001530844718218, 0.005838139448314905, -1]}
{"idB": "1006281_18_item1_p68_s5", "idA": "1006281_17_item1_p10_s0", "sentA": "PRX-102 for the Treatment of Fabry disease .", "sentB": "These results provide strong rationale for the clinical evaluation of a once-monthly dosing.", "type": 2, "words": ["<tag1>", "PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", ".", "<tag2>", "These", "results", "provide", "strong", "rationale", "for", "the", "clinical", "evaluation", "of", "a", "once-monthly", "dosing.", "<tag3>"], "wordsA": ["PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", "."], "wordsB": ["These", "results", "provide", "strong", "rationale", "for", "the", "clinical", "evaluation", "of", "a", "once-monthly", "dosing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.02359311282634735, 0.060337044298648834, 0.04308440908789635, 0.051655206829309464, 0.07902374863624573, 0.0082449521869421, 0.00729353679344058, 0.05049290508031845, 0.06040126085281372, 0.023201677948236465, 0.03168017417192459, 0.5612823963165283, 0.5401859879493713, -1]}
{"idB": "1006281_18_item1_p14_s1", "idA": "1006281_17_item1_p10_s1", "sentA": "PRX-102 , or alpha-GAL-A, is designed to be an improved enzyme replacement therapy product for the treatment of Fabry disease given its potential for clinically superior outcomes and enhanced safety when compared to currently marketed enzyme replacement therapies.", "sentB": "pegunigalsidase alfa, or PRX-102 , is designed to be an improved enzyme replacement therapy product for the treatment of Fabry disease given its potential for clinically superior outcomes and enhanced safety when compared to currently marketed enzyme replacement therapies.", "type": 2, "words": ["<tag1>", "PRX-102", ",", "or", "alpha-GAL-A,", "is", "designed", "to", "be", "an", "improved", "enzyme", "replacement", "therapy", "product", "for", "the", "treatment", "of", "Fabry", "disease", "given", "its", "potential", "for", "clinically", "superior", "outcomes", "and", "enhanced", "safety", "when", "compared", "to", "currently", "marketed", "enzyme", "replacement", "therapies.", "<tag2>", "pegunigalsidase", "alfa,", "or", "PRX-102", ",", "is", "designed", "to", "be", "an", "improved", "enzyme", "replacement", "therapy", "product", "for", "the", "treatment", "of", "Fabry", "disease", "given", "its", "potential", "for", "clinically", "superior", "outcomes", "and", "enhanced", "safety", "when", "compared", "to", "currently", "marketed", "enzyme", "replacement", "therapies.", "<tag3>"], "wordsA": ["PRX-102", ",", "or", "alpha-GAL-A,", "is", "designed", "to", "be", "an", "improved", "enzyme", "replacement", "therapy", "product", "for", "the", "treatment", "of", "Fabry", "disease", "given", "its", "potential", "for", "clinically", "superior", "outcomes", "and", "enhanced", "safety", "when", "compared", "to", "currently", "marketed", "enzyme", "replacement", "therapies."], "wordsB": ["pegunigalsidase", "alfa,", "or", "PRX-102", ",", "is", "designed", "to", "be", "an", "improved", "enzyme", "replacement", "therapy", "product", "for", "the", "treatment", "of", "Fabry", "disease", "given", "its", "potential", "for", "clinically", "superior", "outcomes", "and", "enhanced", "safety", "when", "compared", "to", "currently", "marketed", "enzyme", "replacement", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.9164283871650696, 0.912617027759552, 0.0021865644957870245, 0.0027424348518252373, 8.632396929897368e-05, 0.0025600160006433725, 0.0024123014882206917, 0.0019083641236647964, 0.0017399248899891973, 0.001634395681321621, 0.002667342545464635, 0.0031319716945290565, 0.002524558687582612, 0.0028748083859682083, 0.003558553522452712, 0.0014415287878364325, 0.0016625472344458103, 0.0028544594533741474, 0.0016294687520712614, 0.0029851964209228754, 0.0023110085166990757, 0.0019263147842139006, 0.0017646485939621925, 0.001939697191119194, 0.0018633999861776829, 0.0021483462769538164, 0.0021979401353746653, 0.0018800459802150726, 0.002596275880932808, 0.0020524831488728523, 0.0019996757619082928, 0.00162803428247571, 0.001847245846875012, 0.001442698878236115, 0.001759756705723703, 0.001968440366908908, 0.002069026231765747, 0.0022050754632800817, 0.00247783656232059, -1]}
{"idB": "1006281_18_item1_p14_s3", "idA": "1006281_17_item1_p10_s3", "sentA": "We enrolled our first patient in a phase III clinical trial of PRX-102 in the fourth quarter of 2016, and our phase I/II clinical trial is ongoing in an extension period .", "sentB": "We are continuing to enroll patients and recruit clinical sites for our phase III clinical trials of PRX-102, and our phase I/II clinical trial remains ongoing in an extension period .", "type": 2, "words": ["<tag1>", "We", "enrolled", "our", "first", "patient", "in", "a", "phase", "III", "clinical", "trial", "of", "PRX-102", "in", "the", "fourth", "quarter", "of", "2016,", "and", "our", "phase", "I/II", "clinical", "trial", "is", "ongoing", "in", "an", "extension", "period", ".", "<tag2>", "We", "are", "continuing", "to", "enroll", "patients", "and", "recruit", "clinical", "sites", "for", "our", "phase", "III", "clinical", "trials", "of", "PRX-102,", "and", "our", "phase", "I/II", "clinical", "trial", "remains", "ongoing", "in", "an", "extension", "period", ".", "<tag3>"], "wordsA": ["We", "enrolled", "our", "first", "patient", "in", "a", "phase", "III", "clinical", "trial", "of", "PRX-102", "in", "the", "fourth", "quarter", "of", "2016,", "and", "our", "phase", "I/II", "clinical", "trial", "is", "ongoing", "in", "an", "extension", "period", "."], "wordsB": ["We", "are", "continuing", "to", "enroll", "patients", "and", "recruit", "clinical", "sites", "for", "our", "phase", "III", "clinical", "trials", "of", "PRX-102,", "and", "our", "phase", "I/II", "clinical", "trial", "remains", "ongoing", "in", "an", "extension", "period", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.025610165670514107, 0.012200647033751011, 0.34816277027130127, 0.12739461660385132, 0.29708290100097656, 0.2772541046142578, 0.028004614636301994, 0.35056865215301514, 0.352783739566803, 0.347561240196228, 0.006631126627326012, 0.005257085431367159, 0.014018961228430271, 0.008871158584952354, 0.012476819567382336, 0.016960375010967255, 0.002366991713643074, 0.00982128269970417, 0.0002351838193135336, 0.0025568935088813305, 0.006661004386842251, 0.005128748249262571, 0.008186089806258678, 0.015711583197116852, 0.07653720676898956, 0.07261063158512115, 0.0032863456290215254, 0.003212029580026865, 0.00891683530062437, 0.007887568324804306, 4.996853749617003e-05, -1]}
{"idB": "1006281_18_item1_p68_s2", "idA": "1006281_17_item1_p10_s3", "sentA": "We enrolled our first patient in a phase III clinical trial of PRX-102 in the fourth quarter of 2016, and our phase I/II clinical trial is ongoing in an extension period .", "sentB": "Additionally, in our phase I/II clinical trial, 2 mg/kg of PRX-102 demonstrated approximately a 40 times higher circulatory half-life compared with other enzyme replacement therapies, and, as demonstrated in a Fabry mice model, with materially higher active enzyme reaching target organs affected by Fabry disease.", "type": 2, "words": ["<tag1>", "We", "enrolled", "our", "first", "patient", "in", "a", "phase", "III", "clinical", "trial", "of", "PRX-102", "in", "the", "fourth", "quarter", "of", "2016,", "and", "our", "phase", "I/II", "clinical", "trial", "is", "ongoing", "in", "an", "extension", "period", ".", "<tag2>", "Additionally,", "in", "our", "phase", "I/II", "clinical", "trial,", "2", "mg/kg", "of", "PRX-102", "demonstrated", "approximately", "a", "40", "times", "higher", "circulatory", "half-life", "compared", "with", "other", "enzyme", "replacement", "therapies,", "and,", "as", "demonstrated", "in", "a", "Fabry", "mice", "model,", "with", "materially", "higher", "active", "enzyme", "reaching", "target", "organs", "affected", "by", "Fabry", "disease.", "<tag3>"], "wordsA": ["We", "enrolled", "our", "first", "patient", "in", "a", "phase", "III", "clinical", "trial", "of", "PRX-102", "in", "the", "fourth", "quarter", "of", "2016,", "and", "our", "phase", "I/II", "clinical", "trial", "is", "ongoing", "in", "an", "extension", "period", "."], "wordsB": ["Additionally,", "in", "our", "phase", "I/II", "clinical", "trial,", "2", "mg/kg", "of", "PRX-102", "demonstrated", "approximately", "a", "40", "times", "higher", "circulatory", "half-life", "compared", "with", "other", "enzyme", "replacement", "therapies,", "and,", "as", "demonstrated", "in", "a", "Fabry", "mice", "model,", "with", "materially", "higher", "active", "enzyme", "reaching", "target", "organs", "affected", "by", "Fabry", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01101662963628769, 0.007193399593234062, 0.006405360531061888, 0.014430372975766659, 0.008119453676044941, 0.017253560945391655, 0.03202582523226738, 0.49309954047203064, 0.4196934998035431, 0.04139259085059166, 0.031206225976347923, 0.11204775422811508, 0.053530678153038025, 0.023412838578224182, 0.18221844732761383, 0.15545333921909332, 0.2211015671491623, 0.336995929479599, 0.41148239374160767, 0.01911752112209797, 0.011209403164684772, 0.01074704434722662, 0.07596436887979507, 0.07696206122636795, 0.06198612600564957, 0.00034181572846136987, 0.0048943920992314816, 0.012264937162399292, 0.005370624829083681, 0.006535737309604883, 0.11119814962148666, 0.1141083613038063, 0.09525851905345917, 0.005663929507136345, 0.10590891540050507, 0.2015274316072464, 0.24044500291347504, 0.2916262447834015, 0.13172034919261932, 0.15331675112247467, 0.15422914922237396, 0.019435325637459755, 0.00830923393368721, 0.022660458460450172, 0.03902094438672066, -1]}
{"idB": "1006281_18_item1_p68_s4", "idA": "1006281_17_item1_p10_s3", "sentA": "We enrolled our first patient in a phase III clinical trial of PRX-102 in the fourth quarter of 2016, and our phase I/II clinical trial is ongoing in an extension period .", "sentB": "Moreover, the amount of PRX-102 in the circulation at weeks three and four, are higher than those of Fabrazyme during the two-week treatments.", "type": 2, "words": ["<tag1>", "We", "enrolled", "our", "first", "patient", "in", "a", "phase", "III", "clinical", "trial", "of", "PRX-102", "in", "the", "fourth", "quarter", "of", "2016,", "and", "our", "phase", "I/II", "clinical", "trial", "is", "ongoing", "in", "an", "extension", "period", ".", "<tag2>", "Moreover,", "the", "amount", "of", "PRX-102", "in", "the", "circulation", "at", "weeks", "three", "and", "four,", "are", "higher", "than", "those", "of", "Fabrazyme", "during", "the", "two-week", "treatments.", "<tag3>"], "wordsA": ["We", "enrolled", "our", "first", "patient", "in", "a", "phase", "III", "clinical", "trial", "of", "PRX-102", "in", "the", "fourth", "quarter", "of", "2016,", "and", "our", "phase", "I/II", "clinical", "trial", "is", "ongoing", "in", "an", "extension", "period", "."], "wordsB": ["Moreover,", "the", "amount", "of", "PRX-102", "in", "the", "circulation", "at", "weeks", "three", "and", "four,", "are", "higher", "than", "those", "of", "Fabrazyme", "during", "the", "two-week", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.015462803654372692, 0.02255961298942566, 0.21434053778648376, 0.1583179086446762, 0.17663270235061646, 0.24131634831428528, 0.13288062810897827, 0.257112979888916, 0.02413490228354931, 0.09742338955402374, 0.3123212456703186, 0.21083033084869385, 0.3065539598464966, 0.04498835653066635, 0.29197096824645996, 0.11062703281641006, 0.08555658161640167, 0.0764818787574768, 0.19319498538970947, 0.01751743257045746, 0.011041033081710339, 0.27432355284690857, 0.14354632794857025, -1]}
{"idB": "1006281_18_item1_p117_s0", "idA": "1006281_17_item1_p110_s0", "sentA": "We held three patent families containing eight pending applications relating to plant recombinant human DNase I and uses in therapy.", "sentB": "We held three patent families containing two granted patents in the United States and six pending applications relating to plant recombinant human DNase I and uses in therapy.", "type": 2, "words": ["<tag1>", "We", "held", "three", "patent", "families", "containing", "eight", "pending", "applications", "relating", "to", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy.", "<tag2>", "We", "held", "three", "patent", "families", "containing", "two", "granted", "patents", "in", "the", "United", "States", "and", "six", "pending", "applications", "relating", "to", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy.", "<tag3>"], "wordsA": ["We", "held", "three", "patent", "families", "containing", "eight", "pending", "applications", "relating", "to", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy."], "wordsB": ["We", "held", "three", "patent", "families", "containing", "two", "granted", "patents", "in", "the", "United", "States", "and", "six", "pending", "applications", "relating", "to", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0032923545222729445, 0.005696420092135668, 0.0067167445085942745, 0.01047424040734768, 0.0058298842050135136, 0.01033756323158741, 0.7297114133834839, 0.4686492681503296, 0.3894581198692322, 0.003739326260983944, 0.003721549641340971, 0.006335997022688389, 0.01029058825224638, 0.004726060666143894, 0.7292677760124207, 0.1085137352347374, 0.1219576895236969, 0.0020407983101904392, 0.0017891174647957087, 0.0019238601671531796, 0.0022061311174184084, 0.0018682560184970498, 0.0021252240985631943, 0.0016078775515779853, 0.0018435217207297683, 0.0017850990407168865, 0.0016731003997847438, 0.002067425986751914, -1]}
{"idB": "1006281_18_item1_p118_s0", "idA": "1006281_17_item1_p111_s0", "sentA": "We held a PCT application relating to chemically modified plant recombinant human DNase I and uses in therapy.", "sentB": "We held a a patent family containing 11 patent applications relating to chemically modified plant recombinant human DNase I and uses in therapy.", "type": 2, "words": ["<tag1>", "We", "held", "a", "PCT", "application", "relating", "to", "chemically", "modified", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy.", "<tag2>", "We", "held", "a", "a", "patent", "family", "containing", "11", "patent", "applications", "relating", "to", "chemically", "modified", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy.", "<tag3>"], "wordsA": ["We", "held", "a", "PCT", "application", "relating", "to", "chemically", "modified", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy."], "wordsB": ["We", "held", "a", "a", "patent", "family", "containing", "11", "patent", "applications", "relating", "to", "chemically", "modified", "plant", "recombinant", "human", "DNase", "I", "and", "uses", "in", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.008708221837878227, 0.03417454659938812, 0.008909733034670353, 0.012365473434329033, 0.5632084012031555, 0.2574431896209717, 0.010115684941411018, 0.26764729619026184, 0.5925769209861755, 0.303090900182724, 0.00500569399446249, 0.003925274591892958, 0.005536364391446114, 0.004827274475246668, 0.0038567299488931894, 0.00482976296916604, 0.003780046943575144, 0.004833582788705826, 0.0033745653927326202, 0.0041144541464746, 0.002905883826315403, 0.0026187270414084196, 0.0034918298479169607, -1]}
{"idB": "1006281_18_item1_p52_s0", "idA": "1006281_17_item1_p115_s0", "sentA": "We have licensed the rights to a United States patent application covering oral composition comprising a TNF antagonist.", "sentB": "We have licensed to Pfizer the worldwide rights to Elelyso with the exception of Brazil, a market where we have retained own full rights.", "type": 2, "words": ["<tag1>", "We", "have", "licensed", "the", "rights", "to", "a", "United", "States", "patent", "application", "covering", "oral", "composition", "comprising", "a", "TNF", "antagonist.", "<tag2>", "We", "have", "licensed", "to", "Pfizer", "the", "worldwide", "rights", "to", "Elelyso", "with", "the", "exception", "of", "Brazil,", "a", "market", "where", "we", "have", "retained", "own", "full", "rights.", "<tag3>"], "wordsA": ["We", "have", "licensed", "the", "rights", "to", "a", "United", "States", "patent", "application", "covering", "oral", "composition", "comprising", "a", "TNF", "antagonist."], "wordsB": ["We", "have", "licensed", "to", "Pfizer", "the", "worldwide", "rights", "to", "Elelyso", "with", "the", "exception", "of", "Brazil,", "a", "market", "where", "we", "have", "retained", "own", "full", "rights."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.013089757412672043, 0.00711003877222538, 0.10693397372961044, 0.07533693313598633, 0.5421493053436279, 0.039320576936006546, 0.32976827025413513, 0.2014094591140747, 0.09274376928806305, 0.3664371073246002, 0.00016003577911760658, 0.00026514733326621354, 0.03368087485432625, 0.026073388755321503, 0.18083372712135315, 9.591372509021312e-05, 0.05920148640871048, 0.0024120407178997993, 0.010648079216480255, 0.013894413597881794, 0.06052588298916817, 0.0916302502155304, 0.17217421531677246, 0.1744413673877716, -1]}
{"idB": "1006281_18_item1_p101_s0", "idA": "1006281_17_item1_p117_s0", "sentA": "In April 2005, Protalix Ltd. entered into a license agreement with Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize Icon s technology to express certain proteins in our ProCellEx protein expression system.", "sentB": "On October 19, 2017, Protalix Ltd. and Chiesi entered into the Chiesi Agreement pursuant to which Chiesi was granted an exclusive, license for all markets outside of the United States to develop and commercialize pegunigalsidase alfa.", "type": 2, "words": ["<tag1>", "In", "April", "2005,", "Protalix", "Ltd.", "entered", "into", "a", "license", "agreement", "with", "Icon", "Genetics", "AG,", "or", "Icon,", "pursuant", "to", "which", "we", "received", "an", "exclusive", "worldwide", "license", "to", "develop,", "test,", "use", "and", "commercialize", "Icon", "s", "technology", "to", "express", "certain", "proteins", "in", "our", "ProCellEx", "protein", "expression", "system.", "<tag2>", "On", "October", "19,", "2017,", "Protalix", "Ltd.", "and", "Chiesi", "entered", "into", "the", "Chiesi", "Agreement", "pursuant", "to", "which", "Chiesi", "was", "granted", "an", "exclusive,", "license", "for", "all", "markets", "outside", "of", "the", "United", "States", "to", "develop", "and", "commercialize", "pegunigalsidase", "alfa.", "<tag3>"], "wordsA": ["In", "April", "2005,", "Protalix", "Ltd.", "entered", "into", "a", "license", "agreement", "with", "Icon", "Genetics", "AG,", "or", "Icon,", "pursuant", "to", "which", "we", "received", "an", "exclusive", "worldwide", "license", "to", "develop,", "test,", "use", "and", "commercialize", "Icon", "s", "technology", "to", "express", "certain", "proteins", "in", "our", "ProCellEx", "protein", "expression", "system."], "wordsB": ["On", "October", "19,", "2017,", "Protalix", "Ltd.", "and", "Chiesi", "entered", "into", "the", "Chiesi", "Agreement", "pursuant", "to", "which", "Chiesi", "was", "granted", "an", "exclusive,", "license", "for", "all", "markets", "outside", "of", "the", "United", "States", "to", "develop", "and", "commercialize", "pegunigalsidase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.028986331075429916, 0.4058402478694916, 0.31944024562835693, 0.8075886368751526, 0.02113240957260132, 0.023268142715096474, 0.025138389319181442, 0.19570258259773254, 0.01641714572906494, 0.010998628102242947, 0.009792592376470566, 0.10357331484556198, 0.0574544295668602, 0.0058316695503890514, 0.0031907521188259125, 0.002465328900143504, 0.039368122816085815, 0.006465465296059847, 0.025355875492095947, 0.006588498130440712, 0.01831141486763954, 0.02382679656147957, 0.008458302356302738, 0.09448394179344177, 0.10944393277168274, 0.15730656683444977, 0.08442743867635727, 0.06663315743207932, 0.10299129039049149, 0.15380847454071045, 0.00944431684911251, 0.06013365089893341, 0.016656603664159775, 0.06783974170684814, 0.5305256843566895, 0.384413480758667, -1]}
{"idB": "1006281_18_item1_p101_s3", "idA": "1006281_17_item1_p117_s3", "sentA": "In addition, we are obligated to make milestone payments equal to $350,000, in the aggregate, for each product developed under the license, upon the achievement of certain milestones.", "sentB": "Protalix Ltd. is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "obligated", "to", "make", "milestone", "payments", "equal", "to", "$350,000,", "in", "the", "aggregate,", "for", "each", "product", "developed", "under", "the", "license,", "upon", "the", "achievement", "of", "certain", "milestones.", "<tag2>", "Protalix", "Ltd.", "is", "also", "eligible", "to", "receive", "an", "additional", "up", "to", "$320", "million,", "in", "the", "aggregate,", "in", "regulatory", "and", "commercial", "milestone", "payments.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "obligated", "to", "make", "milestone", "payments", "equal", "to", "$350,000,", "in", "the", "aggregate,", "for", "each", "product", "developed", "under", "the", "license,", "upon", "the", "achievement", "of", "certain", "milestones."], "wordsB": ["Protalix", "Ltd.", "is", "also", "eligible", "to", "receive", "an", "additional", "up", "to", "$320", "million,", "in", "the", "aggregate,", "in", "regulatory", "and", "commercial", "milestone", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.39595356583595276, 0.1114211231470108, 0.023953668773174286, 0.019508924335241318, 0.13926011323928833, 0.02995692379772663, 0.06758066266775131, 0.024342797696590424, 0.05287747085094452, 0.0992601290345192, 0.04231556877493858, 0.762466549873352, 0.628101110458374, 0.0043033454567193985, 0.0052689979784190655, 0.012474706396460533, 0.004709054250270128, 0.04514715448021889, 0.03260069340467453, 0.0690101906657219, 0.0894026830792427, 0.039685603231191635, -1]}
{"idB": "1006281_18_item1_p3_s3", "idA": "1006281_17_item1_p117_s3", "sentA": "In addition, we are obligated to make milestone payments equal to $350,000, in the aggregate, for each product developed under the license, upon the achievement of certain milestones.", "sentB": "Protalix Ltd. is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "obligated", "to", "make", "milestone", "payments", "equal", "to", "$350,000,", "in", "the", "aggregate,", "for", "each", "product", "developed", "under", "the", "license,", "upon", "the", "achievement", "of", "certain", "milestones.", "<tag2>", "Protalix", "Ltd.", "is", "also", "eligible", "to", "receive", "an", "additional", "up", "to", "$320", "million,", "in", "the", "aggregate,", "in", "regulatory", "and", "commercial", "milestone", "payments.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "obligated", "to", "make", "milestone", "payments", "equal", "to", "$350,000,", "in", "the", "aggregate,", "for", "each", "product", "developed", "under", "the", "license,", "upon", "the", "achievement", "of", "certain", "milestones."], "wordsB": ["Protalix", "Ltd.", "is", "also", "eligible", "to", "receive", "an", "additional", "up", "to", "$320", "million,", "in", "the", "aggregate,", "in", "regulatory", "and", "commercial", "milestone", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.39595356583595276, 0.1114211231470108, 0.023953668773174286, 0.019508924335241318, 0.13926011323928833, 0.02995692379772663, 0.06758066266775131, 0.024342797696590424, 0.05287747085094452, 0.0992601290345192, 0.04231556877493858, 0.762466549873352, 0.628101110458374, 0.0043033454567193985, 0.0052689979784190655, 0.012474706396460533, 0.004709054250270128, 0.04514715448021889, 0.03260069340467453, 0.0690101906657219, 0.0894026830792427, 0.039685603231191635, -1]}
{"idB": "1006281_18_item1_p101_s5", "idA": "1006281_17_item1_p119_s0", "sentA": "We are obligated to manufacture all of the taliglucerase alfa drug product needed under the Amended Pfizer Agreement, subject to certain terms and conditions.", "sentB": "Protalix Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions.", "type": 2, "words": ["<tag1>", "We", "are", "obligated", "to", "manufacture", "all", "of", "the", "taliglucerase", "alfa", "drug", "product", "needed", "under", "the", "Amended", "Pfizer", "Agreement,", "subject", "to", "certain", "terms", "and", "conditions.", "<tag2>", "Protalix", "Ltd.", "agreed", "to", "manufacture", "all", "of", "the", "PRX-102", "needed", "for", "all", "purposes", "under", "the", "agreement,", "subject", "to", "certain", "exceptions,", "and", "Chiesi", "will", "purchase", "pegunigalsidase", "alfa", "from", "Protalix,", "subject", "to", "certain", "terms", "and", "conditions.", "<tag3>"], "wordsA": ["We", "are", "obligated", "to", "manufacture", "all", "of", "the", "taliglucerase", "alfa", "drug", "product", "needed", "under", "the", "Amended", "Pfizer", "Agreement,", "subject", "to", "certain", "terms", "and", "conditions."], "wordsB": ["Protalix", "Ltd.", "agreed", "to", "manufacture", "all", "of", "the", "PRX-102", "needed", "for", "all", "purposes", "under", "the", "agreement,", "subject", "to", "certain", "exceptions,", "and", "Chiesi", "will", "purchase", "pegunigalsidase", "alfa", "from", "Protalix,", "subject", "to", "certain", "terms", "and", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.29171034693717957, 0.12996232509613037, 0.11389167606830597, 0.04463290050625801, 0.04423334822058678, 0.032313134521245956, 0.02881794609129429, 0.028008677065372467, 0.6489769816398621, 0.003951963037252426, 0.003806616645306349, 0.013549122959375381, 0.005158629268407822, 0.003104065777733922, 0.002584215486422181, 0.0096824886277318, 0.004476779140532017, 0.0031353856902569532, 0.008699113503098488, 0.01991763897240162, 0.0034715994261205196, 0.1833631992340088, 0.027189625427126884, 0.09285710006952286, 0.4959889352321625, 0.2759873867034912, 0.014676717109978199, 0.022859837859869003, 0.0033399593085050583, 8.64807516336441e-05, 0.0033992170356214046, 0.003279053373262286, 0.0024753508623689413, 0.003013080917298794, -1]}
{"idB": "1006281_18_item1_p3_s5", "idA": "1006281_17_item1_p119_s0", "sentA": "We are obligated to manufacture all of the taliglucerase alfa drug product needed under the Amended Pfizer Agreement, subject to certain terms and conditions.", "sentB": "Protalix Ltd. will manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions.", "type": 2, "words": ["<tag1>", "We", "are", "obligated", "to", "manufacture", "all", "of", "the", "taliglucerase", "alfa", "drug", "product", "needed", "under", "the", "Amended", "Pfizer", "Agreement,", "subject", "to", "certain", "terms", "and", "conditions.", "<tag2>", "Protalix", "Ltd.", "will", "manufacture", "all", "of", "the", "PRX-102", "needed", "for", "all", "purposes", "under", "the", "agreement,", "subject", "to", "certain", "exceptions,", "and", "Chiesi", "will", "purchase", "pegunigalsidase", "alfa", "from", "Protalix,", "subject", "to", "certain", "terms", "and", "conditions.", "<tag3>"], "wordsA": ["We", "are", "obligated", "to", "manufacture", "all", "of", "the", "taliglucerase", "alfa", "drug", "product", "needed", "under", "the", "Amended", "Pfizer", "Agreement,", "subject", "to", "certain", "terms", "and", "conditions."], "wordsB": ["Protalix", "Ltd.", "will", "manufacture", "all", "of", "the", "PRX-102", "needed", "for", "all", "purposes", "under", "the", "agreement,", "subject", "to", "certain", "exceptions,", "and", "Chiesi", "will", "purchase", "pegunigalsidase", "alfa", "from", "Protalix,", "subject", "to", "certain", "terms", "and", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.38030165433883667, 0.17086169123649597, 0.06829264760017395, 0.06910964846611023, 0.03923185542225838, 0.03403734415769577, 0.03205355256795883, 0.6056479811668396, 0.005251492839306593, 0.005031456705182791, 0.018612192943692207, 0.006750256288796663, 0.003818185068666935, 0.002985216211527586, 0.011102159507572651, 0.005383666139096022, 0.0035618215333670378, 0.012058043852448463, 0.0217653326690197, 0.005009842105209827, 0.21609434485435486, 0.03653093799948692, 0.11055593192577362, 0.5685858726501465, 0.3239341676235199, 0.014958000741899014, 0.024718791246414185, 0.003071048529818654, 8.021709800232202e-05, 0.003144277958199382, 0.0032071431633085012, 0.002574058948084712, 0.003111585509032011, -1]}
{"idB": "1006281_18_item1_p126_s1", "idA": "1006281_17_item1_p119_s1", "sentA": "Our drug product candidates, as well as taliglucerase alfa, must be manufactured in a sterile environment and in compliance with cGMPs set by the FDA and other relevant foreign regulatory authorities.", "sentB": "Pegunigalsidase alfa and our other drug product candidates, as well as taliglucerase alfa, must be manufactured in a sterile environment and in compliance with cGMPs set by the FDA and other relevant foreign regulatory authorities.", "type": 2, "words": ["<tag1>", "Our", "drug", "product", "candidates,", "as", "well", "as", "taliglucerase", "alfa,", "must", "be", "manufactured", "in", "a", "sterile", "environment", "and", "in", "compliance", "with", "cGMPs", "set", "by", "the", "FDA", "and", "other", "relevant", "foreign", "regulatory", "authorities.", "<tag2>", "Pegunigalsidase", "alfa", "and", "our", "other", "drug", "product", "candidates,", "as", "well", "as", "taliglucerase", "alfa,", "must", "be", "manufactured", "in", "a", "sterile", "environment", "and", "in", "compliance", "with", "cGMPs", "set", "by", "the", "FDA", "and", "other", "relevant", "foreign", "regulatory", "authorities.", "<tag3>"], "wordsA": ["Our", "drug", "product", "candidates,", "as", "well", "as", "taliglucerase", "alfa,", "must", "be", "manufactured", "in", "a", "sterile", "environment", "and", "in", "compliance", "with", "cGMPs", "set", "by", "the", "FDA", "and", "other", "relevant", "foreign", "regulatory", "authorities."], "wordsB": ["Pegunigalsidase", "alfa", "and", "our", "other", "drug", "product", "candidates,", "as", "well", "as", "taliglucerase", "alfa,", "must", "be", "manufactured", "in", "a", "sterile", "environment", "and", "in", "compliance", "with", "cGMPs", "set", "by", "the", "FDA", "and", "other", "relevant", "foreign", "regulatory", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.9478658437728882, 0.408993661403656, 0.004051089286804199, 0.0023805617820471525, 0.003005094127729535, 0.004433512222021818, 0.004804970696568489, 0.005889426916837692, 0.004264162387698889, 0.003029070096090436, 0.0036576702259480953, 0.004609935451298952, 0.004089664202183485, 0.002900589955970645, 0.002900761319324374, 0.0044065844267606735, 0.00278963940218091, 0.0028847833164036274, 0.004468505270779133, 0.0039032676722854376, 0.0008957632235251367, 0.0031705207657068968, 0.0036053310614079237, 0.003385608782991767, 0.0044892774894833565, 0.0028842089232057333, 0.002499905414879322, 0.0028625926934182644, 0.0031106891110539436, 0.00281810131855309, 0.0026483903639018536, 0.002949193585664034, 0.0031191601883620024, 0.0032702472526580095, 0.0034419402945786715, -1]}
{"idB": "1006281_18_item1_p126_s0", "idA": "1006281_17_item1_p119_s2", "sentA": "We use our current facility, which has approximately 20,000 sq/ft of clean rooms built according to industry standards, to develop, process and manufacture taliglucerase alfa and other recombinant proteins.", "sentB": "We use our current facility, which has approximately 20,000 sq/ft of clean rooms built according to industry standards, to develop, process and manufacture pegunigalsidase alfa, taliglucerase alfa and other recombinant proteins.", "type": 2, "words": ["<tag1>", "We", "use", "our", "current", "facility,", "which", "has", "approximately", "20,000", "sq/ft", "of", "clean", "rooms", "built", "according", "to", "industry", "standards,", "to", "develop,", "process", "and", "manufacture", "taliglucerase", "alfa", "and", "other", "recombinant", "proteins.", "<tag2>", "We", "use", "our", "current", "facility,", "which", "has", "approximately", "20,000", "sq/ft", "of", "clean", "rooms", "built", "according", "to", "industry", "standards,", "to", "develop,", "process", "and", "manufacture", "pegunigalsidase", "alfa,", "taliglucerase", "alfa", "and", "other", "recombinant", "proteins.", "<tag3>"], "wordsA": ["We", "use", "our", "current", "facility,", "which", "has", "approximately", "20,000", "sq/ft", "of", "clean", "rooms", "built", "according", "to", "industry", "standards,", "to", "develop,", "process", "and", "manufacture", "taliglucerase", "alfa", "and", "other", "recombinant", "proteins."], "wordsB": ["We", "use", "our", "current", "facility,", "which", "has", "approximately", "20,000", "sq/ft", "of", "clean", "rooms", "built", "according", "to", "industry", "standards,", "to", "develop,", "process", "and", "manufacture", "pegunigalsidase", "alfa,", "taliglucerase", "alfa", "and", "other", "recombinant", "proteins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004065949469804764, 0.006747794803231955, 0.003719350788742304, 0.005950287915766239, 0.010057171806693077, 0.006523917894810438, 0.00346368714235723, 0.004308346658945084, 0.0070896814577281475, 0.007325878366827965, 0.0044717369601130486, 0.005566553678363562, 0.00498710572719574, 0.0032650509383529425, 0.003623025957494974, 0.0036477267276495695, 0.0036902574356645346, 0.004210683051496744, 0.00295349326916039, 0.003942244686186314, 0.0042445422150194645, 0.0036973520182073116, 0.015454836189746857, 0.9887036681175232, 0.38718870282173157, 0.006182333920150995, 0.004226539749652147, 0.002750670537352562, 0.003074472304433584, 0.004914202261716127, 0.004689877852797508, -1]}
{"idB": "1006281_18_item1_p126_s2", "idA": "1006281_17_item1_p119_s3", "sentA": "We intend to use our current manufacturing space to produce all of the taliglucerase alfa we need in the near future, included the taliglucerase alfa to be purchased by Pfizer.", "sentB": "We are currently producing Fabry drug substance for our phase III and other clinical trials, as well as the manufacture of the taliglucerase alfa we need in the near future, included the taliglucerase alfa to be purchased by Pfizer under the Pfizer Agreement.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "use", "our", "current", "manufacturing", "space", "to", "produce", "all", "of", "the", "taliglucerase", "alfa", "we", "need", "in", "the", "near", "future,", "included", "the", "taliglucerase", "alfa", "to", "be", "purchased", "by", "Pfizer.", "<tag2>", "We", "are", "currently", "producing", "Fabry", "drug", "substance", "for", "our", "phase", "III", "and", "other", "clinical", "trials,", "as", "well", "as", "the", "manufacture", "of", "the", "taliglucerase", "alfa", "we", "need", "in", "the", "near", "future,", "included", "the", "taliglucerase", "alfa", "to", "be", "purchased", "by", "Pfizer", "under", "the", "Pfizer", "Agreement.", "<tag3>"], "wordsA": ["We", "intend", "to", "use", "our", "current", "manufacturing", "space", "to", "produce", "all", "of", "the", "taliglucerase", "alfa", "we", "need", "in", "the", "near", "future,", "included", "the", "taliglucerase", "alfa", "to", "be", "purchased", "by", "Pfizer."], "wordsB": ["We", "are", "currently", "producing", "Fabry", "drug", "substance", "for", "our", "phase", "III", "and", "other", "clinical", "trials,", "as", "well", "as", "the", "manufacture", "of", "the", "taliglucerase", "alfa", "we", "need", "in", "the", "near", "future,", "included", "the", "taliglucerase", "alfa", "to", "be", "purchased", "by", "Pfizer", "under", "the", "Pfizer", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0379096083343029, 0.009637483395636082, 0.01859276182949543, 0.22530712187290192, 0.6608882546424866, 0.5592048168182373, 0.4843025803565979, 0.005962809082120657, 0.005202875472605228, 0.01708340272307396, 0.016255348920822144, 0.005812289193272591, 0.006044133100658655, 0.019934188574552536, 0.02423664554953575, 0.0015749615849927068, 0.007642853539437056, 0.006205316632986069, 0.005186154972761869, 0.04863366484642029, 0.0073168775998055935, 0.007284848485141993, 0.028391951695084572, 0.029476776719093323, 0.005599719937890768, 0.006469319574534893, 0.0038449973799288273, 0.004833390470594168, 0.005934297107160091, 0.006317195948213339, 0.006735716015100479, 0.00699527096003294, 0.024732377380132675, 0.02907951921224594, 0.005422137677669525, 0.005451246630400419, 0.0247809961438179, 0.014899083413183689, 0.024788405746221542, 0.027907196432352066, 0.01669909618794918, 0.029170121997594833, 0.13011552393436432, -1]}
{"idB": "1006281_18_item1_p15_s0", "idA": "1006281_17_item1_p11_s0", "sentA": "alidornase alfa (PRX-110) for Cystic Fibrosis .", "sentB": "alidornase alfa (PRX-110) for the Treatment of Cystic Fibrosis .", "type": 2, "words": ["<tag1>", "alidornase", "alfa", "(PRX-110)", "for", "Cystic", "Fibrosis", ".", "<tag2>", "alidornase", "alfa", "(PRX-110)", "for", "the", "Treatment", "of", "Cystic", "Fibrosis", ".", "<tag3>"], "wordsA": ["alidornase", "alfa", "(PRX-110)", "for", "Cystic", "Fibrosis", "."], "wordsB": ["alidornase", "alfa", "(PRX-110)", "for", "the", "Treatment", "of", "Cystic", "Fibrosis", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 0.6151475310325623, 0.24675936996936798, 0.23933127522468567, 0.06322856992483139, 0.07631402462720871, 0.6276506781578064, 0.29132184386253357, 0.5611691474914551, 0.47851237654685974, 3.8171558117028326e-05, -1]}
{"idB": "1006281_18_item1_p15_s4", "idA": "1006281_17_item1_p11_s5", "sentA": "Upon review of the final results of the trial, we will consider different collaboration alternatives as part of our further development plans.", "sentB": "We are currently studying the final results of the trial and are considering different collaboration alternatives as part of our further development plans.", "type": 2, "words": ["<tag1>", "Upon", "review", "of", "the", "final", "results", "of", "the", "trial,", "we", "will", "consider", "different", "collaboration", "alternatives", "as", "part", "of", "our", "further", "development", "plans.", "<tag2>", "We", "are", "currently", "studying", "the", "final", "results", "of", "the", "trial", "and", "are", "considering", "different", "collaboration", "alternatives", "as", "part", "of", "our", "further", "development", "plans.", "<tag3>"], "wordsA": ["Upon", "review", "of", "the", "final", "results", "of", "the", "trial,", "we", "will", "consider", "different", "collaboration", "alternatives", "as", "part", "of", "our", "further", "development", "plans."], "wordsB": ["We", "are", "currently", "studying", "the", "final", "results", "of", "the", "trial", "and", "are", "considering", "different", "collaboration", "alternatives", "as", "part", "of", "our", "further", "development", "plans."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.06662473827600479, 0.05308009684085846, 0.2467830777168274, 0.8001957535743713, 0.09685999900102615, 0.07877131551504135, 0.09231220185756683, 0.011973750777542591, 0.017933260649442673, 0.042648740112781525, 0.0015595967415720224, 0.02159324288368225, 0.07784335315227509, 0.02373487502336502, 0.01956336572766304, 0.023088375106453896, 0.004330315627157688, 0.004365736618638039, 0.003337530419230461, 0.0035958178341388702, 0.003542217193171382, 0.005767444148659706, 0.006865744479000568, -1]}
{"idB": "1006281_18_item1_p127_s1", "idA": "1006281_17_item1_p120_s0", "sentA": "In addition, we are currently producing Fabry drug substance for our phase III clinical trial as part of the process of converting our current approved manufacturing facility to an approved multi-product facility, thereby introducing potentially significant operational savings.", "sentB": "We expect that the conversion will allow us to realize potentially significant operational savings.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "currently", "producing", "Fabry", "drug", "substance", "for", "our", "phase", "III", "clinical", "trial", "as", "part", "of", "the", "process", "of", "converting", "our", "current", "approved", "manufacturing", "facility", "to", "an", "approved", "multi-product", "facility,", "thereby", "introducing", "potentially", "significant", "operational", "savings.", "<tag2>", "We", "expect", "that", "the", "conversion", "will", "allow", "us", "to", "realize", "potentially", "significant", "operational", "savings.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "currently", "producing", "Fabry", "drug", "substance", "for", "our", "phase", "III", "clinical", "trial", "as", "part", "of", "the", "process", "of", "converting", "our", "current", "approved", "manufacturing", "facility", "to", "an", "approved", "multi-product", "facility,", "thereby", "introducing", "potentially", "significant", "operational", "savings."], "wordsB": ["We", "expect", "that", "the", "conversion", "will", "allow", "us", "to", "realize", "potentially", "significant", "operational", "savings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08322124183177948, 0.2714077830314636, 0.057995282113552094, 0.024312611669301987, 0.36145639419555664, 0.09950163960456848, 0.27106308937072754, 0.15018333494663239, 0.15000417828559875, 0.24559658765792847, 0.03773456811904907, 0.034021247178316116, 0.13599419593811035, 0.1798810064792633, -1]}
{"idB": "1006281_18_item1_p5_s0", "idA": "1006281_17_item1_p121_s0", "sentA": "O ur manufacturing facilities in Carmiel, Israel, have undergone successful audits by the Israeli MOH, the FDA, ANVISA, and the European Union under the European Union s centralized marketing authorization procedure, the Australian TGA and Health Canada .", "sentB": "Orphan Drug Designation for pegunigalsidase alfa qualifies Protalix Ltd. for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance.", "type": 2, "words": ["<tag1>", "O", "ur", "manufacturing", "facilities", "in", "Carmiel,", "Israel,", "have", "undergone", "successful", "audits", "by", "the", "Israeli", "MOH,", "the", "FDA,", "ANVISA,", "and", "the", "European", "Union", "under", "the", "European", "Union", "s", "centralized", "marketing", "authorization", "procedure,", "the", "Australian", "TGA", "and", "Health", "Canada", ".", "<tag2>", "Orphan", "Drug", "Designation", "for", "pegunigalsidase", "alfa", "qualifies", "Protalix", "Ltd.", "for", "access", "to", "a", "centralized", "marketing", "authorization", "procedure,", "including", "applications", "for", "inspections", "and", "for", "protocol", "assistance.", "<tag3>"], "wordsA": ["O", "ur", "manufacturing", "facilities", "in", "Carmiel,", "Israel,", "have", "undergone", "successful", "audits", "by", "the", "Israeli", "MOH,", "the", "FDA,", "ANVISA,", "and", "the", "European", "Union", "under", "the", "European", "Union", "s", "centralized", "marketing", "authorization", "procedure,", "the", "Australian", "TGA", "and", "Health", "Canada", "."], "wordsB": ["Orphan", "Drug", "Designation", "for", "pegunigalsidase", "alfa", "qualifies", "Protalix", "Ltd.", "for", "access", "to", "a", "centralized", "marketing", "authorization", "procedure,", "including", "applications", "for", "inspections", "and", "for", "protocol", "assistance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.5200349688529968, 0.49168315529823303, 0.2866378128528595, 0.04773182049393654, 0.2425190806388855, 0.09593359380960464, 0.10544729232788086, 0.19936633110046387, 0.15500186383724213, 0.03364360332489014, 0.04970605671405792, 0.01825525052845478, 0.007736592553555965, 0.021164190024137497, 0.03994661942124367, 0.03556766360998154, 0.046440478414297104, 0.00032819260377436876, 0.08787393569946289, 0.027853278443217278, 0.11349505931138992, 0.010465895757079124, 0.013390072621405125, 0.04735010117292404, 0.0579577274620533, -1]}
{"idB": "1006281_18_item1_p101_s1", "idA": "1006281_17_item1_p126_s1", "sentA": "Fabrazyme is available in the United States and the European Union.", "sentB": "Protalix Ltd. retained the right to commercialize pegunigalsidase alfa in the United States.", "type": 2, "words": ["<tag1>", "Fabrazyme", "is", "available", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "Protalix", "Ltd.", "retained", "the", "right", "to", "commercialize", "pegunigalsidase", "alfa", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Fabrazyme", "is", "available", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["Protalix", "Ltd.", "retained", "the", "right", "to", "commercialize", "pegunigalsidase", "alfa", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.7033326625823975, 0.28613999485969543, 0.10741589218378067, 0.04680469259619713, 0.11678988486528397, 0.07808475196361542, 0.16126789152622223, 0.3010084629058838, 0.1260245144367218, 0.006138700060546398, 0.0071082208305597305, 0.0265288595110178, 0.02490009367465973, -1]}
{"idB": "1006281_18_item1_p3_s1", "idA": "1006281_17_item1_p126_s1", "sentA": "Fabrazyme is available in the United States and the European Union.", "sentB": "Under the terms and conditions of the Chiesi Agreement, Protalix Ltd. retained the right to commercialize pegunigalsidase alfa in the United States.", "type": 2, "words": ["<tag1>", "Fabrazyme", "is", "available", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "Under", "the", "terms", "and", "conditions", "of", "the", "Chiesi", "Agreement,", "Protalix", "Ltd.", "retained", "the", "right", "to", "commercialize", "pegunigalsidase", "alfa", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Fabrazyme", "is", "available", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["Under", "the", "terms", "and", "conditions", "of", "the", "Chiesi", "Agreement,", "Protalix", "Ltd.", "retained", "the", "right", "to", "commercialize", "pegunigalsidase", "alfa", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0409543514251709, 0.010907825082540512, 0.03342917561531067, 0.01980637013912201, 0.035598039627075195, 0.013282508589327335, 0.015470661222934723, 0.0948418453335762, 0.10513702780008316, 0.39172181487083435, 0.19937820732593536, 0.1271352767944336, 0.06443075090646744, 0.1276320070028305, 0.13568732142448425, 0.258272647857666, 0.490050733089447, 0.11758611351251602, 0.007799370214343071, 0.007529507391154766, 0.0294105913490057, 0.027828462421894073, -1]}
{"idB": "1006281_18_item1_p133_s2", "idA": "1006281_17_item1_p126_s2", "sentA": "Replagal is available in the European Union.", "sentB": "Replagal is available in the European Union and certain other territories outside the United States.", "type": 2, "words": ["<tag1>", "Replagal", "is", "available", "in", "the", "European", "Union.", "<tag2>", "Replagal", "is", "available", "in", "the", "European", "Union", "and", "certain", "other", "territories", "outside", "the", "United", "States.", "<tag3>"], "wordsA": ["Replagal", "is", "available", "in", "the", "European", "Union."], "wordsB": ["Replagal", "is", "available", "in", "the", "European", "Union", "and", "certain", "other", "territories", "outside", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 0.06165226921439171, 0.022248895838856697, 0.07014600187540054, 0.016973596066236496, 0.009068855084478855, 0.03722907230257988, 0.04480509087443352, 0.024271396920084953, 0.06922335922718048, 0.07164576649665833, 0.34745433926582336, 0.7444027066230774, 0.530666172504425, 0.793789267539978, 0.8504965901374817, -1]}
{"idB": "1006281_18_item1_p88_s0", "idA": "1006281_17_item1_p126_s2", "sentA": "Replagal is available in the European Union.", "sentB": "PK analysis performed indicated alidornase alfa is not absorbed into a patient s circulatory system, suggesting higher levels of alidornase alfa remains available in the patient s lungs.", "type": 2, "words": ["<tag1>", "Replagal", "is", "available", "in", "the", "European", "Union.", "<tag2>", "PK", "analysis", "performed", "indicated", "alidornase", "alfa", "is", "not", "absorbed", "into", "a", "patient", "s", "circulatory", "system,", "suggesting", "higher", "levels", "of", "alidornase", "alfa", "remains", "available", "in", "the", "patient", "s", "lungs.", "<tag3>"], "wordsA": ["Replagal", "is", "available", "in", "the", "European", "Union."], "wordsB": ["PK", "analysis", "performed", "indicated", "alidornase", "alfa", "is", "not", "absorbed", "into", "a", "patient", "s", "circulatory", "system,", "suggesting", "higher", "levels", "of", "alidornase", "alfa", "remains", "available", "in", "the", "patient", "s", "lungs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 0.4915279448032379, 0.2571175992488861, 0.019879495725035667, 0.014347836375236511, 0.06602911651134491, 0.1503225564956665, 0.20430679619312286, 0.6102027297019958, 0.4580928683280945, 0.162679061293602, 0.0863243043422699, 0.17671862244606018, 0.11001860350370407, 0.31762418150901794, 0.3121804893016815, 0.0019228644669055939, 0.05565495789051056, 0.06055416911840439, 0.05504811182618141, 0.03773004934191704, 0.04410547763109207, 0.07264287024736404, 0.07316739857196808, 0.04203139618039131, 0.015583056025207043, 0.14653362333774567, 0.0752401202917099, 0.23072847723960876, -1]}
{"idB": "1006281_18_item1_p133_s4", "idA": "1006281_17_item1_p126_s4", "sentA": "In addition, in May 2016, Galafold (migalastat), an oral small molecule pharmacological chaperone marketed by Amicus Therapeutics, Inc. was approved as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.", "sentB": "In addition, in May 2016, Galafold (migalastat), an oral small molecule pharmacological chaperone marketed by Amicus was approved in the European Union and other countries, but not in the United States, as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.", "type": 2, "words": ["<tag1>", "In", "addition,", "in", "May", "2016,", "Galafold", "(migalastat),", "an", "oral", "small", "molecule", "pharmacological", "chaperone", "marketed", "by", "Amicus", "Therapeutics,", "Inc.", "was", "approved", "as", "a", "first", "line", "therapy", "for", "long-term", "treatment", "of", "adults", "and", "adolescents", "aged", "16", "years", "and", "older", "with", "a", "confirmed", "diagnosis", "of", "Fabry", "disease", "and", "who", "have", "an", "amenable", "mutation.", "<tag2>", "In", "addition,", "in", "May", "2016,", "Galafold", "(migalastat),", "an", "oral", "small", "molecule", "pharmacological", "chaperone", "marketed", "by", "Amicus", "was", "approved", "in", "the", "European", "Union", "and", "other", "countries,", "but", "not", "in", "the", "United", "States,", "as", "a", "first", "line", "therapy", "for", "long-term", "treatment", "of", "adults", "and", "adolescents", "aged", "16", "years", "and", "older", "with", "a", "confirmed", "diagnosis", "of", "Fabry", "disease", "and", "who", "have", "an", "amenable", "mutation.", "<tag3>"], "wordsA": ["In", "addition,", "in", "May", "2016,", "Galafold", "(migalastat),", "an", "oral", "small", "molecule", "pharmacological", "chaperone", "marketed", "by", "Amicus", "Therapeutics,", "Inc.", "was", "approved", "as", "a", "first", "line", "therapy", "for", "long-term", "treatment", "of", "adults", "and", "adolescents", "aged", "16", "years", "and", "older", "with", "a", "confirmed", "diagnosis", "of", "Fabry", "disease", "and", "who", "have", "an", "amenable", "mutation."], "wordsB": ["In", "addition,", "in", "May", "2016,", "Galafold", "(migalastat),", "an", "oral", "small", "molecule", "pharmacological", "chaperone", "marketed", "by", "Amicus", "was", "approved", "in", "the", "European", "Union", "and", "other", "countries,", "but", "not", "in", "the", "United", "States,", "as", "a", "first", "line", "therapy", "for", "long-term", "treatment", "of", "adults", "and", "adolescents", "aged", "16", "years", "and", "older", "with", "a", "confirmed", "diagnosis", "of", "Fabry", "disease", "and", "who", "have", "an", "amenable", "mutation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.009025182574987411, 0.016167860478162766, 0.008524653501808643, 0.016217583790421486, 0.025206921622157097, 0.11636313796043396, 0.10769537091255188, 0.008879228495061398, 0.022263772785663605, 0.027174273505806923, 0.01769980974495411, 0.025122180581092834, 0.033481091260910034, 0.009539005346596241, 0.006195176858454943, 0.02246260829269886, 0.011627293191850185, 0.0634537860751152, 0.03041529469192028, 0.030477076768875122, 0.11534864455461502, 0.25393474102020264, 0.04817115142941475, 0.04759422317147255, 0.1002032533288002, 0.015401497483253479, 0.33587363362312317, 0.24898934364318848, 0.2723178565502167, 0.6272054314613342, 0.6702297925949097, 0.009582215920090675, 0.007295615505427122, 0.009002151899039745, 0.017909660935401917, 0.02289893478155136, 0.004381758160889149, 0.009959455579519272, 0.010065664537250996, 0.00659547746181488, 0.022030744701623917, 0.013403035700321198, 0.020884975790977478, 0.01245822012424469, 0.021078508347272873, 0.020267266780138016, 0.015113838948309422, 0.019420981407165527, 0.008365796878933907, 0.007523359265178442, 0.008251426741480827, 0.012656837701797485, 0.006636338774114847, 0.022563470527529716, 0.015248937532305717, 0.01063202228397131, 0.008590949699282646, 0.010212567634880543, 0.007638456765562296, 0.01558669749647379, 0.02456512115895748, -1]}
{"idB": "1006281_18_item1_p16_s3", "idA": "1006281_17_item1_p12_s3", "sentA": "The first patient in our phase II proof of concept efficacy study of OPRX-106 for the treatment of ulcerative colitis was dosed in November 2016.", "sentB": "Currently, the first 14 patients have completed our phase II proof of concept efficacy study of OPRX-106 for the treatment of ulcerative colitis , and four patients are currently in treatment and follow-up.", "type": 2, "words": ["<tag1>", "The", "first", "patient", "in", "our", "phase", "II", "proof", "of", "concept", "efficacy", "study", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis", "was", "dosed", "in", "November", "2016.", "<tag2>", "Currently,", "the", "first", "14", "patients", "have", "completed", "our", "phase", "II", "proof", "of", "concept", "efficacy", "study", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis", ",", "and", "four", "patients", "are", "currently", "in", "treatment", "and", "follow-up.", "<tag3>"], "wordsA": ["The", "first", "patient", "in", "our", "phase", "II", "proof", "of", "concept", "efficacy", "study", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis", "was", "dosed", "in", "November", "2016."], "wordsB": ["Currently,", "the", "first", "14", "patients", "have", "completed", "our", "phase", "II", "proof", "of", "concept", "efficacy", "study", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis", ",", "and", "four", "patients", "are", "currently", "in", "treatment", "and", "follow-up."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.02451639249920845, 0.005090965889394283, 0.14899474382400513, 0.8221245408058167, 0.4653767943382263, 0.03191180154681206, 0.40725675225257874, 0.015923524275422096, 0.022463951259851456, 0.018885672092437744, 0.019145270809531212, 0.007523594424128532, 0.007489177864044905, 0.011119544506072998, 0.02785126492381096, 0.003546444233506918, 0.010020597837865353, 0.0018257516203448176, 0.0017949320608749986, 0.0051142629235982895, 0.0014961246633902192, 0.002807300304993987, 0.003479612525552511, 5.242515908321366e-05, 0.00012710338342003524, 0.3886404037475586, 0.29253044724464417, 0.007838640362024307, 0.021064061671495438, 0.028549836948513985, 0.052468523383140564, 0.016404470428824425, 0.11143115162849426, -1]}
{"idB": "1006281_18_item1_p95_s1", "idA": "1006281_17_item1_p12_s3", "sentA": "The first patient in our phase II proof of concept efficacy study of OPRX-106 for the treatment of ulcerative colitis was dosed in November 2016.", "sentB": "The first patient was enrolled in the trial in November 2016.", "type": 2, "words": ["<tag1>", "The", "first", "patient", "in", "our", "phase", "II", "proof", "of", "concept", "efficacy", "study", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis", "was", "dosed", "in", "November", "2016.", "<tag2>", "The", "first", "patient", "was", "enrolled", "in", "the", "trial", "in", "November", "2016.", "<tag3>"], "wordsA": ["The", "first", "patient", "in", "our", "phase", "II", "proof", "of", "concept", "efficacy", "study", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis", "was", "dosed", "in", "November", "2016."], "wordsB": ["The", "first", "patient", "was", "enrolled", "in", "the", "trial", "in", "November", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0040589882992208, 0.04917214810848236, 0.13085269927978516, 0.06025443226099014, 0.8654199242591858, 0.29029327630996704, 0.26262718439102173, 0.636284589767456, 0.026755694299936295, 0.02298111654818058, 0.02903757430613041, -1]}
{"idB": "1006281_18_item1_p16_s7", "idA": "1006281_17_item1_p13_s2", "sentA": "Upon review of the proof of concept data, we intend to identify and collaborate with a well-suited partner for further development.", "sentB": "Upon review of the final proof of concept data, we intend to identify and collaborate with a well-suited partner for further development.", "type": 2, "words": ["<tag1>", "Upon", "review", "of", "the", "proof", "of", "concept", "data,", "we", "intend", "to", "identify", "and", "collaborate", "with", "a", "well-suited", "partner", "for", "further", "development.", "<tag2>", "Upon", "review", "of", "the", "final", "proof", "of", "concept", "data,", "we", "intend", "to", "identify", "and", "collaborate", "with", "a", "well-suited", "partner", "for", "further", "development.", "<tag3>"], "wordsA": ["Upon", "review", "of", "the", "proof", "of", "concept", "data,", "we", "intend", "to", "identify", "and", "collaborate", "with", "a", "well-suited", "partner", "for", "further", "development."], "wordsB": ["Upon", "review", "of", "the", "final", "proof", "of", "concept", "data,", "we", "intend", "to", "identify", "and", "collaborate", "with", "a", "well-suited", "partner", "for", "further", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.003715642262250185, 0.015051617287099361, 0.005551580805331469, 0.005806466564536095, 0.9760112762451172, 0.10675695538520813, 0.01391049288213253, 0.03258693218231201, 0.032857511192560196, 0.005166534800082445, 0.007127742748707533, 0.004633503500372171, 0.006353731267154217, 0.004743889439851046, 0.006787597201764584, 0.004822846502065659, 0.003443046472966671, 0.008100420236587524, 0.009431859478354454, 0.0030079244170337915, 0.0035594094078987837, 0.004986043553799391, -1]}
{"idB": "1006281_18_item1_p66_s2", "idA": "1006281_17_item1_p13_s2", "sentA": "Upon review of the proof of concept data, we intend to identify and collaborate with a well-suited partner for further development.", "sentB": "At the same time, we intend to approach the FDA to request its review of the then totality of data.", "type": 2, "words": ["<tag1>", "Upon", "review", "of", "the", "proof", "of", "concept", "data,", "we", "intend", "to", "identify", "and", "collaborate", "with", "a", "well-suited", "partner", "for", "further", "development.", "<tag2>", "At", "the", "same", "time,", "we", "intend", "to", "approach", "the", "FDA", "to", "request", "its", "review", "of", "the", "then", "totality", "of", "data.", "<tag3>"], "wordsA": ["Upon", "review", "of", "the", "proof", "of", "concept", "data,", "we", "intend", "to", "identify", "and", "collaborate", "with", "a", "well-suited", "partner", "for", "further", "development."], "wordsB": ["At", "the", "same", "time,", "we", "intend", "to", "approach", "the", "FDA", "to", "request", "its", "review", "of", "the", "then", "totality", "of", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.010096232406795025, 0.01698140799999237, 0.025044450536370277, 0.02807951159775257, 0.028992703184485435, 0.037772078067064285, 0.03319805487990379, 0.5528125166893005, 0.24816572666168213, 0.4910168945789337, 0.012303619645535946, 0.1429632157087326, 0.03408663719892502, 0.13903886079788208, 0.015760695561766624, 0.015105878002941608, 0.06408613920211792, 0.38092178106307983, 0.20316743850708008, 0.28257837891578674, -1]}
{"idB": "1006281_18_item1_p147_s0", "idA": "1006281_17_item1_p141_s0", "sentA": "The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria.", "sentB": "The FDA has a fast track program that is is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the purpose being to make important new drugs available to patients earlier.", "type": 2, "words": ["<tag1>", "The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "intended", "to", "expedite", "or", "facilitate", "the", "process", "for", "reviewing", "new", "drugs", "and", "biological", "products", "that", "meet", "certain", "criteria.", "<tag2>", "The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "is", "designed", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drugs", "to", "treat", "serious", "conditions", "and", "fill", "an", "unmet", "medical", "need,", "the", "purpose", "being", "to", "make", "important", "new", "drugs", "available", "to", "patients", "earlier.", "<tag3>"], "wordsA": ["The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "intended", "to", "expedite", "or", "facilitate", "the", "process", "for", "reviewing", "new", "drugs", "and", "biological", "products", "that", "meet", "certain", "criteria."], "wordsB": ["The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "is", "designed", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drugs", "to", "treat", "serious", "conditions", "and", "fill", "an", "unmet", "medical", "need,", "the", "purpose", "being", "to", "make", "important", "new", "drugs", "available", "to", "patients", "earlier."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.003752524731680751, 0.014658791944384575, 0.0034899255260825157, 0.0029353369027376175, 0.005408040713518858, 0.006721340119838715, 0.012772654183208942, 0.0038627013564109802, 0.003412829013541341, 0.003865375416353345, 0.009240994229912758, 0.004339265637099743, 0.01193628367036581, 0.005452208686619997, 0.01792593114078045, 0.004116721451282501, 0.01045969408005476, 0.0040980433113873005, 0.02084934711456299, 0.011999500915408134, 0.07854492962360382, 0.00786550622433424, 0.07231036573648453, 0.15309305489063263, 0.07892583310604095, 0.00499975960701704, 0.03452322632074356, 0.024721011519432068, 0.23215723037719727, 0.12797275185585022, 0.11433336138725281, 0.0003525145584717393, 0.023490073159337044, 0.011385996825993061, 0.008319046348333359, 0.06163449212908745, 0.14529907703399658, 0.22370241582393646, 0.41934922337532043, 0.28241583704948425, 0.05273684859275818, 0.1841575652360916, 0.28187498450279236, -1]}
{"idB": "1006281_18_item1_p147_s3", "idA": "1006281_17_item1_p142_s2", "sentA": "We used the rolling submission option for our taliglucerase alfa NDA, which we completed in April 2010.", "sentB": "We used the Rolling Review option for our taliglucerase alfa NDA, which we completed in April 2010.", "type": 2, "words": ["<tag1>", "We", "used", "the", "rolling", "submission", "option", "for", "our", "taliglucerase", "alfa", "NDA,", "which", "we", "completed", "in", "April", "2010.", "<tag2>", "We", "used", "the", "Rolling", "Review", "option", "for", "our", "taliglucerase", "alfa", "NDA,", "which", "we", "completed", "in", "April", "2010.", "<tag3>"], "wordsA": ["We", "used", "the", "rolling", "submission", "option", "for", "our", "taliglucerase", "alfa", "NDA,", "which", "we", "completed", "in", "April", "2010."], "wordsB": ["We", "used", "the", "Rolling", "Review", "option", "for", "our", "taliglucerase", "alfa", "NDA,", "which", "we", "completed", "in", "April", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006003447808325291, 0.010351667180657387, 0.004107020329684019, 0.3308636546134949, 0.9936747550964355, 0.25089752674102783, 0.002592414151877165, 0.0018832323839887977, 0.003838330041617155, 0.0030742501839995384, 0.003226660657674074, 0.00206870143301785, 0.0032485455740243196, 0.010678947903215885, 0.0016973917372524738, 0.0022782678715884686, 0.0029811093118041754, -1]}
{"idB": "1006281_18_item1_p16_s4", "idA": "1006281_17_item1_p149_s2", "sentA": "Regulatory requirements are constantly changing in accordance with scientific advances as well as social and ethical values.", "sentB": "The trial is evaluating key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.", "type": 2, "words": ["<tag1>", "Regulatory", "requirements", "are", "constantly", "changing", "in", "accordance", "with", "scientific", "advances", "as", "well", "as", "social", "and", "ethical", "values.", "<tag2>", "The", "trial", "is", "evaluating", "key", "efficacy", "endpoints", "including", "clinical", "response", "and", "remission", "utilizing", "the", "Mayo", "score,", "as", "well", "as", "safety", "and", "pharmacokinetics.", "<tag3>"], "wordsA": ["Regulatory", "requirements", "are", "constantly", "changing", "in", "accordance", "with", "scientific", "advances", "as", "well", "as", "social", "and", "ethical", "values."], "wordsB": ["The", "trial", "is", "evaluating", "key", "efficacy", "endpoints", "including", "clinical", "response", "and", "remission", "utilizing", "the", "Mayo", "score,", "as", "well", "as", "safety", "and", "pharmacokinetics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.013012256473302841, 0.341154545545578, 0.011256612837314606, 0.21899248659610748, 0.06685202568769455, 0.14850333333015442, 0.1324779987335205, 0.02568635530769825, 0.20323927700519562, 0.24481596052646637, 0.15142524242401123, 0.30427610874176025, 0.0253884419798851, 0.024506285786628723, 0.07649528980255127, 0.06445159018039703, 0.00044284301111474633, 0.007737503852695227, 0.010744170285761356, 0.16771849989891052, 0.07306748628616333, 0.2885493338108063, -1]}
{"idB": "1006281_18_item1_p96_s3", "idA": "1006281_17_item1_p149_s2", "sentA": "Regulatory requirements are constantly changing in accordance with scientific advances as well as social and ethical values.", "sentB": "The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.", "type": 2, "words": ["<tag1>", "Regulatory", "requirements", "are", "constantly", "changing", "in", "accordance", "with", "scientific", "advances", "as", "well", "as", "social", "and", "ethical", "values.", "<tag2>", "The", "trial", "evaluated", "key", "efficacy", "endpoints", "including", "clinical", "response", "and", "remission", "utilizing", "the", "Mayo", "score,", "as", "well", "as", "safety", "and", "pharmacokinetics.", "<tag3>"], "wordsA": ["Regulatory", "requirements", "are", "constantly", "changing", "in", "accordance", "with", "scientific", "advances", "as", "well", "as", "social", "and", "ethical", "values."], "wordsB": ["The", "trial", "evaluated", "key", "efficacy", "endpoints", "including", "clinical", "response", "and", "remission", "utilizing", "the", "Mayo", "score,", "as", "well", "as", "safety", "and", "pharmacokinetics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.019622545689344406, 0.3773191571235657, 0.15158618986606598, 0.062158916145563126, 0.15291190147399902, 0.12638776004314423, 0.030418559908866882, 0.24309565126895905, 0.26013290882110596, 0.15793436765670776, 0.3105703890323639, 0.02946539968252182, 0.028504762798547745, 0.08251175284385681, 0.07279078662395477, 0.00046720533282496035, 0.007707639597356319, 0.010975886136293411, 0.15167072415351868, 0.0660075917840004, 0.3286767303943634, -1]}
{"idB": "1006281_18_item1_p17_s1", "idA": "1006281_17_item1_p14_s1", "sentA": "The focus is expected to be on biologics with improved clinical profiles than the currently marketed proteins for these indications.", "sentB": "The focus is expected to be on biologics with significantly improved clinical profiles than the currently marketed proteins for these indications.", "type": 2, "words": ["<tag1>", "The", "focus", "is", "expected", "to", "be", "on", "biologics", "with", "improved", "clinical", "profiles", "than", "the", "currently", "marketed", "proteins", "for", "these", "indications.", "<tag2>", "The", "focus", "is", "expected", "to", "be", "on", "biologics", "with", "significantly", "improved", "clinical", "profiles", "than", "the", "currently", "marketed", "proteins", "for", "these", "indications.", "<tag3>"], "wordsA": ["The", "focus", "is", "expected", "to", "be", "on", "biologics", "with", "improved", "clinical", "profiles", "than", "the", "currently", "marketed", "proteins", "for", "these", "indications."], "wordsB": ["The", "focus", "is", "expected", "to", "be", "on", "biologics", "with", "significantly", "improved", "clinical", "profiles", "than", "the", "currently", "marketed", "proteins", "for", "these", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004142086952924728, 0.014672400429844856, 0.006547125522047281, 0.010845311917364597, 0.006068122573196888, 0.005243975203484297, 0.0069466265849769115, 0.01263525988906622, 0.007521764375269413, 0.8844296336174011, 0.5506791472434998, 0.05644021928310394, 0.0332091823220253, 0.05159270763397217, 0.015121778473258018, 0.02240139991044998, 0.028602950274944305, 0.040073931217193604, 0.007200887892395258, 0.006930422503501177, 0.011212985962629318, -1]}
{"idB": "1006281_18_item1_p69_s1", "idA": "1006281_17_item1_p150_s1", "sentA": "Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities.", "sentB": "A safety and efficacy evaluation will occur at 12 months with additional long term follow-up.", "type": 2, "words": ["<tag1>", "Authorizations", "are", "granted", "after", "the", "assessment", "of", "quality,", "safety", "and", "efficacy", "by", "the", "respective", "health", "authorities.", "<tag2>", "A", "safety", "and", "efficacy", "evaluation", "will", "occur", "at", "12", "months", "with", "additional", "long", "term", "follow-up.", "<tag3>"], "wordsA": ["Authorizations", "are", "granted", "after", "the", "assessment", "of", "quality,", "safety", "and", "efficacy", "by", "the", "respective", "health", "authorities."], "wordsB": ["A", "safety", "and", "efficacy", "evaluation", "will", "occur", "at", "12", "months", "with", "additional", "long", "term", "follow-up."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01518032792955637, 0.04791673272848129, 0.01022285409271717, 0.02767989970743656, 0.1352895200252533, 0.022778496146202087, 0.05307960510253906, 0.03915630653500557, 0.4708698093891144, 0.2774566411972046, 0.01746932603418827, 0.08836545795202255, 0.41185837984085083, 0.4447121322154999, 0.41951730847358704, -1]}
{"idB": "1006281_18_item1_p159_s3", "idA": "1006281_17_item1_p154_s3", "sentA": "As a result, the corporate tax rate will be 24% in 2017 and 23% in 2018 and thereafter.", "sentB": "As a result, the corporate tax rate was 24% in 2017 and will be 23% in 2018 and thereafter.", "type": 2, "words": ["<tag1>", "As", "a", "result,", "the", "corporate", "tax", "rate", "will", "be", "24%", "in", "2017", "and", "23%", "in", "2018", "and", "thereafter.", "<tag2>", "As", "a", "result,", "the", "corporate", "tax", "rate", "was", "24%", "in", "2017", "and", "will", "be", "23%", "in", "2018", "and", "thereafter.", "<tag3>"], "wordsA": ["As", "a", "result,", "the", "corporate", "tax", "rate", "will", "be", "24%", "in", "2017", "and", "23%", "in", "2018", "and", "thereafter."], "wordsB": ["As", "a", "result,", "the", "corporate", "tax", "rate", "was", "24%", "in", "2017", "and", "will", "be", "23%", "in", "2018", "and", "thereafter."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.007562869228422642, 0.01116995420306921, 0.012293459847569466, 0.004770203493535519, 0.015312192030251026, 0.03140130639076233, 0.04656325653195381, 0.016274331137537956, 0.6029348373413086, 0.012457347474992275, 0.015245063230395317, 0.0011762090725824237, 0.010224837809801102, 0.014021335169672966, 0.8373415470123291, 0.011445024982094765, 0.016743093729019165, 0.009001122787594795, 0.011705855838954449, -1]}
{"idB": "1006281_18_item1_p101_s2", "idA": "1006281_17_item1_p156_s1", "sentA": "Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an Approved Enterprise, is entitled to benefits.", "sentB": "Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $25 million in development costs, capped at $10 million per year.", "type": 2, "words": ["<tag1>", "Generally,", "an", "investment", "program", "that", "is", "implemented", "in", "accordance", "with", "the", "provisions", "of", "the", "Investment", "Law,", "referred", "to", "as", "an", "Approved", "Enterprise,", "is", "entitled", "to", "benefits.", "<tag2>", "Chiesi", "made", "an", "upfront", "payment", "to", "Protalix", "Ltd.", "of", "$25.0", "million", "in", "connection", "with", "the", "execution", "of", "the", "agreement", "and", "Protalix", "Ltd.", "is", "entitled", "to", "additional", "payments", "of", "up", "to", "$25", "million", "in", "development", "costs,", "capped", "at", "$10", "million", "per", "year.", "<tag3>"], "wordsA": ["Generally,", "an", "investment", "program", "that", "is", "implemented", "in", "accordance", "with", "the", "provisions", "of", "the", "Investment", "Law,", "referred", "to", "as", "an", "Approved", "Enterprise,", "is", "entitled", "to", "benefits."], "wordsB": ["Chiesi", "made", "an", "upfront", "payment", "to", "Protalix", "Ltd.", "of", "$25.0", "million", "in", "connection", "with", "the", "execution", "of", "the", "agreement", "and", "Protalix", "Ltd.", "is", "entitled", "to", "additional", "payments", "of", "up", "to", "$25", "million", "in", "development", "costs,", "capped", "at", "$10", "million", "per", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.14310477674007416, 0.05049731582403183, 0.029249491170048714, 0.29623767733573914, 0.48004865646362305, 0.03336063399910927, 0.07611239701509476, 0.05543311685323715, 0.00994119606912136, 0.12172796577215195, 0.15283212065696716, 0.006526659708470106, 0.00800797063857317, 0.004743160214275122, 0.005886094644665718, 0.06016075238585472, 0.00792002771049738, 0.007418590597808361, 0.06382090598344803, 0.005950871855020523, 0.01478901319205761, 0.014847898855805397, 0.004893869627267122, 0.034832317382097244, 0.010597708635032177, 0.1190299391746521, 0.42019930481910706, 0.010388633236289024, 0.06474826484918594, 0.027638811618089676, 0.2291049063205719, 0.17892655730247498, 0.03786267712712288, 0.41392964124679565, 0.3581046164035797, 0.018426837399601936, 0.013461428694427013, 0.29928305745124817, 0.2974530756473541, 0.03117506206035614, 0.057062290608882904, -1]}
{"idB": "1006281_18_item1_p3_s2", "idA": "1006281_17_item1_p156_s1", "sentA": "Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an Approved Enterprise, is entitled to benefits.", "sentB": "Under the Chiesi Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $25 million in development costs, capped at $10 million per year.", "type": 2, "words": ["<tag1>", "Generally,", "an", "investment", "program", "that", "is", "implemented", "in", "accordance", "with", "the", "provisions", "of", "the", "Investment", "Law,", "referred", "to", "as", "an", "Approved", "Enterprise,", "is", "entitled", "to", "benefits.", "<tag2>", "Under", "the", "Chiesi", "Agreement,", "Chiesi", "made", "an", "upfront", "payment", "to", "Protalix", "Ltd.", "of", "$25.0", "million", "in", "connection", "with", "the", "execution", "of", "the", "agreement", "and", "Protalix", "Ltd.", "is", "entitled", "to", "additional", "payments", "of", "up", "to", "$25", "million", "in", "development", "costs,", "capped", "at", "$10", "million", "per", "year.", "<tag3>"], "wordsA": ["Generally,", "an", "investment", "program", "that", "is", "implemented", "in", "accordance", "with", "the", "provisions", "of", "the", "Investment", "Law,", "referred", "to", "as", "an", "Approved", "Enterprise,", "is", "entitled", "to", "benefits."], "wordsB": ["Under", "the", "Chiesi", "Agreement,", "Chiesi", "made", "an", "upfront", "payment", "to", "Protalix", "Ltd.", "of", "$25.0", "million", "in", "connection", "with", "the", "execution", "of", "the", "agreement", "and", "Protalix", "Ltd.", "is", "entitled", "to", "additional", "payments", "of", "up", "to", "$25", "million", "in", "development", "costs,", "capped", "at", "$10", "million", "per", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.05086924135684967, 0.026840008795261383, 0.14618690311908722, 0.20742377638816833, 0.13642831146717072, 0.08365143090486526, 0.0450427308678627, 0.2957269549369812, 0.43735435605049133, 0.04115544632077217, 0.07312344014644623, 0.0711902305483818, 0.01221595611423254, 0.12482551485300064, 0.16380560398101807, 0.009091934189200401, 0.009129173122346401, 0.006874417886137962, 0.008666763082146645, 0.07687555253505707, 0.015193093568086624, 0.011433403939008713, 0.07290297746658325, 0.009624048136174679, 0.025879500433802605, 0.027461998164653778, 0.008356663398444653, 0.040138691663742065, 0.01533955056220293, 0.09211625158786774, 0.32657742500305176, 0.010670050047338009, 0.05473680794239044, 0.026079516857862473, 0.17954014241695404, 0.1420033574104309, 0.028367437422275543, 0.2877398431301117, 0.2776380479335785, 0.01765519566833973, 0.015926692634820938, 0.26483631134033203, 0.2925052344799042, 0.03430546820163727, 0.060823313891887665, -1]}
{"idB": "1006281_18_item1_p18_s0", "idA": "1006281_17_item1_p15_s0", "sentA": "Except for the rights to commercialize taliglucerase alfa worldwide (other than Brazil), which we licensed to Pfizer, we hold the worldwide commercialization rights to all of our proprietary development candidates.", "sentB": "Except for the rights to commercialize taliglucerase alfa worldwide (other than Brazil), which we licensed to Pfizer, and the rights to PRX-102 which we licensed to Chiesi for territories outside the United States, we hold the worldwide commercialization rights to all of our proprietary development candidates.", "type": 2, "words": ["<tag1>", "Except", "for", "the", "rights", "to", "commercialize", "taliglucerase", "alfa", "worldwide", "(other", "than", "Brazil),", "which", "we", "licensed", "to", "Pfizer,", "we", "hold", "the", "worldwide", "commercialization", "rights", "to", "all", "of", "our", "proprietary", "development", "candidates.", "<tag2>", "Except", "for", "the", "rights", "to", "commercialize", "taliglucerase", "alfa", "worldwide", "(other", "than", "Brazil),", "which", "we", "licensed", "to", "Pfizer,", "and", "the", "rights", "to", "PRX-102", "which", "we", "licensed", "to", "Chiesi", "for", "territories", "outside", "the", "United", "States,", "we", "hold", "the", "worldwide", "commercialization", "rights", "to", "all", "of", "our", "proprietary", "development", "candidates.", "<tag3>"], "wordsA": ["Except", "for", "the", "rights", "to", "commercialize", "taliglucerase", "alfa", "worldwide", "(other", "than", "Brazil),", "which", "we", "licensed", "to", "Pfizer,", "we", "hold", "the", "worldwide", "commercialization", "rights", "to", "all", "of", "our", "proprietary", "development", "candidates."], "wordsB": ["Except", "for", "the", "rights", "to", "commercialize", "taliglucerase", "alfa", "worldwide", "(other", "than", "Brazil),", "which", "we", "licensed", "to", "Pfizer,", "and", "the", "rights", "to", "PRX-102", "which", "we", "licensed", "to", "Chiesi", "for", "territories", "outside", "the", "United", "States,", "we", "hold", "the", "worldwide", "commercialization", "rights", "to", "all", "of", "our", "proprietary", "development", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.010005590505897999, 0.011730054393410683, 0.006305980496108532, 0.009274684824049473, 0.005078812595456839, 0.008691634051501751, 0.007922384887933731, 0.006985562853515148, 0.005486055742949247, 0.008738157339394093, 0.009389840066432953, 0.00789326149970293, 0.007137252017855644, 0.005399586167186499, 0.01574263535439968, 0.004377113655209541, 0.007494074292480946, 0.004506959114223719, 0.005901494529098272, 0.025332361459732056, 0.027668634429574013, 0.877953827381134, 0.006384768523275852, 0.005770455580204725, 0.022049399092793465, 0.024451766163110733, 0.2258763611316681, 0.004870254080742598, 0.06329851597547531, 0.35607242584228516, 0.25505131483078003, 0.28765109181404114, 0.34687262773513794, 0.007386298384517431, 0.008252083323895931, 0.007555842399597168, 0.0077848187647759914, 0.006758356466889381, 0.007789644878357649, 0.0036270960699766874, 0.00896525289863348, 0.005306800827383995, 0.004844377748668194, 0.007809283211827278, 0.008124209009110928, 0.011087901890277863, -1]}
{"idB": "1006281_18_item1_p101_s7", "idA": "1006281_17_item1_p164_s2", "sentA": "The current benefits program may not continue to be available and Protalix Ltd. may not continue to qualify for its benefits.", "sentB": "The Chiesi Agreement also provides for reimbursement by Chiesi of certain costs to be incurred by Protalix Ltd.", "type": 2, "words": ["<tag1>", "The", "current", "benefits", "program", "may", "not", "continue", "to", "be", "available", "and", "Protalix", "Ltd.", "may", "not", "continue", "to", "qualify", "for", "its", "benefits.", "<tag2>", "The", "Chiesi", "Agreement", "also", "provides", "for", "reimbursement", "by", "Chiesi", "of", "certain", "costs", "to", "be", "incurred", "by", "Protalix", "Ltd.", "<tag3>"], "wordsA": ["The", "current", "benefits", "program", "may", "not", "continue", "to", "be", "available", "and", "Protalix", "Ltd.", "may", "not", "continue", "to", "qualify", "for", "its", "benefits."], "wordsB": ["The", "Chiesi", "Agreement", "also", "provides", "for", "reimbursement", "by", "Chiesi", "of", "certain", "costs", "to", "be", "incurred", "by", "Protalix", "Ltd."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.014825636520981789, 0.11003272235393524, 0.16588930785655975, 0.032410215586423874, 0.12766751646995544, 0.16251996159553528, 0.7560193538665771, 0.06943207234144211, 0.06129573658108711, 0.15704400837421417, 0.23371203243732452, 0.5199350714683533, 0.04709775373339653, 0.04415019974112511, 0.15650849044322968, 0.027958909049630165, 0.020706508308649063, 0.017720399424433708, -1]}
{"idB": "1006281_18_item1_p3_s7", "idA": "1006281_17_item1_p164_s2", "sentA": "The current benefits program may not continue to be available and Protalix Ltd. may not continue to qualify for its benefits.", "sentB": "The Chiesi Agreement also provides for reimbursement by Chiesi of certain costs to be incurred by Protalix Ltd.", "type": 2, "words": ["<tag1>", "The", "current", "benefits", "program", "may", "not", "continue", "to", "be", "available", "and", "Protalix", "Ltd.", "may", "not", "continue", "to", "qualify", "for", "its", "benefits.", "<tag2>", "The", "Chiesi", "Agreement", "also", "provides", "for", "reimbursement", "by", "Chiesi", "of", "certain", "costs", "to", "be", "incurred", "by", "Protalix", "Ltd.", "<tag3>"], "wordsA": ["The", "current", "benefits", "program", "may", "not", "continue", "to", "be", "available", "and", "Protalix", "Ltd.", "may", "not", "continue", "to", "qualify", "for", "its", "benefits."], "wordsB": ["The", "Chiesi", "Agreement", "also", "provides", "for", "reimbursement", "by", "Chiesi", "of", "certain", "costs", "to", "be", "incurred", "by", "Protalix", "Ltd."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.014825636520981789, 0.11003272235393524, 0.16588930785655975, 0.032410215586423874, 0.12766751646995544, 0.16251996159553528, 0.7560193538665771, 0.06943207234144211, 0.06129573658108711, 0.15704400837421417, 0.23371203243732452, 0.5199350714683533, 0.04709775373339653, 0.04415019974112511, 0.15650849044322968, 0.027958909049630165, 0.020706508308649063, 0.017720399424433708, -1]}
{"idB": "1006281_18_item1_p178_s0", "idA": "1006281_17_item1_p173_s0", "sentA": "To date, Protalix Ltd. has received grants from the Office of the Chief Scientist, or the OCS, under the Israeli Law for the Encouragement of Industrial Research, Development and Technology Innovation, 1984, and related regulations, or the Research Law.", "sentB": "To date, Protalix Ltd. has received grants from the OCS under the Israeli Law for the Encouragement of Industrial Research, Development and Technology Innovation, 1984, and related regulations, or the Research Law.", "type": 2, "words": ["<tag1>", "To", "date,", "Protalix", "Ltd.", "has", "received", "grants", "from", "the", "Office", "of", "the", "Chief", "Scientist,", "or", "the", "OCS,", "under", "the", "Israeli", "Law", "for", "the", "Encouragement", "of", "Industrial", "Research,", "Development", "and", "Technology", "Innovation,", "1984,", "and", "related", "regulations,", "or", "the", "Research", "Law.", "<tag2>", "To", "date,", "Protalix", "Ltd.", "has", "received", "grants", "from", "the", "OCS", "under", "the", "Israeli", "Law", "for", "the", "Encouragement", "of", "Industrial", "Research,", "Development", "and", "Technology", "Innovation,", "1984,", "and", "related", "regulations,", "or", "the", "Research", "Law.", "<tag3>"], "wordsA": ["To", "date,", "Protalix", "Ltd.", "has", "received", "grants", "from", "the", "Office", "of", "the", "Chief", "Scientist,", "or", "the", "OCS,", "under", "the", "Israeli", "Law", "for", "the", "Encouragement", "of", "Industrial", "Research,", "Development", "and", "Technology", "Innovation,", "1984,", "and", "related", "regulations,", "or", "the", "Research", "Law."], "wordsB": ["To", "date,", "Protalix", "Ltd.", "has", "received", "grants", "from", "the", "OCS", "under", "the", "Israeli", "Law", "for", "the", "Encouragement", "of", "Industrial", "Research,", "Development", "and", "Technology", "Innovation,", "1984,", "and", "related", "regulations,", "or", "the", "Research", "Law."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.04967707768082619, 0.06516581773757935, 0.3913399577140808, 0.34660157561302185, 0.04768615961074829, 0.1405566781759262, 0.40489280223846436, 0.04748459905385971, 0.06829781830310822, 0.8908823728561401, 0.02734639309346676, 0.021078409627079964, 0.14317743480205536, 0.1818782091140747, 0.022824514657258987, 0.0161126758903265, 0.03719647228717804, 0.020388703793287277, 0.03428070247173309, 0.03447896987199783, 0.02094114199280739, 0.01839902624487877, 0.020935889333486557, 0.02816769666969776, 0.02611382305622101, 0.016393832862377167, 0.022288130596280098, 0.028560234233736992, 0.012278033420443535, 0.0100772175937891, 0.024396268650889397, 0.04976864531636238, -1]}
{"idB": "1006281_18_item1_p102_s0", "idA": "1006281_17_item1_p173_s1", "sentA": "On January 1, 2016, the Israeli government established the National Authority for Technological Innovation, or NATI.", "sentB": "We are required to pay a royalty equal to 3% of the PRX-102-related revenues Chiesi records under the Chiesi Agreement to the National Authority for Technological Innovation, or NATI .", "type": 2, "words": ["<tag1>", "On", "January", "1,", "2016,", "the", "Israeli", "government", "established", "the", "National", "Authority", "for", "Technological", "Innovation,", "or", "NATI.", "<tag2>", "We", "are", "required", "to", "pay", "a", "royalty", "equal", "to", "3%", "of", "the", "PRX-102-related", "revenues", "Chiesi", "records", "under", "the", "Chiesi", "Agreement", "to", "the", "National", "Authority", "for", "Technological", "Innovation,", "or", "NATI", ".", "<tag3>"], "wordsA": ["On", "January", "1,", "2016,", "the", "Israeli", "government", "established", "the", "National", "Authority", "for", "Technological", "Innovation,", "or", "NATI."], "wordsB": ["We", "are", "required", "to", "pay", "a", "royalty", "equal", "to", "3%", "of", "the", "PRX-102-related", "revenues", "Chiesi", "records", "under", "the", "Chiesi", "Agreement", "to", "the", "National", "Authority", "for", "Technological", "Innovation,", "or", "NATI", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.1549779176712036, 0.03973590210080147, 0.38331612944602966, 0.17256376147270203, 0.6379899978637695, 0.29769060015678406, 0.5896372199058533, 0.02306537516415119, 0.01573043502867222, 0.09030745178461075, 0.01569385826587677, 0.020304251462221146, 0.16927863657474518, 0.057621121406555176, 0.09686263650655746, 0.02341504395008087, 0.01580812782049179, 0.014717325568199158, 0.06026674062013626, 0.06085652858018875, 0.041230376809835434, 0.016167011111974716, 0.030277496203780174, 0.02312735840678215, 0.005729439668357372, 0.006696452386677265, 0.007906539365649223, 0.003776493016630411, 0.014837982133030891, 0.00011193729733349755, -1]}
{"idB": "1006281_18_item1_p179_s0", "idA": "1006281_17_item1_p173_s2", "sentA": "NATI has replaced many of the functions of the OCS.", "sentB": "On January 1, 2016, the Israeli government established NATI which replaced many of the functions of the Office of the Chief Scientist of the Israeli Department of Labor, or the OCS.", "type": 2, "words": ["<tag1>", "NATI", "has", "replaced", "many", "of", "the", "functions", "of", "the", "OCS.", "<tag2>", "On", "January", "1,", "2016,", "the", "Israeli", "government", "established", "NATI", "which", "replaced", "many", "of", "the", "functions", "of", "the", "Office", "of", "the", "Chief", "Scientist", "of", "the", "Israeli", "Department", "of", "Labor,", "or", "the", "OCS.", "<tag3>"], "wordsA": ["NATI", "has", "replaced", "many", "of", "the", "functions", "of", "the", "OCS."], "wordsB": ["On", "January", "1,", "2016,", "the", "Israeli", "government", "established", "NATI", "which", "replaced", "many", "of", "the", "functions", "of", "the", "Office", "of", "the", "Chief", "Scientist", "of", "the", "Israeli", "Department", "of", "Labor,", "or", "the", "OCS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0459335558116436, 0.04719485715031624, 0.055249787867069244, 0.10580369830131531, 0.03145555034279823, 0.1404743492603302, 0.15895479917526245, 0.09989074617624283, 0.058829549700021744, 0.006949633825570345, 0.060512688010931015, 0.014051037840545177, 0.007683479692786932, 0.013059927150607109, 0.05415080487728119, 0.025360431522130966, 0.03715100511908531, 0.2783829867839813, 0.16222400963306427, 0.1463899314403534, 0.40588974952697754, 0.31733444333076477, 0.015765363350510597, 0.0162203386425972, 0.040136341005563736, 0.0550437793135643, 0.03171364217996597, 0.04113782197237015, 0.015387381426990032, 0.007667805068194866, 0.032245784997940063, -1]}
{"idB": "1006281_18_item1_p101_s6", "idA": "1006281_17_item1_p174_s2", "sentA": "Protalix Ltd. is required to repay up to 100% of grants actually received (plus interest at the LIBOR rate applied to the grants received on or after January 1, 1999) to NATI through payments of royalties at a rate of 3% to 6% of the revenues generated from NATI-funded project, depending on the period in which revenues were generated.", "sentB": "Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.", "type": 2, "words": ["<tag1>", "Protalix", "Ltd.", "is", "required", "to", "repay", "up", "to", "100%", "of", "grants", "actually", "received", "(plus", "interest", "at", "the", "LIBOR", "rate", "applied", "to", "the", "grants", "received", "on", "or", "after", "January", "1,", "1999)", "to", "NATI", "through", "payments", "of", "royalties", "at", "a", "rate", "of", "3%", "to", "6%", "of", "the", "revenues", "generated", "from", "NATI-funded", "project,", "depending", "on", "the", "period", "in", "which", "revenues", "were", "generated.", "<tag2>", "Chiesi", "is", "required", "to", "make", "tiered", "payments", "of", "15%", "to", "35%", "of", "its", "net", "sales,", "depending", "on", "the", "amount", "of", "annual", "sales,", "as", "consideration", "for", "the", "supply", "of", "pegunigalsidase", "alfa.", "<tag3>"], "wordsA": ["Protalix", "Ltd.", "is", "required", "to", "repay", "up", "to", "100%", "of", "grants", "actually", "received", "(plus", "interest", "at", "the", "LIBOR", "rate", "applied", "to", "the", "grants", "received", "on", "or", "after", "January", "1,", "1999)", "to", "NATI", "through", "payments", "of", "royalties", "at", "a", "rate", "of", "3%", "to", "6%", "of", "the", "revenues", "generated", "from", "NATI-funded", "project,", "depending", "on", "the", "period", "in", "which", "revenues", "were", "generated."], "wordsB": ["Chiesi", "is", "required", "to", "make", "tiered", "payments", "of", "15%", "to", "35%", "of", "its", "net", "sales,", "depending", "on", "the", "amount", "of", "annual", "sales,", "as", "consideration", "for", "the", "supply", "of", "pegunigalsidase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.23571959137916565, 0.008111032657325268, 0.04138429835438728, 0.014975623227655888, 0.08488576114177704, 0.4393419921398163, 0.4867890179157257, 0.02581568993628025, 0.5213483572006226, 0.04496311768889427, 0.4703522026538849, 0.04428710415959358, 0.03250555694103241, 0.20036980509757996, 0.3629069924354553, 0.006142827216535807, 0.0046784039586782455, 0.004741208627820015, 0.02161896601319313, 0.009059766307473183, 0.11152597516775131, 0.1190953329205513, 0.006727015599608421, 0.008030775934457779, 0.003019156400114298, 0.00424968870356679, 0.033025555312633514, 0.024223769083619118, 0.2394583374261856, 0.15465126931667328, -1]}
{"idB": "1006281_18_item1_p101_s4", "idA": "1006281_17_item1_p185_s0", "sentA": "We believe that Protalix Ltd. currently qualifies as an Industrial Company within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law.", "sentB": "Protalix Ltd. and Chiesi have agreed to a specific allocation of the responsibilities for the continued development efforts for pegunigalsidase alfa.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "Protalix", "Ltd.", "currently", "qualifies", "as", "an", "Industrial", "Company", "within", "the", "meaning", "of", "the", "Law", "for", "the", "Encouragement", "of", "Industry", "(Taxes),", "1969,", "or", "the", "Industry", "Encouragement", "Law.", "<tag2>", "Protalix", "Ltd.", "and", "Chiesi", "have", "agreed", "to", "a", "specific", "allocation", "of", "the", "responsibilities", "for", "the", "continued", "development", "efforts", "for", "pegunigalsidase", "alfa.", "<tag3>"], "wordsA": ["We", "believe", "that", "Protalix", "Ltd.", "currently", "qualifies", "as", "an", "Industrial", "Company", "within", "the", "meaning", "of", "the", "Law", "for", "the", "Encouragement", "of", "Industry", "(Taxes),", "1969,", "or", "the", "Industry", "Encouragement", "Law."], "wordsB": ["Protalix", "Ltd.", "and", "Chiesi", "have", "agreed", "to", "a", "specific", "allocation", "of", "the", "responsibilities", "for", "the", "continued", "development", "efforts", "for", "pegunigalsidase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.05643479526042938, 0.08118952065706253, 0.05753181874752045, 0.2595197856426239, 0.04064096137881279, 0.2258097529411316, 0.04900902882218361, 0.0462128110229969, 0.15347979962825775, 0.26022711396217346, 0.0635555163025856, 0.05873452499508858, 0.20677407085895538, 0.013070402666926384, 0.01482012216001749, 0.05579683557152748, 0.22382040321826935, 0.1357475072145462, 0.06219291687011719, 0.22271490097045898, 0.11767160147428513, -1]}
{"idB": "1006281_18_item1_p3_s4", "idA": "1006281_17_item1_p185_s0", "sentA": "We believe that Protalix Ltd. currently qualifies as an Industrial Company within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law.", "sentB": "Protalix Ltd. and Chiesi have agreed to a specific allocation of the responsibilities for the continued development efforts for pegunigalsidase alfa.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "Protalix", "Ltd.", "currently", "qualifies", "as", "an", "Industrial", "Company", "within", "the", "meaning", "of", "the", "Law", "for", "the", "Encouragement", "of", "Industry", "(Taxes),", "1969,", "or", "the", "Industry", "Encouragement", "Law.", "<tag2>", "Protalix", "Ltd.", "and", "Chiesi", "have", "agreed", "to", "a", "specific", "allocation", "of", "the", "responsibilities", "for", "the", "continued", "development", "efforts", "for", "pegunigalsidase", "alfa.", "<tag3>"], "wordsA": ["We", "believe", "that", "Protalix", "Ltd.", "currently", "qualifies", "as", "an", "Industrial", "Company", "within", "the", "meaning", "of", "the", "Law", "for", "the", "Encouragement", "of", "Industry", "(Taxes),", "1969,", "or", "the", "Industry", "Encouragement", "Law."], "wordsB": ["Protalix", "Ltd.", "and", "Chiesi", "have", "agreed", "to", "a", "specific", "allocation", "of", "the", "responsibilities", "for", "the", "continued", "development", "efforts", "for", "pegunigalsidase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.05643479526042938, 0.08118952065706253, 0.05753181874752045, 0.2595197856426239, 0.04064096137881279, 0.2258097529411316, 0.04900902882218361, 0.0462128110229969, 0.15347979962825775, 0.26022711396217346, 0.0635555163025856, 0.05873452499508858, 0.20677407085895538, 0.013070402666926384, 0.01482012216001749, 0.05579683557152748, 0.22382040321826935, 0.1357475072145462, 0.06219291687011719, 0.22271490097045898, 0.11767160147428513, -1]}
{"idB": "1006281_18_item1_p97_s1", "idA": "1006281_17_item1_p186_s1", "sentA": "An Industrial Enterprise is defined as an enterprise whose major activity in a given tax year is industrial production.", "sentB": "Clinical remission at week 8 is defined as clinically symptom free, a Mayo score 2, with no individual sub-score exceeding 1 point after treatment.", "type": 2, "words": ["<tag1>", "An", "Industrial", "Enterprise", "is", "defined", "as", "an", "enterprise", "whose", "major", "activity", "in", "a", "given", "tax", "year", "is", "industrial", "production.", "<tag2>", "Clinical", "remission", "at", "week", "8", "is", "defined", "as", "clinically", "symptom", "free,", "a", "Mayo", "score", "2,", "with", "no", "individual", "sub-score", "exceeding", "1", "point", "after", "treatment.", "<tag3>"], "wordsA": ["An", "Industrial", "Enterprise", "is", "defined", "as", "an", "enterprise", "whose", "major", "activity", "in", "a", "given", "tax", "year", "is", "industrial", "production."], "wordsB": ["Clinical", "remission", "at", "week", "8", "is", "defined", "as", "clinically", "symptom", "free,", "a", "Mayo", "score", "2,", "with", "no", "individual", "sub-score", "exceeding", "1", "point", "after", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.6845104098320007, 0.6234109401702881, 0.009497988037765026, 0.04554971307516098, 0.04615585505962372, 0.0037086729425936937, 0.02057051658630371, 0.016221148893237114, 0.11143738031387329, 0.28387749195098877, 0.3661782741546631, 0.007291934918612242, 0.05780979245901108, 0.05119564011693001, 0.0456777922809124, 0.0001666125754127279, 0.17837539315223694, 0.2660317122936249, 0.21192264556884766, 0.13998258113861084, 0.1587258130311966, 0.1310170739889145, 0.06913898140192032, 0.09307194501161575, -1]}
{"idB": "1006281_18_item1_p3_s6", "idA": "1006281_17_item1_p190_s3", "sentA": "However, the amount of such deductible expenditures is reduced by the sum of any funds received through government grants for the finance of such scientific research and development projects.", "sentB": "Chiesi will make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.", "type": 2, "words": ["<tag1>", "However,", "the", "amount", "of", "such", "deductible", "expenditures", "is", "reduced", "by", "the", "sum", "of", "any", "funds", "received", "through", "government", "grants", "for", "the", "finance", "of", "such", "scientific", "research", "and", "development", "projects.", "<tag2>", "Chiesi", "will", "make", "tiered", "payments", "of", "15%", "to", "35%", "of", "its", "net", "sales,", "depending", "on", "the", "amount", "of", "annual", "sales,", "as", "consideration", "for", "the", "supply", "of", "pegunigalsidase", "alfa.", "<tag3>"], "wordsA": ["However,", "the", "amount", "of", "such", "deductible", "expenditures", "is", "reduced", "by", "the", "sum", "of", "any", "funds", "received", "through", "government", "grants", "for", "the", "finance", "of", "such", "scientific", "research", "and", "development", "projects."], "wordsB": ["Chiesi", "will", "make", "tiered", "payments", "of", "15%", "to", "35%", "of", "its", "net", "sales,", "depending", "on", "the", "amount", "of", "annual", "sales,", "as", "consideration", "for", "the", "supply", "of", "pegunigalsidase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.14373601973056793, 0.029020091518759727, 0.11799205094575882, 0.4181371331214905, 0.5223212838172913, 0.036138299852609634, 0.2169313281774521, 0.04531848430633545, 0.2492317408323288, 0.042467571794986725, 0.01951478235423565, 0.12834294140338898, 0.3177155554294586, 0.007468860596418381, 0.004920166451483965, 0.004978366196155548, 0.01350763812661171, 0.0044405898079276085, 0.03172782436013222, 0.05757586658000946, 0.004215819761157036, 0.021562542766332626, 0.003326440928503871, 0.004700011108070612, 0.025481317192316055, 0.016180669888854027, 0.14114710688591003, 0.05767103657126427, -1]}
{"idB": "1006281_18_item1_p197_s0", "idA": "1006281_17_item1_p191_s0", "sentA": "As of December 31, 2016, we had 232 employees, of whom 29 have a Ph.D. or an M.D.in their respective scientific fields.", "sentB": "As of December 31, 2017, we had 190 employees, of whom 21 have a Ph.D. or an M.D.in their respective scientific fields.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2016,", "we", "had", "232", "employees,", "of", "whom", "29", "have", "a", "Ph.D.", "or", "an", "M.D.in", "their", "respective", "scientific", "fields.", "<tag2>", "As", "of", "December", "31,", "2017,", "we", "had", "190", "employees,", "of", "whom", "21", "have", "a", "Ph.D.", "or", "an", "M.D.in", "their", "respective", "scientific", "fields.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2016,", "we", "had", "232", "employees,", "of", "whom", "29", "have", "a", "Ph.D.", "or", "an", "M.D.in", "their", "respective", "scientific", "fields."], "wordsB": ["As", "of", "December", "31,", "2017,", "we", "had", "190", "employees,", "of", "whom", "21", "have", "a", "Ph.D.", "or", "an", "M.D.in", "their", "respective", "scientific", "fields."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.003907823469489813, 0.0042955889366567135, 0.012129935435950756, 0.01659402623772621, 0.45410430431365967, 0.0050627426244318485, 0.01634940505027771, 0.8263967633247375, 0.3140246868133545, 0.007043719757348299, 0.006527930963784456, 0.38905417919158936, 0.0184837244451046, 0.004791984334588051, 0.012455307878553867, 0.0028621871024370193, 0.003207493806257844, 0.008839430287480354, 0.0015807700110599399, 0.00255629513412714, 0.0023592610377818346, 0.0034515548031777143, -1]}
{"idB": "1006281_18_item1_p71_s0", "idA": "1006281_17_item1_p193_s0", "sentA": "Our principal business address is set forth below.", "sentB": "The data set forth below was recorded at 24 months from 11 patients enrolled and treated in the long-term open-label extension trial.", "type": 2, "words": ["<tag1>", "Our", "principal", "business", "address", "is", "set", "forth", "below.", "<tag2>", "The", "data", "set", "forth", "below", "was", "recorded", "at", "24", "months", "from", "11", "patients", "enrolled", "and", "treated", "in", "the", "long-term", "open-label", "extension", "trial.", "<tag3>"], "wordsA": ["Our", "principal", "business", "address", "is", "set", "forth", "below."], "wordsB": ["The", "data", "set", "forth", "below", "was", "recorded", "at", "24", "months", "from", "11", "patients", "enrolled", "and", "treated", "in", "the", "long-term", "open-label", "extension", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005419119261205196, 0.20272290706634521, 0.011529996991157532, 0.010247644037008286, 0.013376854360103607, 0.0061067938804626465, 0.09809665381908417, 0.03382745757699013, 0.33109715580940247, 0.2629374861717224, 0.03045075386762619, 0.37692275643348694, 0.4047338366508484, 0.06202782690525055, 0.0380769819021225, 0.07107339799404144, 0.017567332834005356, 0.013495596125721931, 0.13414931297302246, 0.32386747002601624, 0.19641448557376862, 0.19120103120803833, -1]}
{"idB": "1006281_18_item1_p26_s0", "idA": "1006281_17_item1_p23_s0", "sentA": "We have successfully demonstrated the feasibility of our ProCellEx system through: (i) the FDA s approval of taliglucerase alfa, and its subsequent approval by other regulatory authorities; (ii) the clinical and preclinical studies we have performed to date, including the positive efficacy and safety data in our clinical trials for taliglucerase alfa, PRX-102; (iii) alidornase alfa; OPRX-106 for the treatment of ulcerative colitis; (iv) preclinical results in well-known models in our enzyme for each of Fabry disease, DNase and antiTNF; and (v) by expressing, on an exploratory, research scale, many additional complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines.", "sentB": "We have successfully demonstrated the feasibility of our ProCellEx system through: (i) the FDA s approval of taliglucerase alfa, and its subsequent approval by other regulatory authorities; (ii) the clinical and preclinical studies we have performed to date, including the positive efficacy and safety data in our clinical trials for taliglucerase alfa, pegunigalsidase alfa, alidornase alfa and OPRX-106 for the treatment of ulcerative colitis; (iii) preclinical results in well-known models in our enzyme for each of Fabry disease, DNase and antiTNF; and (iv) by expressing, on an exploratory, research scale, many additional complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines.", "type": 2, "words": ["<tag1>", "We", "have", "successfully", "demonstrated", "the", "feasibility", "of", "our", "ProCellEx", "system", "through:", "(i)", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa,", "and", "its", "subsequent", "approval", "by", "other", "regulatory", "authorities;", "(ii)", "the", "clinical", "and", "preclinical", "studies", "we", "have", "performed", "to", "date,", "including", "the", "positive", "efficacy", "and", "safety", "data", "in", "our", "clinical", "trials", "for", "taliglucerase", "alfa,", "PRX-102;", "(iii)", "alidornase", "alfa;", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis;", "(iv)", "preclinical", "results", "in", "well-known", "models", "in", "our", "enzyme", "for", "each", "of", "Fabry", "disease,", "DNase", "and", "antiTNF;", "and", "(v)", "by", "expressing,", "on", "an", "exploratory,", "research", "scale,", "many", "additional", "complex", "therapeutic", "proteins", "belonging", "to", "different", "drug", "classes,", "such", "as", "enzymes,", "hormones,", "monoclonal", "antibodies,", "cytokines", "and", "vaccines.", "<tag2>", "We", "have", "successfully", "demonstrated", "the", "feasibility", "of", "our", "ProCellEx", "system", "through:", "(i)", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa,", "and", "its", "subsequent", "approval", "by", "other", "regulatory", "authorities;", "(ii)", "the", "clinical", "and", "preclinical", "studies", "we", "have", "performed", "to", "date,", "including", "the", "positive", "efficacy", "and", "safety", "data", "in", "our", "clinical", "trials", "for", "taliglucerase", "alfa,", "pegunigalsidase", "alfa,", "alidornase", "alfa", "and", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis;", "(iii)", "preclinical", "results", "in", "well-known", "models", "in", "our", "enzyme", "for", "each", "of", "Fabry", "disease,", "DNase", "and", "antiTNF;", "and", "(iv)", "by", "expressing,", "on", "an", "exploratory,", "research", "scale,", "many", "additional", "complex", "therapeutic", "proteins", "belonging", "to", "different", "drug", "classes,", "such", "as", "enzymes,", "hormones,", "monoclonal", "antibodies,", "cytokines", "and", "vaccines.", "<tag3>"], "wordsA": ["We", "have", "successfully", "demonstrated", "the", "feasibility", "of", "our", "ProCellEx", "system", "through:", "(i)", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa,", "and", "its", "subsequent", "approval", "by", "other", "regulatory", "authorities;", "(ii)", "the", "clinical", "and", "preclinical", "studies", "we", "have", "performed", "to", "date,", "including", "the", "positive", "efficacy", "and", "safety", "data", "in", "our", "clinical", "trials", "for", "taliglucerase", "alfa,", "PRX-102;", "(iii)", "alidornase", "alfa;", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis;", "(iv)", "preclinical", "results", "in", "well-known", "models", "in", "our", "enzyme", "for", "each", "of", "Fabry", "disease,", "DNase", "and", "antiTNF;", "and", "(v)", "by", "expressing,", "on", "an", "exploratory,", "research", "scale,", "many", "additional", "complex", "therapeutic", "proteins", "belonging", "to", "different", "drug", "classes,", "such", "as", "enzymes,", "hormones,", "monoclonal", "antibodies,", "cytokines", "and", "vaccines."], "wordsB": ["We", "have", "successfully", "demonstrated", "the", "feasibility", "of", "our", "ProCellEx", "system", "through:", "(i)", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa,", "and", "its", "subsequent", "approval", "by", "other", "regulatory", "authorities;", "(ii)", "the", "clinical", "and", "preclinical", "studies", "we", "have", "performed", "to", "date,", "including", "the", "positive", "efficacy", "and", "safety", "data", "in", "our", "clinical", "trials", "for", "taliglucerase", "alfa,", "pegunigalsidase", "alfa,", "alidornase", "alfa", "and", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis;", "(iii)", "preclinical", "results", "in", "well-known", "models", "in", "our", "enzyme", "for", "each", "of", "Fabry", "disease,", "DNase", "and", "antiTNF;", "and", "(iv)", "by", "expressing,", "on", "an", "exploratory,", "research", "scale,", "many", "additional", "complex", "therapeutic", "proteins", "belonging", "to", "different", "drug", "classes,", "such", "as", "enzymes,", "hormones,", "monoclonal", "antibodies,", "cytokines", "and", "vaccines."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01332912314683199, 0.02077857032418251, 0.02255093865096569, 0.020321140065789223, 0.019988125190138817, 0.024245427921414375, 0.01651766151189804, 0.016804514452815056, 0.04115493968129158, 0.021156402304768562, 0.018911929801106453, 0.023720890283584595, 0.014523071236908436, 0.020482130348682404, 0.02287507988512516, 0.021743398159742355, 0.012572487816214561, 0.026667669415473938, 0.02366020902991295, 0.013795227743685246, 0.018414992839097977, 0.017374221235513687, 0.018821515142917633, 0.01441399659961462, 0.013692380860447884, 0.020354747772216797, 0.01917904056608677, 0.036649007350206375, 0.012725098058581352, 0.01615648716688156, 0.01569453999400139, 0.027328865602612495, 0.01603434421122074, 0.012914059683680534, 0.016579847782850266, 0.012929994612932205, 0.015847040340304375, 0.016482513397932053, 0.01194800902158022, 0.013247457332909107, 0.0158108938485384, 0.020425252616405487, 0.01641557738184929, 0.01758788712322712, 0.01509195938706398, 0.00980171374976635, 0.0104657132178545, 0.011024955660104752, 0.015414988622069359, 0.00968257151544094, 0.027558254078030586, 0.017909610643982887, 0.8527405261993408, 0.16483674943447113, 0.026183385401964188, 0.022823743522167206, 0.013344846665859222, 0.025418967008590698, 0.012475275434553623, 0.012769186869263649, 0.012220168486237526, 0.012777363881468773, 0.02879413217306137, 0.025229228660464287, 0.03567963093519211, 0.027138900011777878, 0.015330982394516468, 0.011209482327103615, 0.022993657737970352, 0.01749975048005581, 0.014764375053346157, 0.015273385681211948, 0.032511256635189056, 0.015484162606298923, 0.01740928925573826, 0.016221512109041214, 0.048749424517154694, 0.032215770334005356, 0.04043988883495331, 0.018415438011288643, 0.05782758817076683, 0.014538352377712727, 0.02704904042184353, 0.01510550919920206, 0.020725741982460022, 0.015519486740231514, 0.015085801482200623, 0.028344696387648582, 0.019698593765497208, 0.02901832014322281, 0.01471612136811018, 0.015958230942487717, 0.02286422625184059, 0.027326975017786026, 0.03691771253943443, 0.015673767775297165, 0.012072277255356312, 0.012149997055530548, 0.018692409619688988, 0.02516557276248932, 0.016913652420043945, 0.014351215213537216, 0.021201826632022858, 0.02321508899331093, 0.03204305097460747, 0.029318593442440033, 0.03576923906803131, 0.013126199133694172, 0.02636435255408287, -1]}
{"idB": "1006281_18_item1_p27_s0", "idA": "1006281_17_item1_p24_s0", "sentA": "The therapeutic proteins we have expressed to date in research models have produced the intended composition and similar biological activity compared to their respective human-equivalent proteins.", "sentB": "The therapeutic proteins we have expressed to date in research models have produced the intended composition and similar or superior biological activity compared to their respective human-equivalent proteins.", "type": 2, "words": ["<tag1>", "The", "therapeutic", "proteins", "we", "have", "expressed", "to", "date", "in", "research", "models", "have", "produced", "the", "intended", "composition", "and", "similar", "biological", "activity", "compared", "to", "their", "respective", "human-equivalent", "proteins.", "<tag2>", "The", "therapeutic", "proteins", "we", "have", "expressed", "to", "date", "in", "research", "models", "have", "produced", "the", "intended", "composition", "and", "similar", "or", "superior", "biological", "activity", "compared", "to", "their", "respective", "human-equivalent", "proteins.", "<tag3>"], "wordsA": ["The", "therapeutic", "proteins", "we", "have", "expressed", "to", "date", "in", "research", "models", "have", "produced", "the", "intended", "composition", "and", "similar", "biological", "activity", "compared", "to", "their", "respective", "human-equivalent", "proteins."], "wordsB": ["The", "therapeutic", "proteins", "we", "have", "expressed", "to", "date", "in", "research", "models", "have", "produced", "the", "intended", "composition", "and", "similar", "or", "superior", "biological", "activity", "compared", "to", "their", "respective", "human-equivalent", "proteins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.007080090697854757, 0.05223090946674347, 0.04848429933190346, 0.010807004757225513, 0.014566128142178059, 0.026097305119037628, 0.013922108337283134, 0.014702550135552883, 0.008692254312336445, 0.01067330688238144, 0.01593654602766037, 0.009351997636258602, 0.011952715925872326, 0.010565060190856457, 0.012531235814094543, 0.015729978680610657, 0.009673458524048328, 0.01178276538848877, 0.018211273476481438, 0.8371971249580383, 0.3601301908493042, 0.19440582394599915, 0.008400782942771912, 0.0072321402840316296, 0.006906721740961075, 0.00947197712957859, 0.018550533801317215, 0.015764232724905014, -1]}
{"idB": "1006281_18_item1_p61_s0", "idA": "1006281_17_item1_p2_s1", "sentA": "Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries.", "sentB": "Galafold has also been accepted for marketing in a number of other countries.", "type": 2, "words": ["<tag1>", "Subsequently,", "taliglucerase", "alfa", "was", "approved", "for", "marketing", "by", "the", "regulatory", "authorities", "of", "other", "countries.", "<tag2>", "Galafold", "has", "also", "been", "accepted", "for", "marketing", "in", "a", "number", "of", "other", "countries.", "<tag3>"], "wordsA": ["Subsequently,", "taliglucerase", "alfa", "was", "approved", "for", "marketing", "by", "the", "regulatory", "authorities", "of", "other", "countries."], "wordsB": ["Galafold", "has", "also", "been", "accepted", "for", "marketing", "in", "a", "number", "of", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.9416354298591614, 0.0358465351164341, 0.015172245912253857, 0.016968486830592155, 0.08576557040214539, 0.01127997599542141, 0.031824059784412384, 0.0032057836651802063, 0.003414117032662034, 0.006094892974942923, 0.00297490949742496, 0.005676856264472008, 0.013065187260508537, -1]}
{"idB": "1006281_18_item1_p42_s0", "idA": "1006281_17_item1_p39_s0", "sentA": "Potential ability to administer active therapeutic enzymes orally.", "sentB": "Potential ability to administer active therapeutic proteins orally.", "type": 2, "words": ["<tag1>", "Potential", "ability", "to", "administer", "active", "therapeutic", "enzymes", "orally.", "<tag2>", "Potential", "ability", "to", "administer", "active", "therapeutic", "proteins", "orally.", "<tag3>"], "wordsA": ["Potential", "ability", "to", "administer", "active", "therapeutic", "enzymes", "orally."], "wordsB": ["Potential", "ability", "to", "administer", "active", "therapeutic", "proteins", "orally."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004220015835016966, 0.006467842496931553, 0.003250483889132738, 0.024120012298226357, 0.03460982069373131, 0.05777404084801674, 0.9972015619277954, 0.006007907912135124, -1]}
{"idB": "1006281_18_item1_p8_s0", "idA": "1006281_17_item1_p3_s0", "sentA": "Taliglucerase alfa is called alfataliglicerase in Brazil and certain other Latin American countries, where it is marketed under the name Uplyso TM .", "sentB": "Taliglucerase alfa is called alfataliglicerase in Brazil and certain other Latin American countries, where it is marketed under the name alfataliglicerase.", "type": 2, "words": ["<tag1>", "Taliglucerase", "alfa", "is", "called", "alfataliglicerase", "in", "Brazil", "and", "certain", "other", "Latin", "American", "countries,", "where", "it", "is", "marketed", "under", "the", "name", "Uplyso", "TM", ".", "<tag2>", "Taliglucerase", "alfa", "is", "called", "alfataliglicerase", "in", "Brazil", "and", "certain", "other", "Latin", "American", "countries,", "where", "it", "is", "marketed", "under", "the", "name", "alfataliglicerase.", "<tag3>"], "wordsA": ["Taliglucerase", "alfa", "is", "called", "alfataliglicerase", "in", "Brazil", "and", "certain", "other", "Latin", "American", "countries,", "where", "it", "is", "marketed", "under", "the", "name", "Uplyso", "TM", "."], "wordsB": ["Taliglucerase", "alfa", "is", "called", "alfataliglicerase", "in", "Brazil", "and", "certain", "other", "Latin", "American", "countries,", "where", "it", "is", "marketed", "under", "the", "name", "alfataliglicerase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.5757427215576172, 0.5377780199050903, 0.05529894307255745, 0.09370855242013931, 0.64051753282547, 0.012972449883818626, 0.028359292075037956, 0.006036140024662018, 0.007750624790787697, 0.0075325798243284225, 0.012832638807594776, 0.010859481059014797, 0.025799911469221115, 0.005162999499589205, 0.009093459695577621, 0.009617052040994167, 0.08087356388568878, 0.050197310745716095, 0.02764035575091839, 0.228823721408844, 0.7943049073219299, -1]}
{"idB": "1006281_18_item1_p43_s3", "idA": "1006281_17_item1_p40_s3", "sentA": "To date we have completed successful preclinical animal studies for oral GCD and oral antiTNF, and early clinical trials of oral GCD in Gaucher patients and oral antiTNF in a phase I clinical trial in healthy volunteers and a currently ongoing phase IIa proof of concept trial.", "sentB": "To date we have completed successful preclinical animal studies for oral GCD and oral antiTNF, and early clinical trials of oral GCD in Gaucher patients.", "type": 2, "words": ["<tag1>", "To", "date", "we", "have", "completed", "successful", "preclinical", "animal", "studies", "for", "oral", "GCD", "and", "oral", "antiTNF,", "and", "early", "clinical", "trials", "of", "oral", "GCD", "in", "Gaucher", "patients", "and", "oral", "antiTNF", "in", "a", "phase", "I", "clinical", "trial", "in", "healthy", "volunteers", "and", "a", "currently", "ongoing", "phase", "IIa", "proof", "of", "concept", "trial.", "<tag2>", "To", "date", "we", "have", "completed", "successful", "preclinical", "animal", "studies", "for", "oral", "GCD", "and", "oral", "antiTNF,", "and", "early", "clinical", "trials", "of", "oral", "GCD", "in", "Gaucher", "patients.", "<tag3>"], "wordsA": ["To", "date", "we", "have", "completed", "successful", "preclinical", "animal", "studies", "for", "oral", "GCD", "and", "oral", "antiTNF,", "and", "early", "clinical", "trials", "of", "oral", "GCD", "in", "Gaucher", "patients", "and", "oral", "antiTNF", "in", "a", "phase", "I", "clinical", "trial", "in", "healthy", "volunteers", "and", "a", "currently", "ongoing", "phase", "IIa", "proof", "of", "concept", "trial."], "wordsB": ["To", "date", "we", "have", "completed", "successful", "preclinical", "animal", "studies", "for", "oral", "GCD", "and", "oral", "antiTNF,", "and", "early", "clinical", "trials", "of", "oral", "GCD", "in", "Gaucher", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006821815390139818, 0.012133318930864334, 0.012956944294273853, 0.010263748466968536, 0.036773450672626495, 0.05410672351717949, 0.05240940675139427, 0.029441216960549355, 0.033007413148880005, 0.004753421992063522, 0.033797454088926315, 0.11432085931301117, 0.004216841422021389, 0.023406455293297768, 0.04927976429462433, 0.0031151785515248775, 0.006997725460678339, 0.008791640400886536, 0.015834849327802658, 0.0035830936394631863, 0.03324422240257263, 0.29777222871780396, 0.004706506617367268, 0.01968294009566307, 0.04160258546471596, -1]}
{"idB": "1006281_18_item1_p43_s4", "idA": "1006281_17_item1_p40_s4", "sentA": "Our oral antiTNF product candidate is currently the subject of an ongoing phase IIa proof of concept trial and we have completed a phase I clinical trial of oral antiTNF in healthy volunteers.", "sentB": "In addition, we have completed a phase IIa proof of concept trial of oral antiTNF as well as a phase I clinical trial of oral antiTNF in healthy volunteers.", "type": 2, "words": ["<tag1>", "Our", "oral", "antiTNF", "product", "candidate", "is", "currently", "the", "subject", "of", "an", "ongoing", "phase", "IIa", "proof", "of", "concept", "trial", "and", "we", "have", "completed", "a", "phase", "I", "clinical", "trial", "of", "oral", "antiTNF", "in", "healthy", "volunteers.", "<tag2>", "In", "addition,", "we", "have", "completed", "a", "phase", "IIa", "proof", "of", "concept", "trial", "of", "oral", "antiTNF", "as", "well", "as", "a", "phase", "I", "clinical", "trial", "of", "oral", "antiTNF", "in", "healthy", "volunteers.", "<tag3>"], "wordsA": ["Our", "oral", "antiTNF", "product", "candidate", "is", "currently", "the", "subject", "of", "an", "ongoing", "phase", "IIa", "proof", "of", "concept", "trial", "and", "we", "have", "completed", "a", "phase", "I", "clinical", "trial", "of", "oral", "antiTNF", "in", "healthy", "volunteers."], "wordsB": ["In", "addition,", "we", "have", "completed", "a", "phase", "IIa", "proof", "of", "concept", "trial", "of", "oral", "antiTNF", "as", "well", "as", "a", "phase", "I", "clinical", "trial", "of", "oral", "antiTNF", "in", "healthy", "volunteers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.12732364237308502, 0.2144927978515625, 0.173061802983284, 0.08570628613233566, 0.5547922253608704, 0.037442151457071304, 0.0822620764374733, 0.058436792343854904, 0.044552676379680634, 0.03504103794693947, 0.0363023467361927, 0.14198625087738037, 0.02206023782491684, 0.11597463488578796, 0.14773821830749512, 0.0004504317184910178, 0.005647770129144192, 0.009030037559568882, 0.010834994725883007, 0.05304279923439026, 0.050503019243478775, 0.038510676473379135, 0.10693492740392685, 0.018993467092514038, 0.12044817209243774, 0.2014990597963333, 0.007820742204785347, 0.06544766575098038, 0.05005349591374397, -1]}
{"idB": "1006281_18_item1_p56_s0", "idA": "1006281_17_item1_p45_s0", "sentA": "Gaucher disease is caused by mutations or deficiencies in the gene encoding GCD, a lysosomal enzyme that catalyzes the degradation of the fatty substrate, glucosylceramide (GlcCer).", "sentB": "Fabry disease is an X-linked multisystem lysosomal storage disorder caused by the absence or reduction of -galactosidase-A ( -Gal-A) activity, which is a lysosomal enzyme that catalyzes the hydrolysis of globotriaosylceramide (Gb3) from oligosaccharides, glycoproteins and glycolipids.", "type": 2, "words": ["<tag1>", "Gaucher", "disease", "is", "caused", "by", "mutations", "or", "deficiencies", "in", "the", "gene", "encoding", "GCD,", "a", "lysosomal", "enzyme", "that", "catalyzes", "the", "degradation", "of", "the", "fatty", "substrate,", "glucosylceramide", "(GlcCer).", "<tag2>", "Fabry", "disease", "is", "an", "X-linked", "multisystem", "lysosomal", "storage", "disorder", "caused", "by", "the", "absence", "or", "reduction", "of", "-galactosidase-A", "(", "-Gal-A)", "activity,", "which", "is", "a", "lysosomal", "enzyme", "that", "catalyzes", "the", "hydrolysis", "of", "globotriaosylceramide", "(Gb3)", "from", "oligosaccharides,", "glycoproteins", "and", "glycolipids.", "<tag3>"], "wordsA": ["Gaucher", "disease", "is", "caused", "by", "mutations", "or", "deficiencies", "in", "the", "gene", "encoding", "GCD,", "a", "lysosomal", "enzyme", "that", "catalyzes", "the", "degradation", "of", "the", "fatty", "substrate,", "glucosylceramide", "(GlcCer)."], "wordsB": ["Fabry", "disease", "is", "an", "X-linked", "multisystem", "lysosomal", "storage", "disorder", "caused", "by", "the", "absence", "or", "reduction", "of", "-galactosidase-A", "(", "-Gal-A)", "activity,", "which", "is", "a", "lysosomal", "enzyme", "that", "catalyzes", "the", "hydrolysis", "of", "globotriaosylceramide", "(Gb3)", "from", "oligosaccharides,", "glycoproteins", "and", "glycolipids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.41069135069847107, 0.18487779796123505, 0.005555605050176382, 0.008409581147134304, 0.2205384373664856, 0.10781997442245483, 0.10931140184402466, 0.14738383889198303, 0.14974826574325562, 0.007802019361406565, 0.007801406551152468, 0.008024385198950768, 0.3743549585342407, 0.07476227730512619, 0.29112860560417175, 0.20076347887516022, 0.4727655351161957, 0.10623916238546371, 0.3212326467037201, 0.11773254722356796, 0.00011574880045372993, 0.0020283530466258526, 0.002334638498723507, 0.013243008404970169, 0.03980831056833267, 0.00363915809430182, 0.03833265230059624, 0.012777568772435188, 0.2718982696533203, 0.05378469079732895, 0.19901081919670105, 0.42016541957855225, 0.016017677262425423, 0.11390572041273117, 0.17678304016590118, 0.02998690865933895, 0.12859933078289032, -1]}
{"idB": "1006281_18_item1_p2_s0", "idA": "1006281_17_item1_p4_s0", "sentA": "Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer, as provided in the exclusive license and supply agreement by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement.", "sentB": "On October 19, 2017, Protalix Ltd., our wholly-owned subsidiary, and Chiesi entered into an Ex-US license and collaboration agreement, which we refer to as the Chiesi Agreement, pursuant to which Chiesi was granted an exclusive, license for all markets outside of the United States to develop and commercialize pegunigalsidase alfa.", "type": 2, "words": ["<tag1>", "Since", "its", "approval", "by", "the", "FDA,", "taliglucerase", "alfa", "has", "been", "marketed", "mainly", "in", "the", "United", "States", "by", "Pfizer,", "as", "provided", "in", "the", "exclusive", "license", "and", "supply", "agreement", "by", "and", "between", "Protalix", "Ltd.,", "our", "wholly-owned", "subsidiary,", "and", "Pfizer,", "which", "we", "refer", "to", "as", "the", "Pfizer", "Agreement.", "<tag2>", "On", "October", "19,", "2017,", "Protalix", "Ltd.,", "our", "wholly-owned", "subsidiary,", "and", "Chiesi", "entered", "into", "an", "Ex-US", "license", "and", "collaboration", "agreement,", "which", "we", "refer", "to", "as", "the", "Chiesi", "Agreement,", "pursuant", "to", "which", "Chiesi", "was", "granted", "an", "exclusive,", "license", "for", "all", "markets", "outside", "of", "the", "United", "States", "to", "develop", "and", "commercialize", "pegunigalsidase", "alfa.", "<tag3>"], "wordsA": ["Since", "its", "approval", "by", "the", "FDA,", "taliglucerase", "alfa", "has", "been", "marketed", "mainly", "in", "the", "United", "States", "by", "Pfizer,", "as", "provided", "in", "the", "exclusive", "license", "and", "supply", "agreement", "by", "and", "between", "Protalix", "Ltd.,", "our", "wholly-owned", "subsidiary,", "and", "Pfizer,", "which", "we", "refer", "to", "as", "the", "Pfizer", "Agreement."], "wordsB": ["On", "October", "19,", "2017,", "Protalix", "Ltd.,", "our", "wholly-owned", "subsidiary,", "and", "Chiesi", "entered", "into", "an", "Ex-US", "license", "and", "collaboration", "agreement,", "which", "we", "refer", "to", "as", "the", "Chiesi", "Agreement,", "pursuant", "to", "which", "Chiesi", "was", "granted", "an", "exclusive,", "license", "for", "all", "markets", "outside", "of", "the", "United", "States", "to", "develop", "and", "commercialize", "pegunigalsidase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.019947050139307976, 0.16607028245925903, 0.1499473601579666, 0.10869947820901871, 0.02180001698434353, 0.012683052569627762, 0.003600229974836111, 0.009087068028748035, 0.009787340648472309, 0.008890812285244465, 0.16961264610290527, 0.03165091946721077, 0.026827869936823845, 0.022672593593597412, 0.35004904866218567, 0.07314049452543259, 0.027894193306565285, 0.06510267406702042, 0.09433595836162567, 0.0022244893480092287, 0.008836515247821808, 0.010657819919288158, 0.0056687332689762115, 0.0043168761767446995, 0.007358946371823549, 0.16129983961582184, 0.05757296457886696, 0.0054204403422772884, 0.005889857187867165, 0.0049640885554254055, 0.16290101408958435, 0.044896356761455536, 0.04362110421061516, 0.029909519478678703, 0.02674921788275242, 0.08459191024303436, 0.022288557142019272, 0.2363305538892746, 0.11894246190786362, 0.2111900895833969, 0.11208949238061905, 0.07924319803714752, 0.1339767873287201, 0.19925902783870697, 0.012400597333908081, 0.04633067548274994, 0.032604217529296875, 0.05896427854895592, 0.4843747913837433, 0.20261931419372559, -1]}
{"idB": "1006281_18_item1_p9_s0", "idA": "1006281_17_item1_p4_s0", "sentA": "Since its approval by the FDA, taliglucerase alfa has been marketed mainly in the United States by Pfizer, as provided in the exclusive license and supply agreement by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement.", "sentB": "Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer, which we refer to as the Pfizer Agreement.", "type": 2, "words": ["<tag1>", "Since", "its", "approval", "by", "the", "FDA,", "taliglucerase", "alfa", "has", "been", "marketed", "mainly", "in", "the", "United", "States", "by", "Pfizer,", "as", "provided", "in", "the", "exclusive", "license", "and", "supply", "agreement", "by", "and", "between", "Protalix", "Ltd.,", "our", "wholly-owned", "subsidiary,", "and", "Pfizer,", "which", "we", "refer", "to", "as", "the", "Pfizer", "Agreement.", "<tag2>", "Since", "its", "approval", "by", "the", "FDA,", "taliglucerase", "alfa", "has", "been", "marketed", "by", "Pfizer,", "as", "provided", "in", "the", "exclusive", "license", "and", "supply", "agreement", "by", "and", "between", "Protalix", "Ltd.", "and", "Pfizer,", "which", "we", "refer", "to", "as", "the", "Pfizer", "Agreement.", "<tag3>"], "wordsA": ["Since", "its", "approval", "by", "the", "FDA,", "taliglucerase", "alfa", "has", "been", "marketed", "mainly", "in", "the", "United", "States", "by", "Pfizer,", "as", "provided", "in", "the", "exclusive", "license", "and", "supply", "agreement", "by", "and", "between", "Protalix", "Ltd.,", "our", "wholly-owned", "subsidiary,", "and", "Pfizer,", "which", "we", "refer", "to", "as", "the", "Pfizer", "Agreement."], "wordsB": ["Since", "its", "approval", "by", "the", "FDA,", "taliglucerase", "alfa", "has", "been", "marketed", "by", "Pfizer,", "as", "provided", "in", "the", "exclusive", "license", "and", "supply", "agreement", "by", "and", "between", "Protalix", "Ltd.", "and", "Pfizer,", "which", "we", "refer", "to", "as", "the", "Pfizer", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0897262766957283, 0.0335397832095623, 0.09646204113960266, 0.02610759437084198, 0.02337143011391163, 0.07060227543115616, 0.12231229245662689, 0.17852143943309784, 0.02585817500948906, 0.017586469650268555, 0.09922792762517929, 0.039788901805877686, 0.2631697654724121, 0.0190721582621336, 0.02129073441028595, 0.011677991598844528, 0.011907367035746574, 0.038974035531282425, 0.03197185695171356, 0.01704055443406105, 0.02416064590215683, 0.030641378834843636, 0.014935280196368694, 0.017210211604833603, 0.022556597366929054, 0.09034480899572372, 0.10047736018896103, 0.03317350894212723, 0.37284788489341736, 0.014177922159433365, 0.020530948415398598, 0.027318386361002922, 0.01477270107716322, 0.020398946478962898, 0.017796210944652557, 0.2539105713367462, 0.3860529661178589, -1]}
{"idB": "1006281_18_item1_p55_s0", "idA": "1006281_17_item1_p50_s0", "sentA": "We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth as there is a significant unmet medical need for Fabry disease treatments.", "sentB": "Fabry disease is a serious, life-threatening condition.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments.", "<tag2>", "Fabry", "disease", "is", "a", "serious,", "life-threatening", "condition.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments."], "wordsB": ["Fabry", "disease", "is", "a", "serious,", "life-threatening", "condition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.03374120220541954, 0.06160711124539375, 0.028997385874390602, 0.022754251956939697, 0.4194367229938507, 0.9229156970977783, 0.46189209818840027, -1]}
{"idB": "1006281_18_item1_p6_s1", "idA": "1006281_17_item1_p50_s0", "sentA": "We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth as there is a significant unmet medical need for Fabry disease treatments.", "sentB": "Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments.", "<tag2>", "Fast", "Track", "designation", "is", "a", "process", "designed", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drugs", "and", "vaccines", "for", "serious", "conditions", "that", "fill", "an", "unmet", "medical", "need.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments."], "wordsB": ["Fast", "Track", "designation", "is", "a", "process", "designed", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drugs", "and", "vaccines", "for", "serious", "conditions", "that", "fill", "an", "unmet", "medical", "need."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.5099363327026367, 0.6409626603126526, 0.50242018699646, 0.005165451671928167, 0.0053292494267225266, 0.05467420071363449, 0.001341380411759019, 0.0061947922222316265, 0.011135529726743698, 0.00902511365711689, 0.042117711156606674, 0.0056699239648878574, 0.021554594859480858, 0.006631980650126934, 0.07554790377616882, 0.01870414800941944, 0.24137523770332336, 0.03003668412566185, 0.36942699551582336, 0.003683771239593625, 0.04957006126642227, 0.039151035249233246, 0.001635357621125877, 0.007798635400831699, 0.0028693596832454205, 0.007329641375690699, 0.011506082490086555, 0.011951927095651627, -1]}
{"idB": "1006281_18_item1_p56_s2", "idA": "1006281_17_item1_p51_s1", "sentA": "The accumulation of Gb3 in body tissues results in Fabry disease.", "sentB": "The accumulation of glycosphingolipids (e.g., Gb3) leads to chronic pain, skin lesions, cardiac, deficiencies, and, in particular, renal involvement.", "type": 2, "words": ["<tag1>", "The", "accumulation", "of", "Gb3", "in", "body", "tissues", "results", "in", "Fabry", "disease.", "<tag2>", "The", "accumulation", "of", "glycosphingolipids", "(e.g.,", "Gb3)", "leads", "to", "chronic", "pain,", "skin", "lesions,", "cardiac,", "deficiencies,", "and,", "in", "particular,", "renal", "involvement.", "<tag3>"], "wordsA": ["The", "accumulation", "of", "Gb3", "in", "body", "tissues", "results", "in", "Fabry", "disease."], "wordsB": ["The", "accumulation", "of", "glycosphingolipids", "(e.g.,", "Gb3)", "leads", "to", "chronic", "pain,", "skin", "lesions,", "cardiac,", "deficiencies,", "and,", "in", "particular,", "renal", "involvement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005471847951412201, 0.11399780958890915, 0.09560459107160568, 0.7888448238372803, 0.05282200127840042, 0.04876023903489113, 0.05944794788956642, 0.0377296507358551, 0.15775689482688904, 0.18530884385108948, 0.3052825331687927, 0.28681784868240356, 0.12067123502492905, 0.23439672589302063, 0.009050465188920498, 0.013702747412025928, 0.031961165368556976, 0.3754367530345917, 0.3992142081260681, -1]}
{"idB": "1006281_18_item1_p5_s1", "idA": "1006281_17_item1_p55_s1", "sentA": "Fabrazyme, marketed by Genzyme Corporation (acquired by Sanofi), is approved for the treatment of Fabry disease in the United States and the European Union.", "sentB": "If the orphan drug designation is maintained at the time pegunigalsidase alfa is approved for marketing in the European Union, if at all, we expect that PRX-102 will benefit from 10 years of market exclusivity within the European Union.", "type": 2, "words": ["<tag1>", "Fabrazyme,", "marketed", "by", "Genzyme", "Corporation", "(acquired", "by", "Sanofi),", "is", "approved", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "If", "the", "orphan", "drug", "designation", "is", "maintained", "at", "the", "time", "pegunigalsidase", "alfa", "is", "approved", "for", "marketing", "in", "the", "European", "Union,", "if", "at", "all,", "we", "expect", "that", "PRX-102", "will", "benefit", "from", "10", "years", "of", "market", "exclusivity", "within", "the", "European", "Union.", "<tag3>"], "wordsA": ["Fabrazyme,", "marketed", "by", "Genzyme", "Corporation", "(acquired", "by", "Sanofi),", "is", "approved", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["If", "the", "orphan", "drug", "designation", "is", "maintained", "at", "the", "time", "pegunigalsidase", "alfa", "is", "approved", "for", "marketing", "in", "the", "European", "Union,", "if", "at", "all,", "we", "expect", "that", "PRX-102", "will", "benefit", "from", "10", "years", "of", "market", "exclusivity", "within", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.040456946939229965, 0.01081723440438509, 0.23356440663337708, 0.2814943194389343, 0.11436337977647781, 0.02446003071963787, 0.05718567967414856, 0.005874167662113905, 0.007013136986643076, 0.010549931786954403, 0.38028794527053833, 0.11907926201820374, 0.012658905237913132, 0.021254701539874077, 0.012158790603280067, 0.029982317239046097, 0.005483745131641626, 0.005848039872944355, 0.017260538414120674, 0.01926497370004654, 0.024890989065170288, 0.02786545641720295, 0.025059586390852928, 0.029077600687742233, 0.028248168528079987, 0.012418877333402634, 0.2820911705493927, 0.016795149073004723, 0.03154411539435387, 0.00749169522896409, 0.016761047765612602, 0.01641188934445381, 0.015650317072868347, 0.08567533642053604, 0.1454322785139084, 0.018041599541902542, 0.01142425648868084, 0.034641727805137634, 0.032629579305648804, -1]}
{"idB": "1006281_18_item1_p58_s2", "idA": "1006281_17_item1_p55_s2", "sentA": "Sanofi reported 674 million (approximately $709 million) in worldwide sales of Fabrazyme in 2016.", "sentB": "Sanofi reported 722 million (approximately $865 million) in worldwide sales of Fabrazyme in 2017.", "type": 2, "words": ["<tag1>", "Sanofi", "reported", "674", "million", "(approximately", "$709", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2016.", "<tag2>", "Sanofi", "reported", "722", "million", "(approximately", "$865", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2017.", "<tag3>"], "wordsA": ["Sanofi", "reported", "674", "million", "(approximately", "$709", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2016."], "wordsB": ["Sanofi", "reported", "722", "million", "(approximately", "$865", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.007811955641955137, 0.022282399237155914, 0.8953468799591064, 0.32835936546325684, 0.014172738417983055, 0.6273919343948364, 0.1859874725341797, 0.0038160362746566534, 0.008538144640624523, 0.008587012067437172, 0.002992006717249751, 0.006030266638845205, 0.00819775927811861, 0.4664599895477295, -1]}
{"idB": "1006281_18_item1_p4_s1", "idA": "1006281_17_item1_p56_s0", "sentA": "The other approved drug for the treatment of Fabry disease in the European Union is Replagal, which is marketed by Shire.", "sentB": "The designation was granted after the EMA s Committee for Orphan Medicinal Products, or the COMP, issued a positive opinion supporting the designation noting that we had established that there was medically plausible evidence that pegunigalsidase alfa will provide a significant benefit over existing approved therapies in the European Union for the treatment of Fabry disease.", "type": 2, "words": ["<tag1>", "The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire.", "<tag2>", "The", "designation", "was", "granted", "after", "the", "EMA", "s", "Committee", "for", "Orphan", "Medicinal", "Products,", "or", "the", "COMP,", "issued", "a", "positive", "opinion", "supporting", "the", "designation", "noting", "that", "we", "had", "established", "that", "there", "was", "medically", "plausible", "evidence", "that", "pegunigalsidase", "alfa", "will", "provide", "a", "significant", "benefit", "over", "existing", "approved", "therapies", "in", "the", "European", "Union", "for", "the", "treatment", "of", "Fabry", "disease.", "<tag3>"], "wordsA": ["The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire."], "wordsB": ["The", "designation", "was", "granted", "after", "the", "EMA", "s", "Committee", "for", "Orphan", "Medicinal", "Products,", "or", "the", "COMP,", "issued", "a", "positive", "opinion", "supporting", "the", "designation", "noting", "that", "we", "had", "established", "that", "there", "was", "medically", "plausible", "evidence", "that", "pegunigalsidase", "alfa", "will", "provide", "a", "significant", "benefit", "over", "existing", "approved", "therapies", "in", "the", "European", "Union", "for", "the", "treatment", "of", "Fabry", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.00713025126606226, 0.1261167675256729, 0.01716565154492855, 0.09330563992261887, 0.011593558825552464, 0.01395400520414114, 0.15424227714538574, 0.12537238001823425, 0.18105486035346985, 0.04533862695097923, 0.17190629243850708, 0.29700595140457153, 0.1804044097661972, 0.014825567603111267, 0.014352306723594666, 0.10201101750135422, 0.025565551593899727, 0.010402816347777843, 0.02666405588388443, 0.03231465443968773, 0.030492331832647324, 0.008922615088522434, 0.03888418897986412, 0.0064013185910880566, 0.0004422119236551225, 0.0168391652405262, 0.006981865968555212, 0.009254949167370796, 0.009271604008972645, 0.00518788630142808, 0.006552489940077066, 0.01822727732360363, 0.017191864550113678, 0.019614066928625107, 0.009977441281080246, 0.30991101264953613, 0.05468704178929329, 0.0214587040245533, 0.02828177995979786, 0.012228851206600666, 0.023739492520689964, 0.023212645202875137, 0.010806973092257977, 0.02012387104332447, 0.04946257174015045, 0.0464136078953743, 0.00308837927877903, 0.0030159170273691416, 0.005184255540370941, 0.005486638285219669, 0.002716049551963806, 0.004095243290066719, 0.012627474963665009, 0.003660208312794566, 0.010799354873597622, 0.009878951124846935, -1]}
{"idB": "1006281_18_item1_p59_s0", "idA": "1006281_17_item1_p56_s0", "sentA": "The other approved drug for the treatment of Fabry disease in the European Union is Replagal, which is marketed by Shire.", "sentB": "The other approved enzyme replacement therapy for the treatment of Fabry disease in the European Union is Replagal, which is marketed by Shire.", "type": 2, "words": ["<tag1>", "The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire.", "<tag2>", "The", "other", "approved", "enzyme", "replacement", "therapy", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire.", "<tag3>"], "wordsA": ["The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire."], "wordsB": ["The", "other", "approved", "enzyme", "replacement", "therapy", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0023130676709115505, 0.006183916702866554, 0.04680413752794266, 0.9594679474830627, 0.9312916994094849, 0.6346182823181152, 0.0019587331917136908, 0.0022274230141192675, 0.004975449293851852, 0.0020876284688711166, 0.004521663300693035, 0.0035289828665554523, 0.0017726480728015304, 0.001991510624065995, 0.0029109048191457987, 0.003218443365767598, 0.0022226569708436728, 0.006190854124724865, 0.0018864135490730405, 0.0023290738463401794, 0.004020731896162033, 0.002459899755194783, 0.01071054395288229, -1]}
{"idB": "1006281_18_item1_p60_s0", "idA": "1006281_17_item1_p56_s0", "sentA": "The other approved drug for the treatment of Fabry disease in the European Union is Replagal, which is marketed by Shire.", "sentB": "In April 2016, Galafold TM , a chaperone therapy manufactured by Amicus Therapeutics, Inc., or Amicus, was approved in the European Union as a monotherapy for Fabry disease in patients with amenable mutations.", "type": 2, "words": ["<tag1>", "The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire.", "<tag2>", "In", "April", "2016,", "Galafold", "TM", ",", "a", "chaperone", "therapy", "manufactured", "by", "Amicus", "Therapeutics,", "Inc.,", "or", "Amicus,", "was", "approved", "in", "the", "European", "Union", "as", "a", "monotherapy", "for", "Fabry", "disease", "in", "patients", "with", "amenable", "mutations.", "<tag3>"], "wordsA": ["The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire."], "wordsB": ["In", "April", "2016,", "Galafold", "TM", ",", "a", "chaperone", "therapy", "manufactured", "by", "Amicus", "Therapeutics,", "Inc.,", "or", "Amicus,", "was", "approved", "in", "the", "European", "Union", "as", "a", "monotherapy", "for", "Fabry", "disease", "in", "patients", "with", "amenable", "mutations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.015264999121427536, 0.04030216485261917, 0.09223363548517227, 0.33724603056907654, 0.33045074343681335, 0.0002746295358520001, 0.011321693658828735, 0.2223043441772461, 0.1852259784936905, 0.043031416833400726, 0.02446681261062622, 0.186435729265213, 0.14110714197158813, 0.0887705385684967, 0.01526658982038498, 0.07274716347455978, 0.0072389161214232445, 0.047575943171978, 0.0036214464344084263, 0.0034628345165401697, 0.006681530270725489, 0.00994373019784689, 0.016219640150666237, 0.017427176237106323, 0.30179694294929504, 0.009385250508785248, 0.015349426306784153, 0.015680214390158653, 0.007459351327270269, 0.10499700903892517, 0.05691896378993988, 0.2870992124080658, 0.5507639646530151, -1]}
{"idB": "1006281_18_item1_p59_s1", "idA": "1006281_17_item1_p56_s1", "sentA": "Shire reported $452 million in sales of Replagal in 2016.", "sentB": "Shire reported $472 million in sales of Replagal in 2017.", "type": 2, "words": ["<tag1>", "Shire", "reported", "$452", "million", "in", "sales", "of", "Replagal", "in", "2016.", "<tag2>", "Shire", "reported", "$472", "million", "in", "sales", "of", "Replagal", "in", "2017.", "<tag3>"], "wordsA": ["Shire", "reported", "$452", "million", "in", "sales", "of", "Replagal", "in", "2016."], "wordsB": ["Shire", "reported", "$472", "million", "in", "sales", "of", "Replagal", "in", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0150945158675313, 0.017687244340777397, 0.9894344210624695, 0.08268479257822037, 0.0032282972242683172, 0.00950112845748663, 0.0024786144495010376, 0.006082732230424881, 0.010547447949647903, 0.5150970220565796, -1]}
{"idB": "1006281_18_item1_p61_s1", "idA": "1006281_17_item1_p56_s1", "sentA": "Shire reported $452 million in sales of Replagal in 2016.", "sentB": "Amicus reported revenues of approximately $36 million in sales of Galafold in 2017.", "type": 2, "words": ["<tag1>", "Shire", "reported", "$452", "million", "in", "sales", "of", "Replagal", "in", "2016.", "<tag2>", "Amicus", "reported", "revenues", "of", "approximately", "$36", "million", "in", "sales", "of", "Galafold", "in", "2017.", "<tag3>"], "wordsA": ["Shire", "reported", "$452", "million", "in", "sales", "of", "Replagal", "in", "2016."], "wordsB": ["Amicus", "reported", "revenues", "of", "approximately", "$36", "million", "in", "sales", "of", "Galafold", "in", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.4466085731983185, 0.019731128588318825, 0.027238130569458008, 0.007662734482437372, 0.0704190656542778, 0.6938105821609497, 0.19961288571357727, 0.008456467650830746, 0.06421095132827759, 0.04582737386226654, 0.8867504596710205, 0.014496090821921825, 0.2415924072265625, -1]}
{"idB": "1006281_18_item1_p3_s0", "idA": "1006281_17_item1_p58_s0", "sentA": "In October 2016, the first patient was dosed in our global phase III clinical trial of PRX-102 for the treatment of Fabry disease.", "sentB": "Pegunigalsidase alfa, or PRX-102, is our chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in phase III clinical trials for the treatment of Fabry disease .", "type": 2, "words": ["<tag1>", "In", "October", "2016,", "the", "first", "patient", "was", "dosed", "in", "our", "global", "phase", "III", "clinical", "trial", "of", "PRX-102", "for", "the", "treatment", "of", "Fabry", "disease.", "<tag2>", "Pegunigalsidase", "alfa,", "or", "PRX-102,", "is", "our", "chemically", "modified", "version", "of", "the", "recombinant", "protein", "alpha-Galactosidase-A", "protein", "that", "is", "currently", "being", "evaluated", "in", "phase", "III", "clinical", "trials", "for", "the", "treatment", "of", "Fabry", "disease", ".", "<tag3>"], "wordsA": ["In", "October", "2016,", "the", "first", "patient", "was", "dosed", "in", "our", "global", "phase", "III", "clinical", "trial", "of", "PRX-102", "for", "the", "treatment", "of", "Fabry", "disease."], "wordsB": ["Pegunigalsidase", "alfa,", "or", "PRX-102,", "is", "our", "chemically", "modified", "version", "of", "the", "recombinant", "protein", "alpha-Galactosidase-A", "protein", "that", "is", "currently", "being", "evaluated", "in", "phase", "III", "clinical", "trials", "for", "the", "treatment", "of", "Fabry", "disease", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.7074272036552429, 0.33118343353271484, 0.007480641361325979, 0.02174895629286766, 0.022160885855555534, 0.02010072022676468, 0.07537954300642014, 0.13200168311595917, 0.09931228309869766, 0.032022975385189056, 0.02699054591357708, 0.1113075315952301, 0.14863823354244232, 0.3853778541088104, 0.08347899466753006, 0.00016968540148809552, 0.003447138937190175, 0.004600544925779104, 0.00894732866436243, 0.022414211183786392, 0.0034422704484313726, 0.008663944900035858, 0.0070732757449150085, 0.009642892517149448, 0.011086135171353817, 0.0023594002705067396, 0.0033732124138623476, 0.008013752289116383, 0.003510393900796771, 0.00638528261333704, 0.007446630857884884, 7.111128797987476e-05, -1]}
{"idB": "1006281_18_item1_p68_s1", "idA": "1006281_17_item1_p58_s0", "sentA": "In October 2016, the first patient was dosed in our global phase III clinical trial of PRX-102 for the treatment of Fabry disease.", "sentB": "PRX-102 with a 2 mg/kg dose was found to be safe and well tolerated with no formation of antibodies in our phase I/II clinical trial of PRX-102 for the treatment of Fabry disease.", "type": 2, "words": ["<tag1>", "In", "October", "2016,", "the", "first", "patient", "was", "dosed", "in", "our", "global", "phase", "III", "clinical", "trial", "of", "PRX-102", "for", "the", "treatment", "of", "Fabry", "disease.", "<tag2>", "PRX-102", "with", "a", "2", "mg/kg", "dose", "was", "found", "to", "be", "safe", "and", "well", "tolerated", "with", "no", "formation", "of", "antibodies", "in", "our", "phase", "I/II", "clinical", "trial", "of", "PRX-102", "for", "the", "treatment", "of", "Fabry", "disease.", "<tag3>"], "wordsA": ["In", "October", "2016,", "the", "first", "patient", "was", "dosed", "in", "our", "global", "phase", "III", "clinical", "trial", "of", "PRX-102", "for", "the", "treatment", "of", "Fabry", "disease."], "wordsB": ["PRX-102", "with", "a", "2", "mg/kg", "dose", "was", "found", "to", "be", "safe", "and", "well", "tolerated", "with", "no", "formation", "of", "antibodies", "in", "our", "phase", "I/II", "clinical", "trial", "of", "PRX-102", "for", "the", "treatment", "of", "Fabry", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.10361308604478836, 0.012104884721338749, 0.02625039964914322, 0.6470175385475159, 0.6488752961158752, 0.28689882159233093, 0.007661719340831041, 0.0548018254339695, 0.024301795288920403, 0.035269562155008316, 0.15211467444896698, 0.02394028753042221, 0.16892533004283905, 0.23614342510700226, 0.04439059644937515, 0.4154759645462036, 0.26457521319389343, 0.23214507102966309, 0.34667325019836426, 0.007035480346530676, 0.007569049019366503, 0.01959346979856491, 0.030588185414671898, 0.019047275185585022, 0.023853393271565437, 0.005638401955366135, 0.014531360007822514, 0.0028930632397532463, 0.003730034688487649, 0.013966579921543598, 0.004314540419727564, 0.009634898044168949, 0.00849066860973835, -1]}
{"idB": "1006281_18_item1_p62_s1", "idA": "1006281_17_item1_p58_s1", "sentA": "Over 20 sites have been opened to participate in this trial.", "sentB": "Over 40 sites are currently participating in this trial.", "type": 2, "words": ["<tag1>", "Over", "20", "sites", "have", "been", "opened", "to", "participate", "in", "this", "trial.", "<tag2>", "Over", "40", "sites", "are", "currently", "participating", "in", "this", "trial.", "<tag3>"], "wordsA": ["Over", "20", "sites", "have", "been", "opened", "to", "participate", "in", "this", "trial."], "wordsB": ["Over", "40", "sites", "are", "currently", "participating", "in", "this", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0614018589258194, 0.991797685623169, 0.3180232048034668, 0.004374942276626825, 0.02574441395699978, 0.06372205168008804, 0.0035027512349188328, 0.0022814003750681877, 0.008304458111524582, -1]}
{"idB": "1006281_18_item1_p63_s0", "idA": "1006281_17_item1_p59_s0", "sentA": "The phase III efficacy and safety clinical trial, which we refer to as the BALANCE Study, is a 24-month multi-center, randomized, double-blind, active control study of PRX-102 in Fabry patients with impaired renal function.", "sentB": "The phase III efficacy and safety clinical trial, which we refer to as the BALANCE Study, is a multi-center, randomized, double-blind, active control study of PRX-102 in Fabry patients with impaired renal function.", "type": 2, "words": ["<tag1>", "The", "phase", "III", "efficacy", "and", "safety", "clinical", "trial,", "which", "we", "refer", "to", "as", "the", "BALANCE", "Study,", "is", "a", "24-month", "multi-center,", "randomized,", "double-blind,", "active", "control", "study", "of", "PRX-102", "in", "Fabry", "patients", "with", "impaired", "renal", "function.", "<tag2>", "The", "phase", "III", "efficacy", "and", "safety", "clinical", "trial,", "which", "we", "refer", "to", "as", "the", "BALANCE", "Study,", "is", "a", "multi-center,", "randomized,", "double-blind,", "active", "control", "study", "of", "PRX-102", "in", "Fabry", "patients", "with", "impaired", "renal", "function.", "<tag3>"], "wordsA": ["The", "phase", "III", "efficacy", "and", "safety", "clinical", "trial,", "which", "we", "refer", "to", "as", "the", "BALANCE", "Study,", "is", "a", "24-month", "multi-center,", "randomized,", "double-blind,", "active", "control", "study", "of", "PRX-102", "in", "Fabry", "patients", "with", "impaired", "renal", "function."], "wordsB": ["The", "phase", "III", "efficacy", "and", "safety", "clinical", "trial,", "which", "we", "refer", "to", "as", "the", "BALANCE", "Study,", "is", "a", "multi-center,", "randomized,", "double-blind,", "active", "control", "study", "of", "PRX-102", "in", "Fabry", "patients", "with", "impaired", "renal", "function."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.008298157714307308, 0.03132937103509903, 0.03606550395488739, 0.024828830733895302, 0.015856606885790825, 0.020960746333003044, 0.015890128910541534, 0.019467994570732117, 0.012647789902985096, 0.01689182221889496, 0.02807692438364029, 0.02057104930281639, 0.021439701318740845, 0.012117406353354454, 0.3269656002521515, 0.09239929169416428, 0.0082473149523139, 0.008385098539292812, 0.05956896021962166, 0.03311033174395561, 0.06688793748617172, 0.03002353385090828, 0.03334605693817139, 0.024445459246635437, 0.01027440931648016, 0.05781037360429764, 0.008175775408744812, 0.03756263479590416, 0.030250538140535355, 0.025716116651892662, 0.7499294281005859, 0.3499285578727722, 0.19525350630283356, -1]}
{"idB": "1006281_18_item1_p67_s2", "idA": "1006281_17_item1_p59_s1", "sentA": "The trial is designed to enroll 78 patients previously treated with Fabrazyme (agalsidase beta) with a stable dose for at least six months.", "sentB": "The trial is designed to enroll 22 patients.", "type": 2, "words": ["<tag1>", "The", "trial", "is", "designed", "to", "enroll", "78", "patients", "previously", "treated", "with", "Fabrazyme", "(agalsidase", "beta)", "with", "a", "stable", "dose", "for", "at", "least", "six", "months.", "<tag2>", "The", "trial", "is", "designed", "to", "enroll", "22", "patients.", "<tag3>"], "wordsA": ["The", "trial", "is", "designed", "to", "enroll", "78", "patients", "previously", "treated", "with", "Fabrazyme", "(agalsidase", "beta)", "with", "a", "stable", "dose", "for", "at", "least", "six", "months."], "wordsB": ["The", "trial", "is", "designed", "to", "enroll", "22", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0014797807671129704, 0.01717984862625599, 0.0019606060814112425, 0.012763934209942818, 0.0065091862343251705, 0.07804738730192184, 0.9887639284133911, 0.33700239658355713, -1]}
{"idB": "1006281_18_item1_p63_s2", "idA": "1006281_17_item1_p59_s2", "sentA": "Enrolled patients will be randomized to continue treatment with 1 mg/kg of either Fabrazyme or PRX-102, at a 2:1 ratio of PRX-102 to Fabrazyme, respectively.", "sentB": "Enrolled patients are randomized to continue treatment with 1 mg/kg of either Fabrazyme or PRX-102, at a 2:1 ratio of PRX-102 to Fabrazyme, respectively.", "type": 2, "words": ["<tag1>", "Enrolled", "patients", "will", "be", "randomized", "to", "continue", "treatment", "with", "1", "mg/kg", "of", "either", "Fabrazyme", "or", "PRX-102,", "at", "a", "2:1", "ratio", "of", "PRX-102", "to", "Fabrazyme,", "respectively.", "<tag2>", "Enrolled", "patients", "are", "randomized", "to", "continue", "treatment", "with", "1", "mg/kg", "of", "either", "Fabrazyme", "or", "PRX-102,", "at", "a", "2:1", "ratio", "of", "PRX-102", "to", "Fabrazyme,", "respectively.", "<tag3>"], "wordsA": ["Enrolled", "patients", "will", "be", "randomized", "to", "continue", "treatment", "with", "1", "mg/kg", "of", "either", "Fabrazyme", "or", "PRX-102,", "at", "a", "2:1", "ratio", "of", "PRX-102", "to", "Fabrazyme,", "respectively."], "wordsB": ["Enrolled", "patients", "are", "randomized", "to", "continue", "treatment", "with", "1", "mg/kg", "of", "either", "Fabrazyme", "or", "PRX-102,", "at", "a", "2:1", "ratio", "of", "PRX-102", "to", "Fabrazyme,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.2756293714046478, 0.20687484741210938, 0.03704206645488739, 0.06408105045557022, 0.01739731803536415, 0.04658288136124611, 0.0469735711812973, 0.033846817910671234, 0.421755850315094, 0.2705632448196411, 0.02525651827454567, 0.08585470169782639, 0.1456809639930725, 0.030185384675860405, 0.16623593866825104, 0.022281307727098465, 0.0217974241822958, 0.06290261447429657, 0.03494582697749138, 0.019961975514888763, 0.22854305803775787, 0.026478610932826996, 0.07559766620397568, 0.0628354400396347, -1]}
{"idB": "1006281_18_item1_p9_s5", "idA": "1006281_17_item1_p5_s1", "sentA": "Under the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all revenues globally for Elelyso, excluding Brazil, where we are responsible for all expenses and retain all revenues.", "sentB": "Under the Amended Pfizer Agreement, Pfizer is responsible for 100% of expenses, and entitled to all revenues, globally for Elelyso, excluding Brazil, where we are responsible for all expenses and retain all revenues.", "type": 2, "words": ["<tag1>", "Under", "the", "Amended", "Pfizer", "Agreement,", "Pfizer", "is", "responsible", "for", "100%", "of", "expenses,", "and", "entitled", "to", "all", "revenues", "globally", "for", "Elelyso,", "excluding", "Brazil,", "where", "we", "are", "responsible", "for", "all", "expenses", "and", "retain", "all", "revenues.", "<tag2>", "Under", "the", "Amended", "Pfizer", "Agreement,", "Pfizer", "is", "responsible", "for", "100%", "of", "expenses,", "and", "entitled", "to", "all", "revenues,", "globally", "for", "Elelyso,", "excluding", "Brazil,", "where", "we", "are", "responsible", "for", "all", "expenses", "and", "retain", "all", "revenues.", "<tag3>"], "wordsA": ["Under", "the", "Amended", "Pfizer", "Agreement,", "Pfizer", "is", "responsible", "for", "100%", "of", "expenses,", "and", "entitled", "to", "all", "revenues", "globally", "for", "Elelyso,", "excluding", "Brazil,", "where", "we", "are", "responsible", "for", "all", "expenses", "and", "retain", "all", "revenues."], "wordsB": ["Under", "the", "Amended", "Pfizer", "Agreement,", "Pfizer", "is", "responsible", "for", "100%", "of", "expenses,", "and", "entitled", "to", "all", "revenues,", "globally", "for", "Elelyso,", "excluding", "Brazil,", "where", "we", "are", "responsible", "for", "all", "expenses", "and", "retain", "all", "revenues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.022863630205392838, 0.0141138331964612, 0.034591466188430786, 0.0610145628452301, 0.05700655281543732, 0.07346741855144501, 0.033223044127225876, 0.052657876163721085, 0.03197678178548813, 0.06797380745410919, 0.040990594774484634, 0.07641172409057617, 0.017398491501808167, 0.035497356206178665, 0.03190958499908447, 0.2968856394290924, 0.638581395149231, 0.02636687085032463, 0.017434576526284218, 0.030081814154982567, 0.024495664983987808, 0.030895529314875603, 0.020029135048389435, 0.02096697874367237, 0.02416403591632843, 0.02912861853837967, 0.02278476022183895, 0.03776676580309868, 0.04667891189455986, 0.012554977089166641, 0.06859059631824493, 0.09765192121267319, 0.1966186910867691, -1]}
{"idB": "1006281_18_item1_p66_s3", "idA": "1006281_17_item1_p62_s2", "sentA": "Patients enrolled in the study will continue to be treated for a total of 24 months, at which point the data will be analyzed to test for superiority to support an FDA filing.", "sentB": "Notwithstanding, patients enrolled in the study will continue to be treated for a total of 24 months, at which point the data will be analyzed to test for superiority, which is the original guidance we received from the FDA.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "the", "study", "will", "continue", "to", "be", "treated", "for", "a", "total", "of", "24", "months,", "at", "which", "point", "the", "data", "will", "be", "analyzed", "to", "test", "for", "superiority", "to", "support", "an", "FDA", "filing.", "<tag2>", "Notwithstanding,", "patients", "enrolled", "in", "the", "study", "will", "continue", "to", "be", "treated", "for", "a", "total", "of", "24", "months,", "at", "which", "point", "the", "data", "will", "be", "analyzed", "to", "test", "for", "superiority,", "which", "is", "the", "original", "guidance", "we", "received", "from", "the", "FDA.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "the", "study", "will", "continue", "to", "be", "treated", "for", "a", "total", "of", "24", "months,", "at", "which", "point", "the", "data", "will", "be", "analyzed", "to", "test", "for", "superiority", "to", "support", "an", "FDA", "filing."], "wordsB": ["Notwithstanding,", "patients", "enrolled", "in", "the", "study", "will", "continue", "to", "be", "treated", "for", "a", "total", "of", "24", "months,", "at", "which", "point", "the", "data", "will", "be", "analyzed", "to", "test", "for", "superiority,", "which", "is", "the", "original", "guidance", "we", "received", "from", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.7837890982627869, 0.2030264139175415, 0.06494076550006866, 0.015575682744383812, 0.008923360146582127, 0.026297427713871002, 0.016244899481534958, 0.016896512359380722, 0.007593031506985426, 0.01031098049134016, 0.04402751848101616, 0.007698130328208208, 0.005996042862534523, 0.021568913012742996, 0.0064361016266047955, 0.0132680619135499, 0.0263187438249588, 0.005522583145648241, 0.005230402108281851, 0.008736720308661461, 0.005099968519061804, 0.04844148829579353, 0.006576221901923418, 0.007488193456083536, 0.02665035054087639, 0.006800915580242872, 0.017545482143759727, 0.015560227446258068, 0.05663994327187538, 0.00083031045505777, 0.018889419734477997, 0.01683092676103115, 0.17275109887123108, 0.24636045098304749, 0.042624253779649734, 0.03378137946128845, 0.0192865040153265, 0.034879427403211594, 0.16467733681201935, -1]}
{"idB": "1006281_18_item1_p67_s0", "idA": "1006281_17_item1_p63_s0", "sentA": "In addition, we are preparing for a supportive phase III clinical trial of PRX-102, which shall be run at the same time as the BALANCE Study.", "sentB": "Concurrently with the BALANCE study, we are also performing a supportive phase III clinical trial of PRX-102, which we refer to as the BRIDGE Study.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "preparing", "for", "a", "supportive", "phase", "III", "clinical", "trial", "of", "PRX-102,", "which", "shall", "be", "run", "at", "the", "same", "time", "as", "the", "BALANCE", "Study.", "<tag2>", "Concurrently", "with", "the", "BALANCE", "study,", "we", "are", "also", "performing", "a", "supportive", "phase", "III", "clinical", "trial", "of", "PRX-102,", "which", "we", "refer", "to", "as", "the", "BRIDGE", "Study.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "preparing", "for", "a", "supportive", "phase", "III", "clinical", "trial", "of", "PRX-102,", "which", "shall", "be", "run", "at", "the", "same", "time", "as", "the", "BALANCE", "Study."], "wordsB": ["Concurrently", "with", "the", "BALANCE", "study,", "we", "are", "also", "performing", "a", "supportive", "phase", "III", "clinical", "trial", "of", "PRX-102,", "which", "we", "refer", "to", "as", "the", "BRIDGE", "Study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.3008715808391571, 0.1232588142156601, 0.031023679301142693, 0.06733602285385132, 0.09795399755239487, 0.0313347764313221, 0.015142380259931087, 0.028587201610207558, 0.299562007188797, 0.026592204347252846, 0.02632213570177555, 0.015733040869235992, 0.01231202483177185, 0.02205943502485752, 0.03639470413327217, 0.0049835932441055775, 0.01362233329564333, 0.005980557296425104, 0.022553151473402977, 0.05510205775499344, 0.03468789532780647, 0.035954419523477554, 0.038021646440029144, 0.7594454288482666, 0.563913106918335, -1]}
{"idB": "1006281_18_item1_p67_s1", "idA": "1006281_17_item1_p63_s1", "sentA": "This supportive study, which we refer to as the BRIDGE Study, is designed to be an open-label, single-arm, switchover study to assess the efficacy and safety of PRX-102 in Fabry patients currently treated with Replagal.", "sentB": "The BRIDGE study is an open-label, single-arm, switchover study to assess the efficacy and safety of PRX-102 in Fabry patients currently treated with Replagal.", "type": 2, "words": ["<tag1>", "This", "supportive", "study,", "which", "we", "refer", "to", "as", "the", "BRIDGE", "Study,", "is", "designed", "to", "be", "an", "open-label,", "single-arm,", "switchover", "study", "to", "assess", "the", "efficacy", "and", "safety", "of", "PRX-102", "in", "Fabry", "patients", "currently", "treated", "with", "Replagal.", "<tag2>", "The", "BRIDGE", "study", "is", "an", "open-label,", "single-arm,", "switchover", "study", "to", "assess", "the", "efficacy", "and", "safety", "of", "PRX-102", "in", "Fabry", "patients", "currently", "treated", "with", "Replagal.", "<tag3>"], "wordsA": ["This", "supportive", "study,", "which", "we", "refer", "to", "as", "the", "BRIDGE", "Study,", "is", "designed", "to", "be", "an", "open-label,", "single-arm,", "switchover", "study", "to", "assess", "the", "efficacy", "and", "safety", "of", "PRX-102", "in", "Fabry", "patients", "currently", "treated", "with", "Replagal."], "wordsB": ["The", "BRIDGE", "study", "is", "an", "open-label,", "single-arm,", "switchover", "study", "to", "assess", "the", "efficacy", "and", "safety", "of", "PRX-102", "in", "Fabry", "patients", "currently", "treated", "with", "Replagal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.008292585611343384, 0.7878861427307129, 0.7251421213150024, 0.011750280857086182, 0.008809776976704597, 0.045854926109313965, 0.09089253842830658, 0.026189269497990608, 0.05729354918003082, 0.00944129191339016, 0.029417358338832855, 0.01017251517623663, 0.024221839383244514, 0.012715989723801613, 0.016674363985657692, 0.012215539813041687, 0.07789503782987595, 0.008380905725061893, 0.05840591341257095, 0.047963012009859085, 0.010201040655374527, 0.021263428032398224, 0.02801593951880932, 0.04769686982035637, -1]}
{"idB": "1006281_18_item1_p69_s0", "idA": "1006281_17_item1_p63_s1", "sentA": "This supportive study, which we refer to as the BRIDGE Study, is designed to be an open-label, single-arm, switchover study to assess the efficacy and safety of PRX-102 in Fabry patients currently treated with Replagal.", "sentB": "We plan to enroll up to 30 Fabry patients currently treated with an approved enzyme replacement therapy in this study.", "type": 2, "words": ["<tag1>", "This", "supportive", "study,", "which", "we", "refer", "to", "as", "the", "BRIDGE", "Study,", "is", "designed", "to", "be", "an", "open-label,", "single-arm,", "switchover", "study", "to", "assess", "the", "efficacy", "and", "safety", "of", "PRX-102", "in", "Fabry", "patients", "currently", "treated", "with", "Replagal.", "<tag2>", "We", "plan", "to", "enroll", "up", "to", "30", "Fabry", "patients", "currently", "treated", "with", "an", "approved", "enzyme", "replacement", "therapy", "in", "this", "study.", "<tag3>"], "wordsA": ["This", "supportive", "study,", "which", "we", "refer", "to", "as", "the", "BRIDGE", "Study,", "is", "designed", "to", "be", "an", "open-label,", "single-arm,", "switchover", "study", "to", "assess", "the", "efficacy", "and", "safety", "of", "PRX-102", "in", "Fabry", "patients", "currently", "treated", "with", "Replagal."], "wordsB": ["We", "plan", "to", "enroll", "up", "to", "30", "Fabry", "patients", "currently", "treated", "with", "an", "approved", "enzyme", "replacement", "therapy", "in", "this", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.031973034143447876, 0.03928431496024132, 0.00936170294880867, 0.232778862118721, 0.10533395409584045, 0.04639621824026108, 0.2533216178417206, 0.12707822024822235, 0.14650671184062958, 0.0048215072602033615, 0.042062561959028244, 0.030220728367567062, 0.015184983611106873, 0.3238612115383148, 0.7125900387763977, 0.6418526768684387, 0.5404840707778931, 0.006640559062361717, 0.006187812425196171, 0.061237260699272156, -1]}
{"idB": "1006281_18_item1_p16_s6", "idA": "1006281_17_item1_p63_s2", "sentA": "We expect to enroll 22 patients in the BRIDGE Study during 2017.", "sentB": "We expect to release complete results by the end of March, 2018.", "type": 2, "words": ["<tag1>", "We", "expect", "to", "enroll", "22", "patients", "in", "the", "BRIDGE", "Study", "during", "2017.", "<tag2>", "We", "expect", "to", "release", "complete", "results", "by", "the", "end", "of", "March,", "2018.", "<tag3>"], "wordsA": ["We", "expect", "to", "enroll", "22", "patients", "in", "the", "BRIDGE", "Study", "during", "2017."], "wordsB": ["We", "expect", "to", "release", "complete", "results", "by", "the", "end", "of", "March,", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.02259059064090252, 0.021736694499850273, 0.018050694838166237, 0.4808388352394104, 0.7264745831489563, 0.4871297776699066, 0.0535462349653244, 0.02076287753880024, 0.07567359507083893, 0.060289591550827026, 0.22375312447547913, 0.6307836771011353, -1]}
{"idB": "1006281_18_item1_p67_s3", "idA": "1006281_17_item1_p63_s3", "sentA": "The objective of the study is to generate safety and efficacy data of patients switched from Replagal to PRX-102 over a 12-month period, with interim results at six months.", "sentB": "The objective of the study is to generate safety and efficacy data of patients switched from Replagal to PRX-102 over a 12-month period.", "type": 2, "words": ["<tag1>", "The", "objective", "of", "the", "study", "is", "to", "generate", "safety", "and", "efficacy", "data", "of", "patients", "switched", "from", "Replagal", "to", "PRX-102", "over", "a", "12-month", "period,", "with", "interim", "results", "at", "six", "months.", "<tag2>", "The", "objective", "of", "the", "study", "is", "to", "generate", "safety", "and", "efficacy", "data", "of", "patients", "switched", "from", "Replagal", "to", "PRX-102", "over", "a", "12-month", "period.", "<tag3>"], "wordsA": ["The", "objective", "of", "the", "study", "is", "to", "generate", "safety", "and", "efficacy", "data", "of", "patients", "switched", "from", "Replagal", "to", "PRX-102", "over", "a", "12-month", "period,", "with", "interim", "results", "at", "six", "months."], "wordsB": ["The", "objective", "of", "the", "study", "is", "to", "generate", "safety", "and", "efficacy", "data", "of", "patients", "switched", "from", "Replagal", "to", "PRX-102", "over", "a", "12-month", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0073138936422765255, 0.21066175401210785, 0.019453609362244606, 0.008439079858362675, 0.06566625088453293, 0.0162193663418293, 0.013844834640622139, 0.02770683541893959, 0.02965962514281273, 0.01281422097235918, 0.06654249876737595, 0.0635516569018364, 0.020961729809641838, 0.43157652020454407, 0.26478153467178345, 0.09896848350763321, 0.11609768867492676, 0.034852754324674606, 0.06121182441711426, 0.010457843542098999, 0.009365162812173367, 0.02240992896258831, 0.026256855577230453, -1]}
{"idB": "1006281_18_item1_p56_s3", "idA": "1006281_17_item1_p64_s0", "sentA": "In February 2015, we announced the completion of enrollment in our phase I/II clinical trial in adult Fabry patients.", "sentB": "End-stage renal failure and cardiomyopathy often lead to early death in Fabry patients.", "type": 2, "words": ["<tag1>", "In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients.", "<tag2>", "End-stage", "renal", "failure", "and", "cardiomyopathy", "often", "lead", "to", "early", "death", "in", "Fabry", "patients.", "<tag3>"], "wordsA": ["In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients."], "wordsB": ["End-stage", "renal", "failure", "and", "cardiomyopathy", "often", "lead", "to", "early", "death", "in", "Fabry", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.35713422298431396, 0.5047329664230347, 0.5397173166275024, 0.12980252504348755, 0.24251820147037506, 0.03435849770903587, 0.09368057548999786, 0.06571679562330246, 0.21412013471126556, 0.4540497660636902, 0.021811818704009056, 0.04230927303433418, 0.06769745796918869, -1]}
{"idB": "1006281_18_item1_p68_s3", "idA": "1006281_17_item1_p64_s0", "sentA": "In February 2015, we announced the completion of enrollment in our phase I/II clinical trial in adult Fabry patients.", "sentB": "Pharmacokinetic (PK) analysis and modeling from the phase I/II clinical trial indicate that PRX-102 levels at the second week after infusion remain 10 times higher than published Fabrazyme levels at the day of infusion.", "type": 2, "words": ["<tag1>", "In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients.", "<tag2>", "Pharmacokinetic", "(PK)", "analysis", "and", "modeling", "from", "the", "phase", "I/II", "clinical", "trial", "indicate", "that", "PRX-102", "levels", "at", "the", "second", "week", "after", "infusion", "remain", "10", "times", "higher", "than", "published", "Fabrazyme", "levels", "at", "the", "day", "of", "infusion.", "<tag3>"], "wordsA": ["In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients."], "wordsB": ["Pharmacokinetic", "(PK)", "analysis", "and", "modeling", "from", "the", "phase", "I/II", "clinical", "trial", "indicate", "that", "PRX-102", "levels", "at", "the", "second", "week", "after", "infusion", "remain", "10", "times", "higher", "than", "published", "Fabrazyme", "levels", "at", "the", "day", "of", "infusion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.4481857419013977, 0.30213263630867004, 0.2478797882795334, 0.03485163301229477, 0.24782821536064148, 0.018506255000829697, 0.007494581397622824, 0.013443006202578545, 0.011166021227836609, 0.02376115322113037, 0.02841523289680481, 0.11142188310623169, 0.05329645797610283, 0.28264889121055603, 0.2148417979478836, 0.02488829381763935, 0.015329110436141491, 0.07678889483213425, 0.06900499016046524, 0.07759403437376022, 0.07947009801864624, 0.18927587568759918, 0.30030331015586853, 0.2518501579761505, 0.32638639211654663, 0.15554176270961761, 0.16848930716514587, 0.22526100277900696, 0.16161493957042694, 0.015329492278397083, 0.010923290625214577, 0.02912730537354946, 0.0159708671271801, 0.04468321055173874, -1]}
{"idB": "1006281_18_item1_p68_s0", "idA": "1006281_17_item1_p64_s1", "sentA": "The phase I/II clinical trial is a worldwide, multi-center, open label, dose ranging study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients.", "sentB": "In addition to the BALANCE and BRIDGE studies, we are performing a third clinical trial to evaluate the safety and efficacy of administering 2 mg/kg of PRX-102 once monthly in Fabry patients.", "type": 2, "words": ["<tag1>", "The", "phase", "I/II", "clinical", "trial", "is", "a", "worldwide,", "multi-center,", "open", "label,", "dose", "ranging", "study", "to", "evaluate", "the", "safety,", "tolerability,", "pharmacokinetics,", "immunogenicity", "and", "efficacy", "parameters", "of", "PRX-102", "in", "adult", "Fabry", "patients.", "<tag2>", "In", "addition", "to", "the", "BALANCE", "and", "BRIDGE", "studies,", "we", "are", "performing", "a", "third", "clinical", "trial", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "administering", "2", "mg/kg", "of", "PRX-102", "once", "monthly", "in", "Fabry", "patients.", "<tag3>"], "wordsA": ["The", "phase", "I/II", "clinical", "trial", "is", "a", "worldwide,", "multi-center,", "open", "label,", "dose", "ranging", "study", "to", "evaluate", "the", "safety,", "tolerability,", "pharmacokinetics,", "immunogenicity", "and", "efficacy", "parameters", "of", "PRX-102", "in", "adult", "Fabry", "patients."], "wordsB": ["In", "addition", "to", "the", "BALANCE", "and", "BRIDGE", "studies,", "we", "are", "performing", "a", "third", "clinical", "trial", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "administering", "2", "mg/kg", "of", "PRX-102", "once", "monthly", "in", "Fabry", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.008146391250193119, 0.013331795111298561, 0.008193380199372768, 0.008033069781959057, 0.4183197617530823, 0.3166743218898773, 0.5967840552330017, 0.3665483295917511, 0.013780171982944012, 0.003980139270424843, 0.041649229824543, 0.016409697011113167, 0.44378530979156494, 0.14453397691249847, 0.14395658671855927, 0.002857416868209839, 0.018456706777215004, 0.0022183023393154144, 0.028459979221224785, 0.009647374972701073, 0.027802517637610435, 0.0036608430091291666, 0.10110276937484741, 0.3200693130493164, 0.36425283551216125, 0.03390122205018997, 0.047824397683143616, 0.061131954193115234, 0.05230878293514252, 0.004873296711593866, 0.016433726996183395, 0.026340991258621216, -1]}
{"idB": "1006281_18_item1_p70_s0", "idA": "1006281_17_item1_p64_s1", "sentA": "The phase I/II clinical trial is a worldwide, multi-center, open label, dose ranging study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients.", "sentB": "Our phase I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open label, dose ranging study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients.", "type": 2, "words": ["<tag1>", "The", "phase", "I/II", "clinical", "trial", "is", "a", "worldwide,", "multi-center,", "open", "label,", "dose", "ranging", "study", "to", "evaluate", "the", "safety,", "tolerability,", "pharmacokinetics,", "immunogenicity", "and", "efficacy", "parameters", "of", "PRX-102", "in", "adult", "Fabry", "patients.", "<tag2>", "Our", "phase", "I/II", "clinical", "trial", "of", "PRX-102,", "which", "we", "completed", "in", "2015,", "was", "a", "worldwide,", "multi-center,", "open", "label,", "dose", "ranging", "study", "to", "evaluate", "the", "safety,", "tolerability,", "pharmacokinetics,", "immunogenicity", "and", "efficacy", "parameters", "of", "PRX-102", "in", "adult", "Fabry", "patients.", "<tag3>"], "wordsA": ["The", "phase", "I/II", "clinical", "trial", "is", "a", "worldwide,", "multi-center,", "open", "label,", "dose", "ranging", "study", "to", "evaluate", "the", "safety,", "tolerability,", "pharmacokinetics,", "immunogenicity", "and", "efficacy", "parameters", "of", "PRX-102", "in", "adult", "Fabry", "patients."], "wordsB": ["Our", "phase", "I/II", "clinical", "trial", "of", "PRX-102,", "which", "we", "completed", "in", "2015,", "was", "a", "worldwide,", "multi-center,", "open", "label,", "dose", "ranging", "study", "to", "evaluate", "the", "safety,", "tolerability,", "pharmacokinetics,", "immunogenicity", "and", "efficacy", "parameters", "of", "PRX-102", "in", "adult", "Fabry", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.012097034603357315, 0.0202520452439785, 0.023818736895918846, 0.025342298671603203, 0.0787484273314476, 0.018645426258444786, 0.11155231297016144, 0.008948859758675098, 0.12182025611400604, 0.5002987384796143, 0.19521938264369965, 0.6244190335273743, 0.010900343768298626, 0.011802632361650467, 0.01840573363006115, 0.018430134281516075, 0.019837049767374992, 0.0189797505736351, 0.017712082713842392, 0.018473614007234573, 0.01662544719874859, 0.011178778484463692, 0.013340233825147152, 0.014318821020424366, 0.023821664974093437, 0.02130873315036297, 0.024234775453805923, 0.02172459289431572, 0.015141889452934265, 0.018456226214766502, 0.020404301583766937, 0.011985513381659985, 0.041910286992788315, 0.00773724727332592, 0.016057947650551796, 0.030124777927994728, 0.02940206602215767, -1]}
{"idB": "1006281_18_item1_p70_s1", "idA": "1006281_17_item1_p64_s2", "sentA": "Sixteen adult Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2 mg/kg, 1mg/kg and 2mg/kg.", "sentB": "Sixteen adult naive Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2 mg/kg, 1mg/kg and 2mg/kg.", "type": 2, "words": ["<tag1>", "Sixteen", "adult", "Fabry", "patients", "(9", "male", "and", "7", "female)", "completed", "the", "trial,", "each", "in", "one", "of", "three", "dosing", "groups,", "0.2", "mg/kg,", "1mg/kg", "and", "2mg/kg.", "<tag2>", "Sixteen", "adult", "naive", "Fabry", "patients", "(9", "male", "and", "7", "female)", "completed", "the", "trial,", "each", "in", "one", "of", "three", "dosing", "groups,", "0.2", "mg/kg,", "1mg/kg", "and", "2mg/kg.", "<tag3>"], "wordsA": ["Sixteen", "adult", "Fabry", "patients", "(9", "male", "and", "7", "female)", "completed", "the", "trial,", "each", "in", "one", "of", "three", "dosing", "groups,", "0.2", "mg/kg,", "1mg/kg", "and", "2mg/kg."], "wordsB": ["Sixteen", "adult", "naive", "Fabry", "patients", "(9", "male", "and", "7", "female)", "completed", "the", "trial,", "each", "in", "one", "of", "three", "dosing", "groups,", "0.2", "mg/kg,", "1mg/kg", "and", "2mg/kg."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.06732223927974701, 0.08384327590465546, 0.8611188530921936, 0.2694198489189148, 0.11423971503973007, 0.07295491546392441, 0.04667855426669121, 0.02759966254234314, 0.045908112078905106, 0.053847458213567734, 0.02151275798678398, 0.012346294708549976, 0.02024509198963642, 0.02440861612558365, 0.01469859853386879, 0.01682521589100361, 0.016675608232617378, 0.0205252543091774, 0.02109045721590519, 0.020684514194726944, 0.09145178645849228, 0.060741033405065536, 0.03165072575211525, 0.015015664510428905, 0.043910544365644455, -1]}
{"idB": "1006281_18_item1_p16_s5", "idA": "1006281_17_item1_p64_s4", "sentA": "All patients that completed the trial have opted to continue to receive 1 mg/kg of PRX-102 in an open-label extension trial, 60-month extension study under which all patients have been switched to receive 1 mg/kg of the drug, the selected dose for our phase III studies of PRX-102.", "sentB": "Interim data generated from the first 14 patients that completed the trial was released in January 2018.", "type": 2, "words": ["<tag1>", "All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102.", "<tag2>", "Interim", "data", "generated", "from", "the", "first", "14", "patients", "that", "completed", "the", "trial", "was", "released", "in", "January", "2018.", "<tag3>"], "wordsA": ["All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102."], "wordsB": ["Interim", "data", "generated", "from", "the", "first", "14", "patients", "that", "completed", "the", "trial", "was", "released", "in", "January", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.5123413801193237, 0.4425295889377594, 0.12074470520019531, 0.019420074298977852, 0.011586184613406658, 0.1003945842385292, 0.3350960910320282, 0.13741034269332886, 0.006293723825365305, 0.02888723649084568, 0.008430475369095802, 0.032386086881160736, 0.011286871507763863, 0.11186442524194717, 0.0443258099257946, 0.1564190834760666, 0.15597614645957947, -1]}
{"idB": "1006281_18_item1_p70_s3", "idA": "1006281_17_item1_p64_s4", "sentA": "All patients that completed the trial have opted to continue to receive 1 mg/kg of PRX-102 in an open-label extension trial, 60-month extension study under which all patients have been switched to receive 1 mg/kg of the drug, the selected dose for our phase III studies of PRX-102.", "sentB": "All patients that completed the trial opted to continue to receive 1 mg/kg of PRX-102 in an open-label, 60-month extension study under which all patients have been switched to receive 1 mg/kg of the drug, the selected dose for our phase III studies of PRX-102.", "type": 2, "words": ["<tag1>", "All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102.", "<tag2>", "All", "patients", "that", "completed", "the", "trial", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102.", "<tag3>"], "wordsA": ["All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102."], "wordsB": ["All", "patients", "that", "completed", "the", "trial", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.11636796593666077, 0.14237533509731293, 0.014013235457241535, 0.0315096490085125, 0.011283699423074722, 0.017424719408154488, 0.041051894426345825, 0.021395517513155937, 0.03691704198718071, 0.028867417946457863, 0.08063356578350067, 0.6853570938110352, 0.14707447588443756, 0.020573364570736885, 0.0543985441327095, 0.009981698356568813, 0.012339883483946323, 0.017489789053797722, 0.016027359291911125, 0.018323881551623344, 0.017222395166754723, 0.012913232669234276, 0.012226730585098267, 0.06377353519201279, 0.0894988477230072, 0.015870023518800735, 0.017167214304208755, 0.06248060613870621, 0.02329389750957489, 0.06499400734901428, 0.186528280377388, 0.05620113015174866, 0.014925329945981503, 0.014461418613791466, 0.026829373091459274, 0.013285282999277115, 0.018778929486870766, 0.021720413118600845, 0.009482362307608128, 0.00982727576047182, 0.014852279797196388, 0.013942639343440533, 0.012570973485708237, 0.010262909345328808, 0.04481205344200134, -1]}
{"idB": "1006281_18_item1_p96_s4", "idA": "1006281_17_item1_p64_s4", "sentA": "All patients that completed the trial have opted to continue to receive 1 mg/kg of PRX-102 in an open-label extension trial, 60-month extension study under which all patients have been switched to receive 1 mg/kg of the drug, the selected dose for our phase III studies of PRX-102.", "sentB": "Interim data generated from the first 14 patients that completed the trial was released in January 2018.", "type": 2, "words": ["<tag1>", "All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102.", "<tag2>", "Interim", "data", "generated", "from", "the", "first", "14", "patients", "that", "completed", "the", "trial", "was", "released", "in", "January", "2018.", "<tag3>"], "wordsA": ["All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102."], "wordsB": ["Interim", "data", "generated", "from", "the", "first", "14", "patients", "that", "completed", "the", "trial", "was", "released", "in", "January", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.5123413801193237, 0.4425295889377594, 0.12074470520019531, 0.019420074298977852, 0.011586184613406658, 0.1003945842385292, 0.3350960910320282, 0.13741034269332886, 0.006293723825365305, 0.02888723649084568, 0.008430475369095802, 0.032386086881160736, 0.011286871507763863, 0.11186442524194717, 0.0443258099257946, 0.1564190834760666, 0.15597614645957947, -1]}
{"idB": "1006281_18_item1_p73_s0", "idA": "1006281_17_item1_p73_s0", "sentA": "In summary, in the phase I/II trial, PRX-102 was found to have a markedly extended circulatory half-life compared with other ERTs; it demonstrated a low incidence of treatment induced ADA with reversible and transient effect on pharmacokinetics; ADA response was transient and tolerization was observed; and ADA positivity had no observed impact on safety and efficacy.", "sentB": "The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.", "type": 2, "words": ["<tag1>", "In", "summary,", "in", "the", "phase", "I/II", "trial,", "PRX-102", "was", "found", "to", "have", "a", "markedly", "extended", "circulatory", "half-life", "compared", "with", "other", "ERTs;", "it", "demonstrated", "a", "low", "incidence", "of", "treatment", "induced", "ADA", "with", "reversible", "and", "transient", "effect", "on", "pharmacokinetics;", "ADA", "response", "was", "transient", "and", "tolerization", "was", "observed;", "and", "ADA", "positivity", "had", "no", "observed", "impact", "on", "safety", "and", "efficacy.", "<tag2>", "The", "ADA", "positivity", "effect", "had", "no", "observed", "impact", "on", "the", "safety,", "efficacy", "or", "continuous", "biomarker", "reduction", "of", "PRX-102.", "<tag3>"], "wordsA": ["In", "summary,", "in", "the", "phase", "I/II", "trial,", "PRX-102", "was", "found", "to", "have", "a", "markedly", "extended", "circulatory", "half-life", "compared", "with", "other", "ERTs;", "it", "demonstrated", "a", "low", "incidence", "of", "treatment", "induced", "ADA", "with", "reversible", "and", "transient", "effect", "on", "pharmacokinetics;", "ADA", "response", "was", "transient", "and", "tolerization", "was", "observed;", "and", "ADA", "positivity", "had", "no", "observed", "impact", "on", "safety", "and", "efficacy."], "wordsB": ["The", "ADA", "positivity", "effect", "had", "no", "observed", "impact", "on", "the", "safety,", "efficacy", "or", "continuous", "biomarker", "reduction", "of", "PRX-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.003916227724403143, 0.06416796147823334, 0.03828131780028343, 0.028190702199935913, 0.007215004879981279, 0.0671461895108223, 0.040122345089912415, 0.033442169427871704, 0.016474787145853043, 0.015599358826875687, 0.06405593454837799, 0.0515136681497097, 0.03729262202978134, 0.6309101581573486, 0.6234332919120789, 0.5555285811424255, 0.030506618320941925, 0.09061859548091888, -1]}
{"idB": "1006281_18_item1_p87_s1", "idA": "1006281_17_item1_p74_s1", "sentA": "DNase I cleaves extracellular DNA and thins the thick mucus that accumulates in the lungs of CF patients.", "sentB": "Chronic pulmonary infection is a leading cause of morbidity and mortality in CF patients, despite the aggressive use of antibiotics, and Pseudomonas is the most prevalent organism in the airway colonization of CF patients.", "type": 2, "words": ["<tag1>", "DNase", "I", "cleaves", "extracellular", "DNA", "and", "thins", "the", "thick", "mucus", "that", "accumulates", "in", "the", "lungs", "of", "CF", "patients.", "<tag2>", "Chronic", "pulmonary", "infection", "is", "a", "leading", "cause", "of", "morbidity", "and", "mortality", "in", "CF", "patients,", "despite", "the", "aggressive", "use", "of", "antibiotics,", "and", "Pseudomonas", "is", "the", "most", "prevalent", "organism", "in", "the", "airway", "colonization", "of", "CF", "patients.", "<tag3>"], "wordsA": ["DNase", "I", "cleaves", "extracellular", "DNA", "and", "thins", "the", "thick", "mucus", "that", "accumulates", "in", "the", "lungs", "of", "CF", "patients."], "wordsB": ["Chronic", "pulmonary", "infection", "is", "a", "leading", "cause", "of", "morbidity", "and", "mortality", "in", "CF", "patients,", "despite", "the", "aggressive", "use", "of", "antibiotics,", "and", "Pseudomonas", "is", "the", "most", "prevalent", "organism", "in", "the", "airway", "colonization", "of", "CF", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.21681304275989532, 0.8933278918266296, 0.6149871945381165, 0.0033811309840530157, 0.003228067187592387, 0.013103821314871311, 0.012932970188558102, 0.004292840603739023, 0.02773037925362587, 0.015089754946529865, 0.08086748421192169, 0.0036494494415819645, 0.011200240813195705, 0.01437605731189251, 0.0031100769992917776, 0.0029018206987529993, 0.006222099997103214, 0.011641527526080608, 0.00525415875017643, 0.0733371451497078, 0.004238182678818703, 0.2072446495294571, 0.002807913115248084, 0.002365513937547803, 0.005633258260786533, 0.013370802626013756, 0.04172879830002785, 0.004725092090666294, 0.0032748854719102383, 0.03092532977461815, 0.025493303313851357, 0.0021519502624869347, 0.010044239461421967, 0.012581869028508663, -1]}
{"idB": "1006281_18_item1_p76_s0", "idA": "1006281_17_item1_p75_s1", "sentA": "Preclinical studies of PRX-110 administered by inhalation showed substantial enzymatic activity in lungs.", "sentB": "Preclinical studies of alidornase alfa administered by inhalation showed substantial enzymatic activity in lungs.", "type": 2, "words": ["<tag1>", "Preclinical", "studies", "of", "PRX-110", "administered", "by", "inhalation", "showed", "substantial", "enzymatic", "activity", "in", "lungs.", "<tag2>", "Preclinical", "studies", "of", "alidornase", "alfa", "administered", "by", "inhalation", "showed", "substantial", "enzymatic", "activity", "in", "lungs.", "<tag3>"], "wordsA": ["Preclinical", "studies", "of", "PRX-110", "administered", "by", "inhalation", "showed", "substantial", "enzymatic", "activity", "in", "lungs."], "wordsB": ["Preclinical", "studies", "of", "alidornase", "alfa", "administered", "by", "inhalation", "showed", "substantial", "enzymatic", "activity", "in", "lungs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.009201733395457268, 0.05355241894721985, 0.04366932064294815, 0.8253941535949707, 0.9623405337333679, 0.0044692158699035645, 0.0018831266788765788, 0.0029899971559643745, 0.002582699293270707, 0.0030845659784972668, 0.003374373307451606, 0.004339150153100491, 0.0018574470886960626, 0.004761618096381426, -1]}
{"idB": "1006281_18_item1_p87_s0", "idA": "1006281_17_item1_p77_s0", "sentA": "Actin, a potent inhibitor of DNase, is found in high concentration in CF patients sputum.", "sentB": "Pseudomonas, strains of bacteria that are widely found in the environment, are a major cause of lung infections in CF patients.", "type": 2, "words": ["<tag1>", "Actin,", "a", "potent", "inhibitor", "of", "DNase,", "is", "found", "in", "high", "concentration", "in", "CF", "patients", "sputum.", "<tag2>", "Pseudomonas,", "strains", "of", "bacteria", "that", "are", "widely", "found", "in", "the", "environment,", "are", "a", "major", "cause", "of", "lung", "infections", "in", "CF", "patients.", "<tag3>"], "wordsA": ["Actin,", "a", "potent", "inhibitor", "of", "DNase,", "is", "found", "in", "high", "concentration", "in", "CF", "patients", "sputum."], "wordsB": ["Pseudomonas,", "strains", "of", "bacteria", "that", "are", "widely", "found", "in", "the", "environment,", "are", "a", "major", "cause", "of", "lung", "infections", "in", "CF", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.9485790729522705, 0.15326541662216187, 0.15382567048072815, 0.4221177101135254, 0.0050308359786868095, 0.0033100415021181107, 0.005849012173712254, 0.008571445941925049, 0.0033391122706234455, 0.002954393159598112, 0.013181975111365318, 0.00683615542948246, 0.005475765094161034, 0.028756551444530487, 0.05544017627835274, 0.03109162487089634, 0.21246932446956635, 0.25065866112709045, 0.004975402727723122, 0.017960093915462494, 0.02595416083931923, -1]}
{"idB": "1006281_18_item1_p86_s0", "idA": "1006281_17_item1_p78_s0", "sentA": "In addition, alidornase alfa has demonstrated improved disease parameters in human models sputum testing when compared to the currently marketed product.", "sentB": "In addition, an in vitro study of alidornase alfa demonstrated a significant inhibition of Pseudomonas Aeruginosa, with alidornase alfa treated colonies reduced by over 50%, compared to baseline.", "type": 2, "words": ["<tag1>", "In", "addition,", "alidornase", "alfa", "has", "demonstrated", "improved", "disease", "parameters", "in", "human", "models", "sputum", "testing", "when", "compared", "to", "the", "currently", "marketed", "product.", "<tag2>", "In", "addition,", "an", "in", "vitro", "study", "of", "alidornase", "alfa", "demonstrated", "a", "significant", "inhibition", "of", "Pseudomonas", "Aeruginosa,", "with", "alidornase", "alfa", "treated", "colonies", "reduced", "by", "over", "50%,", "compared", "to", "baseline.", "<tag3>"], "wordsA": ["In", "addition,", "alidornase", "alfa", "has", "demonstrated", "improved", "disease", "parameters", "in", "human", "models", "sputum", "testing", "when", "compared", "to", "the", "currently", "marketed", "product."], "wordsB": ["In", "addition,", "an", "in", "vitro", "study", "of", "alidornase", "alfa", "demonstrated", "a", "significant", "inhibition", "of", "Pseudomonas", "Aeruginosa,", "with", "alidornase", "alfa", "treated", "colonies", "reduced", "by", "over", "50%,", "compared", "to", "baseline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004482822958379984, 0.010022819973528385, 0.011994562111794949, 0.23163717985153198, 0.38180312514305115, 0.2668222486972809, 0.0262614693492651, 0.02110801264643669, 0.021692723035812378, 0.06576625257730484, 0.028578178957104683, 0.1406428962945938, 0.5397874116897583, 0.20732749998569489, 0.5588039755821228, 0.2844444513320923, 0.0036221761256456375, 0.01231805607676506, 0.012824848294258118, 0.06373266130685806, 0.2282055765390396, 0.13572368025779724, 0.03739004582166672, 0.04337288439273834, 0.09844699501991272, 0.018784798681735992, 0.0155800124630332, 0.07263070344924927, -1]}
{"idB": "1006281_18_item1_p57_s0", "idA": "1006281_17_item1_p78_s1", "sentA": "In particular, alidornase alfa has demonstrated a reduction in mucus viscosity in human sputum samples when compared to the currently marketed product.", "sentB": "Fabry disease causes substantial reduction in life-expectancy, by an average of 15 years in female patients and 20 years in male patients, compared to the general population.", "type": 2, "words": ["<tag1>", "In", "particular,", "alidornase", "alfa", "has", "demonstrated", "a", "reduction", "in", "mucus", "viscosity", "in", "human", "sputum", "samples", "when", "compared", "to", "the", "currently", "marketed", "product.", "<tag2>", "Fabry", "disease", "causes", "substantial", "reduction", "in", "life-expectancy,", "by", "an", "average", "of", "15", "years", "in", "female", "patients", "and", "20", "years", "in", "male", "patients,", "compared", "to", "the", "general", "population.", "<tag3>"], "wordsA": ["In", "particular,", "alidornase", "alfa", "has", "demonstrated", "a", "reduction", "in", "mucus", "viscosity", "in", "human", "sputum", "samples", "when", "compared", "to", "the", "currently", "marketed", "product."], "wordsB": ["Fabry", "disease", "causes", "substantial", "reduction", "in", "life-expectancy,", "by", "an", "average", "of", "15", "years", "in", "female", "patients", "and", "20", "years", "in", "male", "patients,", "compared", "to", "the", "general", "population."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.4365362226963043, 0.49368152022361755, 0.030318250879645348, 0.049321867525577545, 0.12158957868814468, 0.056392066180706024, 0.352630078792572, 0.004400570411235094, 0.0048041935078799725, 0.012121368199586868, 0.007226869929581881, 0.10717006772756577, 0.059970423579216, 0.011481442488729954, 0.29592666029930115, 0.1415075659751892, 0.005345968529582024, 0.05153350532054901, 0.03980886563658714, 0.013025625608861446, 0.2157106250524521, 0.11128196865320206, 0.0036007568705826998, 0.0038575672078877687, 0.004438082687556744, 0.05105648934841156, 0.05672907456755638, -1]}
{"idB": "1006281_18_item1_p81_s0", "idA": "1006281_17_item1_p80_s0", "sentA": "In July 2016 we commenced a phase IIa clinical trial of alidornase alfa.", "sentB": "In July 2016 we commenced a phase IIa clinical trial of alidornase alfa for the treatment of CF, and we released the final results of the study in April 2017.", "type": 2, "words": ["<tag1>", "In", "July", "2016", "we", "commenced", "a", "phase", "IIa", "clinical", "trial", "of", "alidornase", "alfa.", "<tag2>", "In", "July", "2016", "we", "commenced", "a", "phase", "IIa", "clinical", "trial", "of", "alidornase", "alfa", "for", "the", "treatment", "of", "CF,", "and", "we", "released", "the", "final", "results", "of", "the", "study", "in", "April", "2017.", "<tag3>"], "wordsA": ["In", "July", "2016", "we", "commenced", "a", "phase", "IIa", "clinical", "trial", "of", "alidornase", "alfa."], "wordsB": ["In", "July", "2016", "we", "commenced", "a", "phase", "IIa", "clinical", "trial", "of", "alidornase", "alfa", "for", "the", "treatment", "of", "CF,", "and", "we", "released", "the", "final", "results", "of", "the", "study", "in", "April", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005018563475459814, 0.01119422260671854, 0.01290911715477705, 0.012992998585104942, 0.022246908396482468, 0.004064265638589859, 0.009862183593213558, 0.0090536680072546, 0.016252199187874794, 0.028362786397337914, 0.004879405256360769, 0.01259444560855627, 0.026004116982221603, 0.02467512898147106, 0.04193511977791786, 0.4614246189594269, 0.5096198320388794, 0.9058189392089844, 0.0014393450692296028, 0.04995058476924896, 0.4094226062297821, 0.12083673477172852, 0.26938551664352417, 0.19710515439510345, 0.03418232128024101, 0.040137868374586105, 0.1306786686182022, 0.06304880976676941, 0.15301035344600677, 0.3161330819129944, -1]}
{"idB": "1006281_18_item1_p82_s0", "idA": "1006281_17_item1_p80_s1", "sentA": "The trial is a 28-day switch-over study of 15 CF patients previously treated with Pulmozyme to evaluate the efficacy and safety of alidornase alfa in CF patients.", "sentB": "The phase II trial was a 28-day switchover study to evaluate the safety and efficacy of alidornase alfa in CF patients previously treated with Pulmozyme (currently the only commercially available DNase therapy).", "type": 2, "words": ["<tag1>", "The", "trial", "is", "a", "28-day", "switch-over", "study", "of", "15", "CF", "patients", "previously", "treated", "with", "Pulmozyme", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "alidornase", "alfa", "in", "CF", "patients.", "<tag2>", "The", "phase", "II", "trial", "was", "a", "28-day", "switchover", "study", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "alidornase", "alfa", "in", "CF", "patients", "previously", "treated", "with", "Pulmozyme", "(currently", "the", "only", "commercially", "available", "DNase", "therapy).", "<tag3>"], "wordsA": ["The", "trial", "is", "a", "28-day", "switch-over", "study", "of", "15", "CF", "patients", "previously", "treated", "with", "Pulmozyme", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "alidornase", "alfa", "in", "CF", "patients."], "wordsB": ["The", "phase", "II", "trial", "was", "a", "28-day", "switchover", "study", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "alidornase", "alfa", "in", "CF", "patients", "previously", "treated", "with", "Pulmozyme", "(currently", "the", "only", "commercially", "available", "DNase", "therapy)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.0033307340927422047, 0.39197129011154175, 0.9270456433296204, 0.17201271653175354, 0.0023366159293800592, 0.0020410914439707994, 0.005857052747160196, 0.01002337597310543, 0.02969784289598465, 0.0016323071904480457, 0.0033474217634648085, 0.0017085886793211102, 0.003390389494597912, 0.0019245974253863096, 0.0030806432478129864, 0.0018105022609233856, 0.003717824351042509, 0.00413525989279151, 0.0030251399148255587, 0.01798013038933277, 0.028749920427799225, 0.0021655838936567307, 0.006044676527380943, 0.002369874157011509, 0.006142725236713886, 0.011377092450857162, 0.0038466379046440125, 0.1253717839717865, 0.1109662801027298, 0.08077798783779144, 0.42919135093688965, 0.30961814522743225, -1]}
{"idB": "1006281_18_item1_p82_s1", "idA": "1006281_17_item1_p80_s2", "sentA": "Participation in the trial is preceded by a two-week washout period from Pulmozyme before treatment with alidornase alfa via inhalation.", "sentB": "Participation in the trial was preceded by a two-week washout period from Pulmozyme before treatment with alidornase alfa via inhalation.", "type": 2, "words": ["<tag1>", "Participation", "in", "the", "trial", "is", "preceded", "by", "a", "two-week", "washout", "period", "from", "Pulmozyme", "before", "treatment", "with", "alidornase", "alfa", "via", "inhalation.", "<tag2>", "Participation", "in", "the", "trial", "was", "preceded", "by", "a", "two-week", "washout", "period", "from", "Pulmozyme", "before", "treatment", "with", "alidornase", "alfa", "via", "inhalation.", "<tag3>"], "wordsA": ["Participation", "in", "the", "trial", "is", "preceded", "by", "a", "two-week", "washout", "period", "from", "Pulmozyme", "before", "treatment", "with", "alidornase", "alfa", "via", "inhalation."], "wordsB": ["Participation", "in", "the", "trial", "was", "preceded", "by", "a", "two-week", "washout", "period", "from", "Pulmozyme", "before", "treatment", "with", "alidornase", "alfa", "via", "inhalation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.3471311628818512, 0.057289231568574905, 0.024888901039958, 0.1623743623495102, 0.05294061452150345, 0.3219190537929535, 0.04356534034013748, 0.024357952177524567, 0.23470483720302582, 0.24076393246650696, 0.08886729180812836, 0.05651604011654854, 0.374737411737442, 0.12544886767864227, 0.2531677782535553, 0.15581895411014557, 0.3624219000339508, 0.3234919309616089, 0.12059041857719421, 0.23704691231250763, -1]}
{"idB": "1006281_18_item1_p81_s1", "idA": "1006281_17_item1_p81_s0", "sentA": "In January 2017, we announced positive interim results from the phase IIa clinical trial for the first 13 CF patients enrolled in the study.", "sentB": "Sixteen patients were enrolled in the study, all of whom completed the study.", "type": 2, "words": ["<tag1>", "In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study.", "<tag2>", "Sixteen", "patients", "were", "enrolled", "in", "the", "study,", "all", "of", "whom", "completed", "the", "study.", "<tag3>"], "wordsA": ["In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study."], "wordsB": ["Sixteen", "patients", "were", "enrolled", "in", "the", "study,", "all", "of", "whom", "completed", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.8065938353538513, 0.39748477935791016, 0.01210265513509512, 0.08969635516405106, 0.01910196989774704, 0.01698164828121662, 0.05650211125612259, 0.13044136762619019, 0.03330043703317642, 0.055236443877220154, 0.6047394275665283, 0.16606158018112183, 0.2863979637622833, -1]}
{"idB": "1006281_18_item1_p83_s0", "idA": "1006281_17_item1_p82_s0", "sentA": "The initial primary efficacy result shows that alidornase alfa improves lung function as demonstrated by a mean absolute increase in the percent predicted forced expiratory volume in one second (ppFEV1) of 4.1 points from baseline and 3.1 points from last treatment of Pulmozyme.", "sentB": "The primary efficacy results show that treatment with alidornase alfa resulted in clinically meaningful lung function improvement, as demonstrated by a mean absolute increase in the percent predicted forced expiratory volume in one second (ppFEV1) of 3.4 points from baseline.", "type": 2, "words": ["<tag1>", "The", "initial", "primary", "efficacy", "result", "shows", "that", "alidornase", "alfa", "improves", "lung", "function", "as", "demonstrated", "by", "a", "mean", "absolute", "increase", "in", "the", "percent", "predicted", "forced", "expiratory", "volume", "in", "one", "second", "(ppFEV1)", "of", "4.1", "points", "from", "baseline", "and", "3.1", "points", "from", "last", "treatment", "of", "Pulmozyme.", "<tag2>", "The", "primary", "efficacy", "results", "show", "that", "treatment", "with", "alidornase", "alfa", "resulted", "in", "clinically", "meaningful", "lung", "function", "improvement,", "as", "demonstrated", "by", "a", "mean", "absolute", "increase", "in", "the", "percent", "predicted", "forced", "expiratory", "volume", "in", "one", "second", "(ppFEV1)", "of", "3.4", "points", "from", "baseline.", "<tag3>"], "wordsA": ["The", "initial", "primary", "efficacy", "result", "shows", "that", "alidornase", "alfa", "improves", "lung", "function", "as", "demonstrated", "by", "a", "mean", "absolute", "increase", "in", "the", "percent", "predicted", "forced", "expiratory", "volume", "in", "one", "second", "(ppFEV1)", "of", "4.1", "points", "from", "baseline", "and", "3.1", "points", "from", "last", "treatment", "of", "Pulmozyme."], "wordsB": ["The", "primary", "efficacy", "results", "show", "that", "treatment", "with", "alidornase", "alfa", "resulted", "in", "clinically", "meaningful", "lung", "function", "improvement,", "as", "demonstrated", "by", "a", "mean", "absolute", "increase", "in", "the", "percent", "predicted", "forced", "expiratory", "volume", "in", "one", "second", "(ppFEV1)", "of", "3.4", "points", "from", "baseline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004798911977559328, 0.014017273671925068, 0.013042294420301914, 0.016108844429254532, 0.012245053425431252, 0.007835430093109608, 0.15543001890182495, 0.052495330572128296, 0.026092061772942543, 0.0162963904440403, 0.01262711826711893, 0.008183837868273258, 0.2587864398956299, 0.33592158555984497, 0.09559932351112366, 0.04609560966491699, 0.0338263139128685, 0.007253631949424744, 0.004889783915132284, 0.003976719453930855, 0.00504391361027956, 0.010299989022314548, 0.011635641567409039, 0.013481522910296917, 0.004450563807040453, 0.005363117437809706, 0.01578747294843197, 0.005368655547499657, 0.009681246243417263, 0.017187869176268578, 0.0076898857951164246, 0.004523256793618202, 0.0072929151356220245, 0.0065652066841721535, 0.01809179224073887, 0.006539624184370041, 0.10764392465353012, 0.036264605820178986, 0.006989665329456329, 0.03219882398843765, -1]}
{"idB": "1006281_18_item1_p83_s1", "idA": "1006281_17_item1_p82_s1", "sentA": "A commercially available small molecule CFTR modulator for the treatment of CF has reported a mean absolute increase in ppFEV1 of 2.5 from baseline in its registration clinical study.", "sentB": "Moreover, a mean absolute increase in ppFEV1 of 2.8 points was also observed in patients participating in the trial when compared to measurements taken from patients at initiation before the switch from Pulmozyme to alidornase alfa.", "type": 2, "words": ["<tag1>", "A", "commercially", "available", "small", "molecule", "CFTR", "modulator", "for", "the", "treatment", "of", "CF", "has", "reported", "a", "mean", "absolute", "increase", "in", "ppFEV1", "of", "2.5", "from", "baseline", "in", "its", "registration", "clinical", "study.", "<tag2>", "Moreover,", "a", "mean", "absolute", "increase", "in", "ppFEV1", "of", "2.8", "points", "was", "also", "observed", "in", "patients", "participating", "in", "the", "trial", "when", "compared", "to", "measurements", "taken", "from", "patients", "at", "initiation", "before", "the", "switch", "from", "Pulmozyme", "to", "alidornase", "alfa.", "<tag3>"], "wordsA": ["A", "commercially", "available", "small", "molecule", "CFTR", "modulator", "for", "the", "treatment", "of", "CF", "has", "reported", "a", "mean", "absolute", "increase", "in", "ppFEV1", "of", "2.5", "from", "baseline", "in", "its", "registration", "clinical", "study."], "wordsB": ["Moreover,", "a", "mean", "absolute", "increase", "in", "ppFEV1", "of", "2.8", "points", "was", "also", "observed", "in", "patients", "participating", "in", "the", "trial", "when", "compared", "to", "measurements", "taken", "from", "patients", "at", "initiation", "before", "the", "switch", "from", "Pulmozyme", "to", "alidornase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.008506065234541893, 0.004396719858050346, 0.030383843928575516, 0.042563971132040024, 0.05081447586417198, 0.008401584811508656, 0.022213289514183998, 0.020359555259346962, 0.862901508808136, 0.6763747334480286, 0.007782215252518654, 0.008033753372728825, 0.0326620489358902, 0.022547228261828423, 0.1421085000038147, 0.03431950882077217, 0.02657238021492958, 0.021710282191634178, 0.06345753371715546, 0.00012113149568904191, 0.047648701816797256, 0.009293143637478352, 0.18936026096343994, 0.02473379857838154, 0.017886929214000702, 0.1592293232679367, 0.023753264918923378, 0.06540591269731522, 0.04196557402610779, 0.013758951798081398, 0.07472594827413559, 0.06259074807167053, 0.5739823579788208, 0.0813293382525444, 0.35837703943252563, 0.2208339422941208, -1]}
{"idB": "1006281_18_item1_p84_s1", "idA": "1006281_17_item1_p82_s2", "sentA": "This score was achieved while 74% of the patients participating in the trial of the CFTR modulator were also treated with Pulmozyme on top of the modulator.", "sentB": "This score was achieved while 74% of the patients participating in the trial of the CFTR modulator were also treated with the modulator on top of Pulmozyme.", "type": 2, "words": ["<tag1>", "This", "score", "was", "achieved", "while", "74%", "of", "the", "patients", "participating", "in", "the", "trial", "of", "the", "CFTR", "modulator", "were", "also", "treated", "with", "Pulmozyme", "on", "top", "of", "the", "modulator.", "<tag2>", "This", "score", "was", "achieved", "while", "74%", "of", "the", "patients", "participating", "in", "the", "trial", "of", "the", "CFTR", "modulator", "were", "also", "treated", "with", "the", "modulator", "on", "top", "of", "Pulmozyme.", "<tag3>"], "wordsA": ["This", "score", "was", "achieved", "while", "74%", "of", "the", "patients", "participating", "in", "the", "trial", "of", "the", "CFTR", "modulator", "were", "also", "treated", "with", "Pulmozyme", "on", "top", "of", "the", "modulator."], "wordsB": ["This", "score", "was", "achieved", "while", "74%", "of", "the", "patients", "participating", "in", "the", "trial", "of", "the", "CFTR", "modulator", "were", "also", "treated", "with", "the", "modulator", "on", "top", "of", "Pulmozyme."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01045239344239235, 0.12546439468860626, 0.018284142017364502, 0.08778633177280426, 0.048440977931022644, 0.5754221081733704, 0.14392635226249695, 0.09253150969743729, 0.4305865168571472, 0.07337816059589386, 0.02441166155040264, 0.02116146869957447, 0.07594838738441467, 0.03221871331334114, 0.03127751499414444, 0.09321507811546326, 0.12782475352287292, 0.08396777510643005, 0.20583957433700562, 0.21619026362895966, 0.13898570835590363, 0.05892853066325188, 0.27119407057762146, 0.08226168900728226, 0.20832479000091553, 0.10682603716850281, 0.19260451197624207, -1]}
{"idB": "1006281_18_item1_p84_s2", "idA": "1006281_17_item1_p82_s3", "sentA": "While this marketed CFTR addresses a certain mutation applicable to less than 50% of CF patients, we are developing alidornase alfa to treat all CF patients.", "sentB": "While this marketed CFTR addresses a certain mutation applicable to less than 50% of CF patients, alidornase alfa is being developed to treat all CF patients.", "type": 2, "words": ["<tag1>", "While", "this", "marketed", "CFTR", "addresses", "a", "certain", "mutation", "applicable", "to", "less", "than", "50%", "of", "CF", "patients,", "we", "are", "developing", "alidornase", "alfa", "to", "treat", "all", "CF", "patients.", "<tag2>", "While", "this", "marketed", "CFTR", "addresses", "a", "certain", "mutation", "applicable", "to", "less", "than", "50%", "of", "CF", "patients,", "alidornase", "alfa", "is", "being", "developed", "to", "treat", "all", "CF", "patients.", "<tag3>"], "wordsA": ["While", "this", "marketed", "CFTR", "addresses", "a", "certain", "mutation", "applicable", "to", "less", "than", "50%", "of", "CF", "patients,", "we", "are", "developing", "alidornase", "alfa", "to", "treat", "all", "CF", "patients."], "wordsB": ["While", "this", "marketed", "CFTR", "addresses", "a", "certain", "mutation", "applicable", "to", "less", "than", "50%", "of", "CF", "patients,", "alidornase", "alfa", "is", "being", "developed", "to", "treat", "all", "CF", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.02321912907063961, 0.014471526257693768, 0.0423545241355896, 0.15013599395751953, 0.04705347493290901, 0.013770435936748981, 0.03027118369936943, 0.06047716364264488, 0.03331327065825462, 0.016133660450577736, 0.5741440653800964, 0.4221678674221039, 0.30453357100486755, 0.029438767582178116, 0.06747371703386307, 0.0944640189409256, 0.22520330548286438, 0.22905488312244415, 0.09970062971115112, 0.12836851179599762, 0.1467779576778412, 0.02899090386927128, 0.04495135694742203, 0.04491783306002617, 0.07673284411430359, 0.11062854528427124, -1]}
{"idB": "1006281_18_item1_p88_s1", "idA": "1006281_17_item1_p82_s3", "sentA": "While this marketed CFTR addresses a certain mutation applicable to less than 50% of CF patients, we are developing alidornase alfa to treat all CF patients.", "sentB": "This provides further support for the potential that alidornase alfa may offer additional efficacy to CF patients.", "type": 2, "words": ["<tag1>", "While", "this", "marketed", "CFTR", "addresses", "a", "certain", "mutation", "applicable", "to", "less", "than", "50%", "of", "CF", "patients,", "we", "are", "developing", "alidornase", "alfa", "to", "treat", "all", "CF", "patients.", "<tag2>", "This", "provides", "further", "support", "for", "the", "potential", "that", "alidornase", "alfa", "may", "offer", "additional", "efficacy", "to", "CF", "patients.", "<tag3>"], "wordsA": ["While", "this", "marketed", "CFTR", "addresses", "a", "certain", "mutation", "applicable", "to", "less", "than", "50%", "of", "CF", "patients,", "we", "are", "developing", "alidornase", "alfa", "to", "treat", "all", "CF", "patients."], "wordsB": ["This", "provides", "further", "support", "for", "the", "potential", "that", "alidornase", "alfa", "may", "offer", "additional", "efficacy", "to", "CF", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.025096379220485687, 0.08732560276985168, 0.0649343952536583, 0.17915382981300354, 0.05908707529306412, 0.0474148653447628, 0.1481022983789444, 0.06899437308311462, 0.2392280548810959, 0.17746694386005402, 0.14003777503967285, 0.29491856694221497, 0.4481674134731293, 0.5624809265136719, 0.09033975750207901, 0.12780137360095978, 0.18125487864017487, -1]}
{"idB": "1006281_18_item1_p85_s0", "idA": "1006281_17_item1_p83_s0", "sentA": "Sputa available DNA samples were analyzed for approximately half of the patients in the phase II trial.", "sentB": "Sputa available DNA samples were analyzed for approximately half of the patients.", "type": 2, "words": ["<tag1>", "Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial.", "<tag2>", "Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients.", "<tag3>"], "wordsA": ["Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial."], "wordsB": ["Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.3315134346485138, 0.10535986721515656, 0.12440240383148193, 0.22290103137493134, 0.03980365768074989, 0.1664813756942749, 0.0667155310511589, 0.101780004799366, 0.7311191558837891, 0.1674109846353531, 0.151014044880867, 0.3890414535999298, -1]}
{"idB": "1006281_18_item1_p96_s5", "idA": "1006281_17_item1_p83_s0", "sentA": "Sputa available DNA samples were analyzed for approximately half of the patients in the phase II trial.", "sentB": "The interim data demonstrates that 57% of the patients achieved clinical response and 36% achieved clinical remission at week 8.", "type": 2, "words": ["<tag1>", "Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial.", "<tag2>", "The", "interim", "data", "demonstrates", "that", "57%", "of", "the", "patients", "achieved", "clinical", "response", "and", "36%", "achieved", "clinical", "remission", "at", "week", "8.", "<tag3>"], "wordsA": ["Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial."], "wordsB": ["The", "interim", "data", "demonstrates", "that", "57%", "of", "the", "patients", "achieved", "clinical", "response", "and", "36%", "achieved", "clinical", "remission", "at", "week", "8."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.008476962335407734, 0.25550878047943115, 0.14588241279125214, 0.0564003549516201, 0.021349173039197922, 0.3209977149963379, 0.06332302838563919, 0.04127991199493408, 0.14136402308940887, 0.1974833905696869, 0.3913106322288513, 0.47290703654289246, 0.004016442224383354, 0.2954767346382141, 0.18508081138134003, 0.4372671842575073, 0.6805523633956909, 0.01612112857401371, 0.0613146647810936, 0.08965457230806351, -1]}
{"idB": "1006281_18_item1_p89_s0", "idA": "1006281_17_item1_p83_s2", "sentA": "This data provides further supportive evidence of improved lung function after treatment with alidornase alfa, as demonstrated by the increase in ppFEV1.", "sentB": "The above-mentioned material decrease in visco-elasticity and DNA presence in CF patients sputa, coupled with the significant inhibition of Pseudomonas and higher levels of alidornase alfa available in the patients lungs, provides further supportive evidence of improved lung function after treatment with alidornase alfa, as demonstrated by the increase in FEV1.", "type": 2, "words": ["<tag1>", "This", "data", "provides", "further", "supportive", "evidence", "of", "improved", "lung", "function", "after", "treatment", "with", "alidornase", "alfa,", "as", "demonstrated", "by", "the", "increase", "in", "ppFEV1.", "<tag2>", "The", "above-mentioned", "material", "decrease", "in", "visco-elasticity", "and", "DNA", "presence", "in", "CF", "patients", "sputa,", "coupled", "with", "the", "significant", "inhibition", "of", "Pseudomonas", "and", "higher", "levels", "of", "alidornase", "alfa", "available", "in", "the", "patients", "lungs,", "provides", "further", "supportive", "evidence", "of", "improved", "lung", "function", "after", "treatment", "with", "alidornase", "alfa,", "as", "demonstrated", "by", "the", "increase", "in", "FEV1.", "<tag3>"], "wordsA": ["This", "data", "provides", "further", "supportive", "evidence", "of", "improved", "lung", "function", "after", "treatment", "with", "alidornase", "alfa,", "as", "demonstrated", "by", "the", "increase", "in", "ppFEV1."], "wordsB": ["The", "above-mentioned", "material", "decrease", "in", "visco-elasticity", "and", "DNA", "presence", "in", "CF", "patients", "sputa,", "coupled", "with", "the", "significant", "inhibition", "of", "Pseudomonas", "and", "higher", "levels", "of", "alidornase", "alfa", "available", "in", "the", "patients", "lungs,", "provides", "further", "supportive", "evidence", "of", "improved", "lung", "function", "after", "treatment", "with", "alidornase", "alfa,", "as", "demonstrated", "by", "the", "increase", "in", "FEV1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004504670854657888, 0.02663440816104412, 0.07483769953250885, 0.2573620080947876, 0.11781894415616989, 0.4803476631641388, 0.04033912718296051, 0.18378734588623047, 0.13318748772144318, 0.009115464054048061, 0.04011882096529007, 0.0954294502735138, 0.048408012837171555, 0.0031749685294926167, 0.002974479692056775, 0.004064253997057676, 0.01260140910744667, 0.02242101915180683, 0.0193440280854702, 0.03791866451501846, 0.004923680797219276, 0.0330289751291275, 0.024130355566740036, 0.030538074672222137, 0.023856965824961662, 0.031409852206707, 0.006629317067563534, 0.00474179582670331, 0.004246487747877836, 0.020554928109049797, 0.04547884687781334, 0.0027788414154201746, 0.001906875055283308, 0.003689920762553811, 0.0055170487612485886, 0.0019748567137867212, 0.007563591469079256, 0.0134884687140584, 0.00816470105201006, 0.0026627974584698677, 0.006506762932986021, 0.0027617113664746284, 0.003470556577667594, 0.004916693549603224, 0.0023880135267972946, 0.0026683195028454065, 0.0019403756596148014, 0.0036299920175224543, 0.0522865429520607, 0.04128589481115341, 0.8698651194572449, -1]}
{"idB": "1006281_18_item1_p90_s0", "idA": "1006281_17_item1_p84_s0", "sentA": "No serious adverse events were reported, and all adverse events that occurred during the study were mild and transient in nature.", "sentB": "alidornase alfa was well tolerated with no serious adverse events reported.", "type": 2, "words": ["<tag1>", "No", "serious", "adverse", "events", "were", "reported,", "and", "all", "adverse", "events", "that", "occurred", "during", "the", "study", "were", "mild", "and", "transient", "in", "nature.", "<tag2>", "alidornase", "alfa", "was", "well", "tolerated", "with", "no", "serious", "adverse", "events", "reported.", "<tag3>"], "wordsA": ["No", "serious", "adverse", "events", "were", "reported,", "and", "all", "adverse", "events", "that", "occurred", "during", "the", "study", "were", "mild", "and", "transient", "in", "nature."], "wordsB": ["alidornase", "alfa", "was", "well", "tolerated", "with", "no", "serious", "adverse", "events", "reported."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.46399787068367004, 0.41716498136520386, 0.039512939751148224, 0.0938248336315155, 0.12623253464698792, 0.006480939220637083, 0.17192557454109192, 0.17746983468532562, 0.10289343446493149, 0.11041296273469925, 0.04272729158401489, -1]}
{"idB": "1006281_18_item1_p98_s0", "idA": "1006281_17_item1_p84_s0", "sentA": "No serious adverse events were reported, and all adverse events that occurred during the study were mild and transient in nature.", "sentB": "Treatment was well tolerated and the majority of adverse events have been mild to moderate and transient in nature, with headaches being the most common.", "type": 2, "words": ["<tag1>", "No", "serious", "adverse", "events", "were", "reported,", "and", "all", "adverse", "events", "that", "occurred", "during", "the", "study", "were", "mild", "and", "transient", "in", "nature.", "<tag2>", "Treatment", "was", "well", "tolerated", "and", "the", "majority", "of", "adverse", "events", "have", "been", "mild", "to", "moderate", "and", "transient", "in", "nature,", "with", "headaches", "being", "the", "most", "common.", "<tag3>"], "wordsA": ["No", "serious", "adverse", "events", "were", "reported,", "and", "all", "adverse", "events", "that", "occurred", "during", "the", "study", "were", "mild", "and", "transient", "in", "nature."], "wordsB": ["Treatment", "was", "well", "tolerated", "and", "the", "majority", "of", "adverse", "events", "have", "been", "mild", "to", "moderate", "and", "transient", "in", "nature,", "with", "headaches", "being", "the", "most", "common."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.21427477896213531, 0.06236850097775459, 0.28855687379837036, 0.3106415569782257, 0.006064002402126789, 0.004877553321421146, 0.12482702732086182, 0.021939268335700035, 0.1085311770439148, 0.06024261936545372, 0.008857429027557373, 0.008265865966677666, 0.03480519726872444, 0.017036492004990578, 0.05533108487725258, 0.011518090032041073, 0.046270135790109634, 0.003615281544625759, 0.008283941075205803, 0.004968372639268637, 0.43525779247283936, 0.022702939808368683, 0.010341940447688103, 0.05010102689266205, 0.04039234295487404, -1]}
{"idB": "1006281_18_item1_p104_s0", "idA": "1006281_17_item1_p8_s0", "sentA": "In December 2016, we received a letter from Fiocruz regarding an order from the Brazilian MoH to purchase alfataliglicerase to treat Gaucher patients in Brazil.", "sentB": "In 2017, we received a purchase order from the Brazilian MoH for the purchase of approximately $24.3 million of alfataliglicerase for the treatment of Gaucher patients in Brazil.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "we", "received", "a", "letter", "from", "Fiocruz", "regarding", "an", "order", "from", "the", "Brazilian", "MoH", "to", "purchase", "alfataliglicerase", "to", "treat", "Gaucher", "patients", "in", "Brazil.", "<tag2>", "In", "2017,", "we", "received", "a", "purchase", "order", "from", "the", "Brazilian", "MoH", "for", "the", "purchase", "of", "approximately", "$24.3", "million", "of", "alfataliglicerase", "for", "the", "treatment", "of", "Gaucher", "patients", "in", "Brazil.", "<tag3>"], "wordsA": ["In", "December", "2016,", "we", "received", "a", "letter", "from", "Fiocruz", "regarding", "an", "order", "from", "the", "Brazilian", "MoH", "to", "purchase", "alfataliglicerase", "to", "treat", "Gaucher", "patients", "in", "Brazil."], "wordsB": ["In", "2017,", "we", "received", "a", "purchase", "order", "from", "the", "Brazilian", "MoH", "for", "the", "purchase", "of", "approximately", "$24.3", "million", "of", "alfataliglicerase", "for", "the", "treatment", "of", "Gaucher", "patients", "in", "Brazil."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08138425648212433, 0.963424801826477, 0.013418820686638355, 0.022061122581362724, 0.005069328472018242, 0.03966781869530678, 0.06192443519830704, 0.005129970144480467, 0.0022224350832402706, 0.008493687026202679, 0.012194948270916939, 0.0037202718667685986, 0.002777275163680315, 0.01654387079179287, 0.004640299826860428, 0.02371760457754135, 0.18115538358688354, 0.09761414676904678, 0.007643428631126881, 0.010909358970820904, 0.002305449917912483, 0.0022314791567623615, 0.005523467902094126, 0.002485353033989668, 0.00425552437081933, 0.006022674031555653, 0.0020796845201402903, 0.0037786662578582764, -1]}
{"idB": "1006281_18_item1_p12_s0", "idA": "1006281_17_item1_p8_s0", "sentA": "In December 2016, we received a letter from Fiocruz regarding an order from the Brazilian MoH to purchase alfataliglicerase to treat Gaucher patients in Brazil.", "sentB": "In 2017, we received a purchase order from the Brazilian MoH for the purchase of approximately $24.3 million of alfataliglicerase for the treatment of Gaucher patients in Brazil.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "we", "received", "a", "letter", "from", "Fiocruz", "regarding", "an", "order", "from", "the", "Brazilian", "MoH", "to", "purchase", "alfataliglicerase", "to", "treat", "Gaucher", "patients", "in", "Brazil.", "<tag2>", "In", "2017,", "we", "received", "a", "purchase", "order", "from", "the", "Brazilian", "MoH", "for", "the", "purchase", "of", "approximately", "$24.3", "million", "of", "alfataliglicerase", "for", "the", "treatment", "of", "Gaucher", "patients", "in", "Brazil.", "<tag3>"], "wordsA": ["In", "December", "2016,", "we", "received", "a", "letter", "from", "Fiocruz", "regarding", "an", "order", "from", "the", "Brazilian", "MoH", "to", "purchase", "alfataliglicerase", "to", "treat", "Gaucher", "patients", "in", "Brazil."], "wordsB": ["In", "2017,", "we", "received", "a", "purchase", "order", "from", "the", "Brazilian", "MoH", "for", "the", "purchase", "of", "approximately", "$24.3", "million", "of", "alfataliglicerase", "for", "the", "treatment", "of", "Gaucher", "patients", "in", "Brazil."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08138425648212433, 0.963424801826477, 0.013418820686638355, 0.022061122581362724, 0.005069328472018242, 0.03966781869530678, 0.06192443519830704, 0.005129970144480467, 0.0022224350832402706, 0.008493687026202679, 0.012194948270916939, 0.0037202718667685986, 0.002777275163680315, 0.01654387079179287, 0.004640299826860428, 0.02371760457754135, 0.18115538358688354, 0.09761414676904678, 0.007643428631126881, 0.010909358970820904, 0.002305449917912483, 0.0022314791567623615, 0.005523467902094126, 0.002485353033989668, 0.00425552437081933, 0.006022674031555653, 0.0020796845201402903, 0.0037786662578582764, -1]}
{"idB": "1006281_18_item1_p104_s1", "idA": "1006281_17_item1_p8_s1", "sentA": "The Brazilian MoH s order consists of a number of shipments during 2017 for a total of approximately $24.3 million.", "sentB": "The purchase order consists of a number of shipments in increasing volumes.", "type": 2, "words": ["<tag1>", "The", "Brazilian", "MoH", "s", "order", "consists", "of", "a", "number", "of", "shipments", "during", "2017", "for", "a", "total", "of", "approximately", "$24.3", "million.", "<tag2>", "The", "purchase", "order", "consists", "of", "a", "number", "of", "shipments", "in", "increasing", "volumes.", "<tag3>"], "wordsA": ["The", "Brazilian", "MoH", "s", "order", "consists", "of", "a", "number", "of", "shipments", "during", "2017", "for", "a", "total", "of", "approximately", "$24.3", "million."], "wordsB": ["The", "purchase", "order", "consists", "of", "a", "number", "of", "shipments", "in", "increasing", "volumes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005520809907466173, 0.357693076133728, 0.24480371177196503, 0.007114890497177839, 0.0025932106655091047, 0.0023721917532384396, 0.008343475870788097, 0.006245649419724941, 0.038572534918785095, 0.06745725125074387, 0.859069287776947, 0.7585286498069763, -1]}
{"idB": "1006281_18_item1_p12_s1", "idA": "1006281_17_item1_p8_s1", "sentA": "The Brazilian MoH s order consists of a number of shipments during 2017 for a total of approximately $24.3 million.", "sentB": "The purchase order consists of a number of shipments in increasing volumes.", "type": 2, "words": ["<tag1>", "The", "Brazilian", "MoH", "s", "order", "consists", "of", "a", "number", "of", "shipments", "during", "2017", "for", "a", "total", "of", "approximately", "$24.3", "million.", "<tag2>", "The", "purchase", "order", "consists", "of", "a", "number", "of", "shipments", "in", "increasing", "volumes.", "<tag3>"], "wordsA": ["The", "Brazilian", "MoH", "s", "order", "consists", "of", "a", "number", "of", "shipments", "during", "2017", "for", "a", "total", "of", "approximately", "$24.3", "million."], "wordsB": ["The", "purchase", "order", "consists", "of", "a", "number", "of", "shipments", "in", "increasing", "volumes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005520809907466173, 0.357693076133728, 0.24480371177196503, 0.007114890497177839, 0.0025932106655091047, 0.0023721917532384396, 0.008343475870788097, 0.006245649419724941, 0.038572534918785095, 0.06745725125074387, 0.859069287776947, 0.7585286498069763, -1]}
{"idB": "1006281_18_item1_p96_s8", "idA": "1006281_17_item1_p8_s2", "sentA": "Shipments are to start in mid-2017 and continue through the end of the year, in increasing volumes.", "sentB": "We except to release complete results by the end of March, 2018.", "type": 2, "words": ["<tag1>", "Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes.", "<tag2>", "We", "except", "to", "release", "complete", "results", "by", "the", "end", "of", "March,", "2018.", "<tag3>"], "wordsA": ["Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes."], "wordsB": ["We", "except", "to", "release", "complete", "results", "by", "the", "end", "of", "March,", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.04030441865324974, 0.10950376093387604, 0.061532191932201385, 0.24593773484230042, 0.49909064173698425, 0.3502822816371918, 0.07148788124322891, 0.028604786843061447, 0.15379448235034943, 0.1505790799856186, 0.4049994945526123, 0.6281730532646179, -1]}
{"idB": "1006281_18_item1_p104_s2", "idA": "1006281_17_item1_p8_s3", "sentA": "Fiocruz s purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement.", "sentB": "Fiocruz s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement.", "type": 2, "words": ["<tag1>", "Fiocruz", "s", "purchases", "of", "Uplyso", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement.", "<tag2>", "Fiocruz", "s", "purchases", "of", "alfataliglicerase", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement.", "<tag3>"], "wordsA": ["Fiocruz", "s", "purchases", "of", "Uplyso", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement."], "wordsB": ["Fiocruz", "s", "purchases", "of", "alfataliglicerase", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004383185412734747, 0.004450391046702862, 0.044081781059503555, 0.03013794496655464, 0.9947085380554199, 0.0018198192119598389, 0.001845163176767528, 0.0013385452330112457, 0.0013365027261897922, 0.002815362298861146, 0.0031302436254918575, 0.0018015742534771562, 0.001897646114230156, 0.001900084549561143, 0.0022206774447113276, 0.002127178478986025, 0.0013321476290002465, 0.001645430689677596, 0.0015225172974169254, 0.0016900685150176287, 0.0013408118393272161, 0.003056335961446166, 0.0017436560010537505, 0.0072739324532449245, 0.0018214830197393894, 0.005136802792549133, 0.005670825019478798, -1]}
{"idB": "1006281_18_item1_p12_s2", "idA": "1006281_17_item1_p8_s3", "sentA": "Fiocruz s purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement.", "sentB": "Fiocruz s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement.", "type": 2, "words": ["<tag1>", "Fiocruz", "s", "purchases", "of", "Uplyso", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement.", "<tag2>", "Fiocruz", "s", "purchases", "of", "alfataliglicerase", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement.", "<tag3>"], "wordsA": ["Fiocruz", "s", "purchases", "of", "Uplyso", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement."], "wordsB": ["Fiocruz", "s", "purchases", "of", "alfataliglicerase", "to", "date", "have", "been", "significantly", "below", "certain", "agreed", "upon", "purchase", "milestones", "and,", "accordingly,", "we", "have", "the", "right", "to", "terminate", "the", "Brazil", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.004383185412734747, 0.004450391046702862, 0.044081781059503555, 0.03013794496655464, 0.9947085380554199, 0.0018198192119598389, 0.001845163176767528, 0.0013385452330112457, 0.0013365027261897922, 0.002815362298861146, 0.0031302436254918575, 0.0018015742534771562, 0.001897646114230156, 0.001900084549561143, 0.0022206774447113276, 0.002127178478986025, 0.0013321476290002465, 0.001645430689677596, 0.0015225172974169254, 0.0016900685150176287, 0.0013408118393272161, 0.003056335961446166, 0.0017436560010537505, 0.0072739324532449245, 0.0018214830197393894, 0.005136802792549133, 0.005670825019478798, -1]}
{"idB": "1006281_18_item1_p104_s3", "idA": "1006281_17_item1_p8_s4", "sentA": "Notwithstanding the low purchase amounts, we are, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil.", "sentB": "Notwithstanding, we are, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.", "type": 2, "words": ["<tag1>", "Notwithstanding", "the", "low", "purchase", "amounts,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "Uplyso", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "Uplyso", "in", "Brazil.", "<tag2>", "Notwithstanding,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "alfataliglicerase", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "alfataliglicerase", "in", "Brazil.", "<tag3>"], "wordsA": ["Notwithstanding", "the", "low", "purchase", "amounts,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "Uplyso", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "Uplyso", "in", "Brazil."], "wordsB": ["Notwithstanding,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "alfataliglicerase", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "alfataliglicerase", "in", "Brazil."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.007067033089697361, 0.005860153120011091, 0.0026700992602854967, 0.0019604789558798075, 0.0017772602150216699, 0.0033352929167449474, 0.009500832296907902, 0.005977150984108448, 0.08263400942087173, 0.9790680408477783, 0.002924972213804722, 0.004144448321312666, 0.0017206224147230387, 0.0014102960703894496, 0.003098443616181612, 0.004004808142781258, 0.0015219049528241158, 0.016024891287088394, 0.00804686639457941, 0.005110682919621468, 0.006591775920242071, 0.030351120978593826, 0.035557083785533905, 0.7156656384468079, 0.0018681208603084087, 0.003385787131264806, -1]}
{"idB": "1006281_18_item1_p12_s3", "idA": "1006281_17_item1_p8_s4", "sentA": "Notwithstanding the low purchase amounts, we are, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil.", "sentB": "Notwithstanding, we are, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.", "type": 2, "words": ["<tag1>", "Notwithstanding", "the", "low", "purchase", "amounts,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "Uplyso", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "Uplyso", "in", "Brazil.", "<tag2>", "Notwithstanding,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "alfataliglicerase", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "alfataliglicerase", "in", "Brazil.", "<tag3>"], "wordsA": ["Notwithstanding", "the", "low", "purchase", "amounts,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "Uplyso", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "Uplyso", "in", "Brazil."], "wordsB": ["Notwithstanding,", "we", "are,", "at", "this", "time,", "continuing", "to", "supply", "alfataliglicerase", "to", "Fiocruz", "under", "the", "Brazil", "Agreement,", "and", "patients", "continue", "to", "be", "treated", "with", "alfataliglicerase", "in", "Brazil."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.007067033089697361, 0.005860153120011091, 0.0026700992602854967, 0.0019604789558798075, 0.0017772602150216699, 0.0033352929167449474, 0.009500832296907902, 0.005977150984108448, 0.08263400942087173, 0.9790680408477783, 0.002924972213804722, 0.004144448321312666, 0.0017206224147230387, 0.0014102960703894496, 0.003098443616181612, 0.004004808142781258, 0.0015219049528241158, 0.016024891287088394, 0.00804686639457941, 0.005110682919621468, 0.006591775920242071, 0.030351120978593826, 0.035557083785533905, 0.7156656384468079, 0.0018681208603084087, 0.003385787131264806, -1]}
{"idB": "1006281_18_item1_p99_s0", "idA": "1006281_17_item1_p91_s0", "sentA": "We have concluded a phase I clinical trial of OPRX-106, which demonstrated that the drug was safe and well tolerated, showing biological activity in the gut.", "sentB": "The results from our phase I clinical trial of OPRX-106 demonstrated that the drug was safe and well tolerated, and showed biological activity in the gut.", "type": 2, "words": ["<tag1>", "We", "have", "concluded", "a", "phase", "I", "clinical", "trial", "of", "OPRX-106,", "which", "demonstrated", "that", "the", "drug", "was", "safe", "and", "well", "tolerated,", "showing", "biological", "activity", "in", "the", "gut.", "<tag2>", "The", "results", "from", "our", "phase", "I", "clinical", "trial", "of", "OPRX-106", "demonstrated", "that", "the", "drug", "was", "safe", "and", "well", "tolerated,", "and", "showed", "biological", "activity", "in", "the", "gut.", "<tag3>"], "wordsA": ["We", "have", "concluded", "a", "phase", "I", "clinical", "trial", "of", "OPRX-106,", "which", "demonstrated", "that", "the", "drug", "was", "safe", "and", "well", "tolerated,", "showing", "biological", "activity", "in", "the", "gut."], "wordsB": ["The", "results", "from", "our", "phase", "I", "clinical", "trial", "of", "OPRX-106", "demonstrated", "that", "the", "drug", "was", "safe", "and", "well", "tolerated,", "and", "showed", "biological", "activity", "in", "the", "gut."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.08272363990545273, 0.619419515132904, 0.16430196166038513, 0.061542410403490067, 0.0684126690030098, 0.06303168833255768, 0.07524386048316956, 0.1444297730922699, 0.03172098100185394, 0.05662094056606293, 0.09377695620059967, 0.024396313354372978, 0.01292660553008318, 0.1427713930606842, 0.04819995164871216, 0.11032047867774963, 0.024356462061405182, 0.034863539040088654, 0.06258559972047806, 0.0092518525198102, 0.029872829094529152, 0.04565566033124924, 0.04895046353340149, 0.01967668905854225, 0.01818569004535675, 0.13676860928535461, -1]}
{"idB": "1006281_18_item1_p85_s2", "idA": "1006281_17_item1_p92_s5", "sentA": "Regulatory T cell activation showing biological activity in the gut was observed.", "sentB": "Correlation between improvement in sputa parameters and pulmonary function was observed.", "type": 2, "words": ["<tag1>", "Regulatory", "T", "cell", "activation", "showing", "biological", "activity", "in", "the", "gut", "was", "observed.", "<tag2>", "Correlation", "between", "improvement", "in", "sputa", "parameters", "and", "pulmonary", "function", "was", "observed.", "<tag3>"], "wordsA": ["Regulatory", "T", "cell", "activation", "showing", "biological", "activity", "in", "the", "gut", "was", "observed."], "wordsB": ["Correlation", "between", "improvement", "in", "sputa", "parameters", "and", "pulmonary", "function", "was", "observed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.1360262781381607, 0.06291911751031876, 0.23879869282245636, 0.09091930836439133, 0.36203426122665405, 0.3438059985637665, 0.05765736475586891, 0.6441122889518738, 0.5868414044380188, 0.003764752298593521, 0.020467139780521393, -1]}
{"idB": "1006281_18_item1_p15_s3", "idA": "1006281_17_item1_p93_s0", "sentA": "In November 2016, the first patient was enrolled in our phase IIa clinical trial of OPRX-106 for the treatment of ulcerative colitis.", "sentB": "We released the final results of our phase II clinical trial of alidornase alfa for the treatment of CF in April 2017.", "type": 2, "words": ["<tag1>", "In", "November", "2016,", "the", "first", "patient", "was", "enrolled", "in", "our", "phase", "IIa", "clinical", "trial", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis.", "<tag2>", "We", "released", "the", "final", "results", "of", "our", "phase", "II", "clinical", "trial", "of", "alidornase", "alfa", "for", "the", "treatment", "of", "CF", "in", "April", "2017.", "<tag3>"], "wordsA": ["In", "November", "2016,", "the", "first", "patient", "was", "enrolled", "in", "our", "phase", "IIa", "clinical", "trial", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis."], "wordsB": ["We", "released", "the", "final", "results", "of", "our", "phase", "II", "clinical", "trial", "of", "alidornase", "alfa", "for", "the", "treatment", "of", "CF", "in", "April", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 1, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.053067896515131, 0.14315445721149445, 0.018249928951263428, 0.19239087402820587, 0.08547811955213547, 0.005173779092729092, 0.008462583646178246, 0.02638363651931286, 0.02278989925980568, 0.04818420484662056, 0.068970687687397, 0.023302292451262474, 0.5403717756271362, 0.529159665107727, 0.01671835407614708, 0.009122032672166824, 0.16675154864788055, 0.109459787607193, 0.5709705948829651, 0.025695471093058586, 0.28338074684143066, 0.4463967978954315, -1]}
{"idB": "1006281_18_item1_p95_s0", "idA": "1006281_17_item1_p93_s0", "sentA": "In November 2016, the first patient was enrolled in our phase IIa clinical trial of OPRX-106 for the treatment of ulcerative colitis.", "sentB": "OPRX-102 for the treatment of ulcerative colitis is currently the subject of a phase IIa clinical trial.", "type": 2, "words": ["<tag1>", "In", "November", "2016,", "the", "first", "patient", "was", "enrolled", "in", "our", "phase", "IIa", "clinical", "trial", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis.", "<tag2>", "OPRX-102", "for", "the", "treatment", "of", "ulcerative", "colitis", "is", "currently", "the", "subject", "of", "a", "phase", "IIa", "clinical", "trial.", "<tag3>"], "wordsA": ["In", "November", "2016,", "the", "first", "patient", "was", "enrolled", "in", "our", "phase", "IIa", "clinical", "trial", "of", "OPRX-106", "for", "the", "treatment", "of", "ulcerative", "colitis."], "wordsB": ["OPRX-102", "for", "the", "treatment", "of", "ulcerative", "colitis", "is", "currently", "the", "subject", "of", "a", "phase", "IIa", "clinical", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.9833061099052429, 0.005105066113173962, 0.002931061200797558, 0.004863492678850889, 0.0017178563866764307, 0.003450805088505149, 0.003993308171629906, 0.01718795672059059, 0.06373360008001328, 0.024495761841535568, 0.1242014467716217, 0.011654362082481384, 0.005353694315999746, 0.00945422425866127, 0.006795940920710564, 0.011303852312266827, 0.018510757014155388, -1]}
{"idB": "1006281_18_item1_p96_s0", "idA": "1006281_17_item1_p93_s1", "sentA": "The phase IIa clinical trial is designed as a randomized, open label, 2-arm study of OPRX-106 in 20 patients with active mild to moderate ulcerative colitis.", "sentB": "The phase II clinical trial is a randomized, open label, 2-arm study of OPRX-106 in patients with active mild to moderate ulcerative colitis.", "type": 2, "words": ["<tag1>", "The", "phase", "IIa", "clinical", "trial", "is", "designed", "as", "a", "randomized,", "open", "label,", "2-arm", "study", "of", "OPRX-106", "in", "20", "patients", "with", "active", "mild", "to", "moderate", "ulcerative", "colitis.", "<tag2>", "The", "phase", "II", "clinical", "trial", "is", "a", "randomized,", "open", "label,", "2-arm", "study", "of", "OPRX-106", "in", "patients", "with", "active", "mild", "to", "moderate", "ulcerative", "colitis.", "<tag3>"], "wordsA": ["The", "phase", "IIa", "clinical", "trial", "is", "designed", "as", "a", "randomized,", "open", "label,", "2-arm", "study", "of", "OPRX-106", "in", "20", "patients", "with", "active", "mild", "to", "moderate", "ulcerative", "colitis."], "wordsB": ["The", "phase", "II", "clinical", "trial", "is", "a", "randomized,", "open", "label,", "2-arm", "study", "of", "OPRX-106", "in", "patients", "with", "active", "mild", "to", "moderate", "ulcerative", "colitis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.013512919656932354, 0.06655911356210709, 0.09930393099784851, 0.04311898350715637, 0.09811750054359436, 0.037096768617630005, 0.0180758498609066, 0.055046964436769485, 0.041226692497730255, 0.043517280369997025, 0.03771548345685005, 0.0899624451994896, 0.021649794653058052, 0.17301788926124573, 0.20311708748340607, 0.31806105375289917, 0.048616111278533936, 0.45438098907470703, 0.25606703758239746, 0.06881453096866608, 0.3125441372394562, 0.11440009623765945, 0.11172392219305038, -1]}
{"idB": "1006281_18_item1_p96_s1", "idA": "1006281_17_item1_p93_s2", "sentA": "Patients will be randomized to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily, for eight weeks.", "sentB": "A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks.", "type": 2, "words": ["<tag1>", "Patients", "will", "be", "randomized", "to", "receive", "2", "mg", "or", "8", "mg", "of", "OPRX-106", "administered", "orally,", "once", "daily,", "for", "eight", "weeks.", "<tag2>", "A", "total", "of", "24", "patients", "were", "enrolled", "and", "randomized", "to", "receive", "2", "mg", "or", "8", "mg", "of", "OPRX-106,", "administered", "orally,", "once", "daily,", "for", "8", "weeks.", "<tag3>"], "wordsA": ["Patients", "will", "be", "randomized", "to", "receive", "2", "mg", "or", "8", "mg", "of", "OPRX-106", "administered", "orally,", "once", "daily,", "for", "eight", "weeks."], "wordsB": ["A", "total", "of", "24", "patients", "were", "enrolled", "and", "randomized", "to", "receive", "2", "mg", "or", "8", "mg", "of", "OPRX-106,", "administered", "orally,", "once", "daily,", "for", "8", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.01551082730293274, 0.0924675315618515, 0.10037054121494293, 0.9451466202735901, 0.4937792122364044, 0.013025405816733837, 0.034430745989084244, 0.0047961752861738205, 0.011349578388035297, 0.004483906552195549, 0.011645549908280373, 0.005785970948636532, 0.0047758799046278, 0.0023344873916357756, 0.00427433243021369, 0.004133504815399647, 0.0021505183540284634, 0.0038492230232805014, 0.00335517805069685, 0.0034904296044260263, 0.0028650735039263964, 0.002822489244863391, 0.002762307645753026, 0.018178770318627357, 0.008630556054413319, -1]}
{"idB": "1006281_18_item1_p72_s0", "idA": "1006281_17_item1_p93_s4", "sentA": "Key efficacy endpoints include relevant disease parameters of the drug, including Mayo score and rectal bleeding.", "sentB": "An improvement was noted in each of the individual parameters of the MSSI.", "type": 2, "words": ["<tag1>", "Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding.", "<tag2>", "An", "improvement", "was", "noted", "in", "each", "of", "the", "individual", "parameters", "of", "the", "MSSI.", "<tag3>"], "wordsA": ["Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding."], "wordsB": ["An", "improvement", "was", "noted", "in", "each", "of", "the", "individual", "parameters", "of", "the", "MSSI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.03904936462640762, 0.41539642214775085, 0.018060581758618355, 0.06162949278950691, 0.05080883949995041, 0.21358366310596466, 0.06300321221351624, 0.04641725495457649, 0.3721387982368469, 0.36888208985328674, 0.03965207561850548, 0.05736016854643822, 0.324055939912796, -1]}
{"idB": "1006281_18_item1_p96_s6", "idA": "1006281_17_item1_p93_s4", "sentA": "Key efficacy endpoints include relevant disease parameters of the drug, including Mayo score and rectal bleeding.", "sentB": "In the rectal bleeding analysis, a sub category of the Mayo score, 79% of those patients show an improvement.", "type": 2, "words": ["<tag1>", "Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding.", "<tag2>", "In", "the", "rectal", "bleeding", "analysis,", "a", "sub", "category", "of", "the", "Mayo", "score,", "79%", "of", "those", "patients", "show", "an", "improvement.", "<tag3>"], "wordsA": ["Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding."], "wordsB": ["In", "the", "rectal", "bleeding", "analysis,", "a", "sub", "category", "of", "the", "Mayo", "score,", "79%", "of", "those", "patients", "show", "an", "improvement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.022023148834705353, 0.012775733135640621, 0.07908466458320618, 0.14755329489707947, 0.09811614453792572, 0.008762208744883537, 0.018135512247681618, 0.06793966889381409, 0.009750274010002613, 0.00593577791005373, 0.034724652767181396, 0.041076451539993286, 0.5889255404472351, 0.08734924346208572, 0.06425434350967407, 0.27018845081329346, 0.34177669882774353, 0.3162848651409149, 0.7515566945075989, -1]}
{"idB": "1006281_18_item1_p97_s0", "idA": "1006281_17_item1_p93_s4", "sentA": "Key efficacy endpoints include relevant disease parameters of the drug, including Mayo score and rectal bleeding.", "sentB": "For purposes of the study, clinical response at week 8 is defined as a decrease in the Mayo score of at least 3 points and either a decrease in the sub-score for rectal bleeding of at least 1 point from baseline, or rectal bleeding sub-score of 0 or 1.", "type": 2, "words": ["<tag1>", "Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding.", "<tag2>", "For", "purposes", "of", "the", "study,", "clinical", "response", "at", "week", "8", "is", "defined", "as", "a", "decrease", "in", "the", "Mayo", "score", "of", "at", "least", "3", "points", "and", "either", "a", "decrease", "in", "the", "sub-score", "for", "rectal", "bleeding", "of", "at", "least", "1", "point", "from", "baseline,", "or", "rectal", "bleeding", "sub-score", "of", "0", "or", "1.", "<tag3>"], "wordsA": ["Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding."], "wordsB": ["For", "purposes", "of", "the", "study,", "clinical", "response", "at", "week", "8", "is", "defined", "as", "a", "decrease", "in", "the", "Mayo", "score", "of", "at", "least", "3", "points", "and", "either", "a", "decrease", "in", "the", "sub-score", "for", "rectal", "bleeding", "of", "at", "least", "1", "point", "from", "baseline,", "or", "rectal", "bleeding", "sub-score", "of", "0", "or", "1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.006695745512843132, 0.023694029077887535, 0.011836896650493145, 0.010028991848230362, 0.06412661075592041, 0.10040578246116638, 0.13804778456687927, 0.010228075087070465, 0.03243672102689743, 0.031055158004164696, 0.010584467090666294, 0.04553309082984924, 0.02370321936905384, 0.02451622113585472, 0.3047443628311157, 0.0654008537530899, 0.032370101660490036, 0.12773379683494568, 0.11776555329561234, 0.016168013215065002, 0.023657482117414474, 0.041566427797079086, 0.3487873673439026, 0.2775948643684387, 0.007332167588174343, 0.012994031421840191, 0.012342220172286034, 0.12376025319099426, 0.01758120022714138, 0.009810429066419601, 0.08405499905347824, 0.0034267238806933165, 0.015435208566486835, 0.02577318623661995, 0.007974464446306229, 0.010552728548645973, 0.019690925255417824, 0.519396185874939, 0.3292854130268097, 0.04021288454532623, 0.1541913002729416, 0.006515050772577524, 0.03027910552918911, 0.0755644291639328, 0.07626641541719437, 0.061466168612241745, 0.8713234066963196, 0.39397040009498596, 0.767207682132721, -1]}
{"idB": "1006281_18_item1_p103_s0", "idA": "1006281_17_item1_p94_s0", "sentA": "We entered into the Brazil Agreement with Fiocruz in June 2013, which became effective in January 2014.", "sentB": "Our Brazil Agreement became effective in January 2014.", "type": 2, "words": ["<tag1>", "We", "entered", "into", "the", "Brazil", "Agreement", "with", "Fiocruz", "in", "June", "2013,", "which", "became", "effective", "in", "January", "2014.", "<tag2>", "Our", "Brazil", "Agreement", "became", "effective", "in", "January", "2014.", "<tag3>"], "wordsA": ["We", "entered", "into", "the", "Brazil", "Agreement", "with", "Fiocruz", "in", "June", "2013,", "which", "became", "effective", "in", "January", "2014."], "wordsB": ["Our", "Brazil", "Agreement", "became", "effective", "in", "January", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 1, 0, 0, 0, 0, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.05648225545883179, 0.5164650678634644, 0.4522530436515808, 0.18886683881282806, 0.33575305342674255, 0.20471541583538055, 0.7369207739830017, 0.517631471157074, -1]}
{"idB": "1006281_18_item1_p106_s1", "idA": "1006281_17_item1_p97_s1", "sentA": "As of December 31, 2016, we held, or had license rights to, 61 patents and 58 pending patent applications with respect to various compositions, methods of production and methods of use relating to our ProCellEx protein expression system and our proprietary product pipeline.", "sentB": "As of December 31, 2017, we held, or had license rights to, 69 patents and 58 pending patent applications with respect to various compositions, methods of production and methods of use relating to our ProCellEx protein expression system and our proprietary product pipeline.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2016,", "we", "held,", "or", "had", "license", "rights", "to,", "61", "patents", "and", "58", "pending", "patent", "applications", "with", "respect", "to", "various", "compositions,", "methods", "of", "production", "and", "methods", "of", "use", "relating", "to", "our", "ProCellEx", "protein", "expression", "system", "and", "our", "proprietary", "product", "pipeline.", "<tag2>", "As", "of", "December", "31,", "2017,", "we", "held,", "or", "had", "license", "rights", "to,", "69", "patents", "and", "58", "pending", "patent", "applications", "with", "respect", "to", "various", "compositions,", "methods", "of", "production", "and", "methods", "of", "use", "relating", "to", "our", "ProCellEx", "protein", "expression", "system", "and", "our", "proprietary", "product", "pipeline.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2016,", "we", "held,", "or", "had", "license", "rights", "to,", "61", "patents", "and", "58", "pending", "patent", "applications", "with", "respect", "to", "various", "compositions,", "methods", "of", "production", "and", "methods", "of", "use", "relating", "to", "our", "ProCellEx", "protein", "expression", "system", "and", "our", "proprietary", "product", "pipeline."], "wordsB": ["As", "of", "December", "31,", "2017,", "we", "held,", "or", "had", "license", "rights", "to,", "69", "patents", "and", "58", "pending", "patent", "applications", "with", "respect", "to", "various", "compositions,", "methods", "of", "production", "and", "methods", "of", "use", "relating", "to", "our", "ProCellEx", "protein", "expression", "system", "and", "our", "proprietary", "product", "pipeline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.005942162126302719, 0.010679071769118309, 0.008483863435685635, 0.011321479454636574, 0.563159704208374, 0.004973743576556444, 0.0066357445903122425, 0.005441475659608841, 0.003657055087387562, 0.004832257051020861, 0.005637362599372864, 0.003182134125381708, 0.9360107779502869, 0.1936601996421814, 0.004877657629549503, 0.005700088106095791, 0.0054322839714586735, 0.005045258905738592, 0.004112473223358393, 0.0048437826335430145, 0.004936727229505777, 0.004289694130420685, 0.0042444560676813126, 0.004753624554723501, 0.004170107655227184, 0.005535613279789686, 0.004776904359459877, 0.005464944988489151, 0.0049099791795015335, 0.005561136640608311, 0.005019200965762138, 0.004935422446578741, 0.003860505297780037, 0.0029606586322188377, 0.007461808621883392, 0.003589377738535404, 0.0046272375620901585, 0.003780759871006012, 0.0032618651166558266, 0.0029255200643092394, 0.004021965898573399, 0.0036276064347475767, 0.0036569717340171337, -1]}
{"idB": "1006281_18_item1_p108_s0", "idA": "1006281_17_item1_p99_s0", "sentA": "We issued as series of 7.5% convertible notes in December 2016, which are guaranteed by our subsidiaries and secured by perfected liens on all of our material assets, primarily consisting of our intellectual property assets, including a stock pledge of our foreign subsidiaries in favor of the holders of outstanding 7.5% convertible notes.", "sentB": "We issued a series of 7.5% convertible notes in December 2016 and July 2017, which are guaranteed by our subsidiaries and secured by perfected liens on all of our material assets, primarily consisting of our intellectual property assets, including a stock pledge of our foreign subsidiaries in favor of the holders of outstanding 7.5% convertible notes.", "type": 2, "words": ["<tag1>", "We", "issued", "as", "series", "of", "7.5%", "convertible", "notes", "in", "December", "2016,", "which", "are", "guaranteed", "by", "our", "subsidiaries", "and", "secured", "by", "perfected", "liens", "on", "all", "of", "our", "material", "assets,", "primarily", "consisting", "of", "our", "intellectual", "property", "assets,", "including", "a", "stock", "pledge", "of", "our", "foreign", "subsidiaries", "in", "favor", "of", "the", "holders", "of", "outstanding", "7.5%", "convertible", "notes.", "<tag2>", "We", "issued", "a", "series", "of", "7.5%", "convertible", "notes", "in", "December", "2016", "and", "July", "2017,", "which", "are", "guaranteed", "by", "our", "subsidiaries", "and", "secured", "by", "perfected", "liens", "on", "all", "of", "our", "material", "assets,", "primarily", "consisting", "of", "our", "intellectual", "property", "assets,", "including", "a", "stock", "pledge", "of", "our", "foreign", "subsidiaries", "in", "favor", "of", "the", "holders", "of", "outstanding", "7.5%", "convertible", "notes.", "<tag3>"], "wordsA": ["We", "issued", "as", "series", "of", "7.5%", "convertible", "notes", "in", "December", "2016,", "which", "are", "guaranteed", "by", "our", "subsidiaries", "and", "secured", "by", "perfected", "liens", "on", "all", "of", "our", "material", "assets,", "primarily", "consisting", "of", "our", "intellectual", "property", "assets,", "including", "a", "stock", "pledge", "of", "our", "foreign", "subsidiaries", "in", "favor", "of", "the", "holders", "of", "outstanding", "7.5%", "convertible", "notes."], "wordsB": ["We", "issued", "a", "series", "of", "7.5%", "convertible", "notes", "in", "December", "2016", "and", "July", "2017,", "which", "are", "guaranteed", "by", "our", "subsidiaries", "and", "secured", "by", "perfected", "liens", "on", "all", "of", "our", "material", "assets,", "primarily", "consisting", "of", "our", "intellectual", "property", "assets,", "including", "a", "stock", "pledge", "of", "our", "foreign", "subsidiaries", "in", "favor", "of", "the", "holders", "of", "outstanding", "7.5%", "convertible", "notes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.009610332548618317, 0.012462968938052654, 0.008541584946215153, 0.009179691784083843, 0.009483715519309044, 0.018873324617743492, 0.028924167156219482, 0.018914958462119102, 0.010535257868468761, 0.0179197508841753, 0.01747746206820011, 0.06119576096534729, 0.5136778950691223, 0.7821557521820068, 0.0147576704621315, 0.010044551454484463, 0.016491252928972244, 0.010795209556818008, 0.010732961818575859, 0.01705380342900753, 0.016071906313300133, 0.015223001129925251, 0.01310052815824747, 0.017824146896600723, 0.018503893166780472, 0.00977021548897028, 0.012628741562366486, 0.011118714697659016, 0.009846792556345463, 0.01795647107064724, 0.01939430832862854, 0.01054441649466753, 0.011465245857834816, 0.012063049711287022, 0.008501273579895496, 0.018129702657461166, 0.020631510764360428, 0.020881865173578262, 0.01297580823302269, 0.012409050017595291, 0.022061306983232498, 0.0205742958933115, 0.011967061087489128, 0.010183192789554596, 0.015343575738370419, 0.019247954711318016, 0.016626659780740738, 0.01242751907557249, 0.012087065726518631, 0.010456961579620838, 0.013373292982578278, 0.010226242244243622, 0.013809149153530598, 0.025490382686257362, 0.03707412630319595, 0.023032644763588905, -1]}
{"idB": "1006281_18_item1_p13_s0", "idA": "1006281_17_item1_p9_s1", "sentA": "The strategy centers around prioritizing existing and new pipeline candidates to focus on products that we believe offer a clear competitive advantage over existing treatments.", "sentB": "Our strategy centers around prioritizing existing and new pipeline candidates to focus on products that we believe offer a clear competitive advantage over existing treatments.", "type": 2, "words": ["<tag1>", "The", "strategy", "centers", "around", "prioritizing", "existing", "and", "new", "pipeline", "candidates", "to", "focus", "on", "products", "that", "we", "believe", "offer", "a", "clear", "competitive", "advantage", "over", "existing", "treatments.", "<tag2>", "Our", "strategy", "centers", "around", "prioritizing", "existing", "and", "new", "pipeline", "candidates", "to", "focus", "on", "products", "that", "we", "believe", "offer", "a", "clear", "competitive", "advantage", "over", "existing", "treatments.", "<tag3>"], "wordsA": ["The", "strategy", "centers", "around", "prioritizing", "existing", "and", "new", "pipeline", "candidates", "to", "focus", "on", "products", "that", "we", "believe", "offer", "a", "clear", "competitive", "advantage", "over", "existing", "treatments."], "wordsB": ["Our", "strategy", "centers", "around", "prioritizing", "existing", "and", "new", "pipeline", "candidates", "to", "focus", "on", "products", "that", "we", "believe", "offer", "a", "clear", "competitive", "advantage", "over", "existing", "treatments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.024958744645118713, 0.10049363225698471, 0.08899939805269241, 0.03169878572225571, 0.10625389218330383, 0.2972407639026642, 0.07303807139396667, 0.1548886001110077, 0.12474159151315689, 0.1771223098039627, 0.0290322694927454, 0.03141459450125694, 0.03145245090126991, 0.03176818788051605, 0.0198613740503788, 0.029867039993405342, 0.03659401088953018, 0.024371648207306862, 0.02573247440159321, 0.03496088460087776, 0.05077310651540756, 0.08635121583938599, 0.030742907896637917, 0.1797756403684616, 0.1093791127204895, -1]}
{"idB": "1006281_18_item1_p13_s1", "idA": "1006281_17_item1_p9_s2", "sentA": "The strategy was the culmination of two months of intensive review by our management of our internal resources and of the markets in which we expect we can operate.", "sentB": "The strategy was the culmination of an intensive review by our management of our internal resources and of the markets in which we expect we can operate.", "type": 2, "words": ["<tag1>", "The", "strategy", "was", "the", "culmination", "of", "two", "months", "of", "intensive", "review", "by", "our", "management", "of", "our", "internal", "resources", "and", "of", "the", "markets", "in", "which", "we", "expect", "we", "can", "operate.", "<tag2>", "The", "strategy", "was", "the", "culmination", "of", "an", "intensive", "review", "by", "our", "management", "of", "our", "internal", "resources", "and", "of", "the", "markets", "in", "which", "we", "expect", "we", "can", "operate.", "<tag3>"], "wordsA": ["The", "strategy", "was", "the", "culmination", "of", "two", "months", "of", "intensive", "review", "by", "our", "management", "of", "our", "internal", "resources", "and", "of", "the", "markets", "in", "which", "we", "expect", "we", "can", "operate."], "wordsB": ["The", "strategy", "was", "the", "culmination", "of", "an", "intensive", "review", "by", "our", "management", "of", "our", "internal", "resources", "and", "of", "the", "markets", "in", "which", "we", "expect", "we", "can", "operate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0.016350723803043365, 0.3093556761741638, 0.04884789511561394, 0.0237264446914196, 0.19445015490055084, 0.026012448593974113, 0.02281327359378338, 0.3918260633945465, 0.32967469096183777, 0.03261667862534523, 0.047087524086236954, 0.06484127044677734, 0.03431914374232292, 0.044130776077508926, 0.07365084439516068, 0.07232268154621124, 0.01670871488749981, 0.021953361108899117, 0.022297782823443413, 0.043089836835861206, 0.024435782805085182, 0.022838735952973366, 0.027220938354730606, 0.03930584713816643, 0.027536002919077873, 0.04226979240775108, 0.06316914409399033, -1]}
